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CHAPTER I 
 
INTRODUCTION TO DEVELOPMENTAL SIGNALING PATHWAYS 
Introduction 
 
 The fundamental processes of metazoan development are widely conserved 
throughout the animal kingdom. Among the conserved components are two critical 
developmental pathways, the Wnt signaling pathway and the Notch signaling pathway. 
These pathways are similar in many ways, including ligand-dependent activation of the 
pathway in wild-type conditions, key transcriptional co-activators which form 
transcriptional activation complexes, and a downstream effector protein in which the 
stability of the protein is tightly regulated in order to regulate the transcriptional activity 
of the pathway. Because these developmental pathways regulate organismal growth 
and development, they can potentially be co-opted when key regulatory genes are 
mutated. Both the Wnt pathway and the Notch pathway are very often misregulated in 
human cancers. In this work, Chapter I sets the historical and scientific foundation for 
key mechanistic questions in both the Wnt and Notch pathways which are explored in 
greater mechanistic detail in Chapters III and IV. Chapters V and VI conclude with 
discussion and future directions from the findings presented in this document. 
Cell Signaling and Signal Transduction of Developmental Pathways 
Cell signaling is a form of cellular communication in which cells interact with their 
surroundings, process this information, and provided an appropriate response to these 
2 
 
signals. The process in which a cell recognizes, processes, and responds to a signal is 
called signal transduction. 
The process of signal transduction regulates and coordinates all metazoan 
developmental processes. Metazoan organismal development is a highly regulated and 
coordinated series of signal transduction events between cells and other cells which 
cooperate to form a fully functional reproducing animal. 
One of the earliest studies involving signal transduction and development comes 
from the work of Hans Spemann in the early 20th century. In this seminal work, 
Spemann, along with Hilde Mangold, showed that transplantation of the dorsal lip of the 
blastopore of an amphibian embryo beginning gastrulation onto the other side of 
another developmentally staged embryo resulted in the formation of two body axes in 
the grafted embryo, producing a mirror image twin. One of these axes was formed by 
the endogenous dorsal lip of the blastopore while the other was formed by the 
transplanted dorsal lip tissue. The transplanted dorsal lip induced the formation of a 
complete dorsal axis in a location that normally forms the ventral side of the embryo. 
Due to its inductive potential, the dorsal lip of the amphibian blastopore was termed the 
organizer (Spemann and Mangold, 1938; Spemann and Mangold, 2001). This landmark 
discovery provided major evidence that cells signal to each other and that these signals 
can induce cooperative growth and development. Because of this work, Spemann was 
awarded the Nobel Prize in Medicine or Physiology in 1935. 
 Currently, 18 signal transduction pathways have been identified (Gerhart, 1999). 
These signaling pathways typically have conserved structural mechanisms in order to 
transduce the signal. Some type of ligand is released into the extracellular environment  
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or expressed at the surface of the siganal-sending cell and binds to a cell surface 
receptor. This ligand-bound receptor gets activated. Then, the activated receptor 
transduces the signal intracellularly. Finally, intracellular signal transduction occurs 
through secondary messengers which send the signal through the cell via other 
messengers to ultimately induce a physiological response. 
 Current evidence suggests that 5 of the 18 currently known signaling pathways 
control developmental processes (Gerhart, 1999). As metazoans evolved multi-
cellularity, a means of signaling between these multiple cells also evolved in order to 
facilitate communication between these cells. These cell-cell signaling pathways that 
evolved in response to multicellularity are the developmental signaling pathways that 
are conserved throughout all metazoans. Two of these developmental pathways, the 
Wnt/β-catenin signaling pathway and the Notch signaling pathway, will be described in 
more detail later in this document. This dissertation will focus primarily on Notch 
signaling. 
 The description of these signaling processes as “pathways” paints an inaccurate 
picture of the diversity and complexity of metazoan development. These signaling 
processes, rather than being discrete, independent “pathways”, are interconnected, 
forming a signaling “network”. Abundant evidence exists that there is crosstalk between 
these “pathways”, in which the activation or non-activation of a receptor of one pathway 
affects another pathway (van Amerongen and Nusse, 2009). In this chapter I will 
describe the history and importance of Wnt/β-catenin signaling, the history and 
importance of Notch signaling, and the evidence of cross-talk between the two that links 
them into a signaling network. 
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Historical Significance: Wnt Signaling in Development and Disease 
 The canonical Wnt/β-catenin signaling pathway plays a critical role in cell fate 
determination, cell proliferation, cell polarity, and cell death during embryonic 
development and in tissue homeostasis in adults. The Wnt pathway is named for its 
ligands, the Wnt family of secreted glycoproteins, was discovered nearly 40 years ago. 
The history of Wnt/β-catenin signaling highlights the roles of this pathway in both 
development and disease. Many of the details of Wnt/β-catenin signaling can be found 
in other reviews [reviewed in (MacDonald et al., 2009; Saito-Diaz et al., 2013)]. 
 In 1976, Sharma and Chopra described a Drosophila melanogaster mutant which 
had absent or reduced wings and halteres, which they named wingless (wg). Based on 
the mutant phenotype, they hypothesized that the wingless locus played a critical role in 
development (Sharma and Chopra, 1976). This hypothesis was confirmed in 1980 when 
Wieschaus and Nusslein-Volhard identified wg as a segmentation gene in a Drosophila 
mutagenesis screen for gene required in segmentation(Nusslein-Volhard and 
Wieschaus, 1980). For this landmark discovery in developmental biology, Nusslein-
Volhard and Wieschaus were awarded the Nobel Prize in Physiology or Medicine in 
1995. 
Several years later, Nusse and Varmus conducted a forward genetic screen to 
identify genes which could lead to tumorigenesis. They used mouse mammary tumor 
virus (MMTV) insertion sites and identified a locus termed int-1, short for integration-1, 
which induced mouse mammary tumors (Nusse et al., 1984; Nusse and Varmus, 1982). 
Later, comparative genomic studies identified wg and int-1 as homologs, and the name 
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was merged into the mnemonic Wnt (Nusse et al., 1991). The injection of int-1 in 
Xenopus embryos induced the formation of a secondary body axis, confirming the role 
of int-1 as both an oncogene and a critical component of vertebrate early axis formation 
(McMahon and Moon, 1989a; McMahon and Moon, 1989b). These studies take 
together suggest that the Wnt proteins play a critical role in normal development as well 
as a critical role in carcinogenesis. 
Drosophila mutagenesis screens (similar to the one described earlier from 
Nusslein-Volhard and Wieschaus) played an important role in identifying components of 
the Wnt/β-catenin signaling pathway (Nusslein-Volhard and Wieschaus, 1980). In the 15 
years after that initial publication, key Wnt pathway components such as armadillo (the 
Drosophila homolog of β-catenin), dishevelled (Dsh), shaggy (the Drosophila homolog 
of glycogen synthase kinase 3, GSK3), frizzled (Fz), and arrow (the Drosophila homolog 
of LRP5/6) (Bhanot et al., 1996; Klingensmith et al., 1994; Riggleman et al., 1990; 
Riggleman et al., 1989; Siegfried et al., 1992; Wehrli et al., 2000) were identified. 
The Wnt/β-catenin pathway was then linked to the formation of the Spemann-
Mangold organizer referenced earlier in this chapter (Spemann and Mangold, 1938). 
Injection of Wnt-1 and XWnt8 into Xenopus blastomeres induces a secondary axis due 
to a second organizer (Smith and Harland, 1991; Sokol et al., 1991). This secondary 
axis formation was also phenocopied using other Wnt/β-catenin pathway components 
(Dominguez et al., 1995; Fagotto et al., 1999; Guger and Gumbiner, 1995; He et al., 
1995; Sokol et al., 1995). Many of these other components were identified by their 
effects on vertebrate development, such as Axin (Zeng et al., 1997), APC (Munemitsu 
et al., 1995; Rubinfeld et al., 1993), and the co-receptor LRP5/6 (Pinson et al., 2000; 
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Tamai et al., 2000; Wehrli et al., 2000). All of these major Wnt components can induce 
secondary axis formation in Xenopus embryos, and the axis duplication assay has 
emerged as a powerful validation tool to identify bona fide regulators of Wnt/β-catenin 
signaling.  
Many developmental signaling pathways are also critical drivers of cell growth 
and cell-cell signaling in cancer. The Wnt/β-catenin signaling pathway is no exception. 
Perturbations in Wnt/β-catenin signaling lead to a large number of diseases, varying 
from congenital birth defects to multiple types of cancer [reviewed in (MacDonald et al., 
2009)]. Perhaps the most well-known connection between Wnt/β-catenin signaling and 
cancer is a genetic lesion in the Wnt pathway component APC that occurs colorectal 
cancer. In familial adenomatous polyposis (FAP), a form of hereditary colorectal cancer 
(Kinzler et al., 1991; Nishisho et al., 1991), patients missing one copy of APC lose their 
second copy of APC and develop benign polyps at an early age. These polyps then 
develop other mutations and lead to invasive colon carcinoma. Later, loss of both APC 
alleles was linked to over 80% of sporadic, nonhereditary colorectal cancers (Kinzler 
and Vogelstein, 1996). Misregulated Wnt/β-catenin signaling was then found in many 
other types of cancers, including liver cancer, skin cancer, lung cancer, Wilms’ Tumor, 
breast cancer, prostate cancer, and others [reviewed in (Klaus and Birchmeier, 2008) 
and (Saito-Diaz et al., 2013)]. Developmental genetic defects can also result from 
misregulated Wnt/β-catenin signaling (Boyden et al., 2002; Gong et al., 2001; Lammi et 
al., 2004; Niemann et al., 2004; Toomes et al., 2004; Xu et al., 2004). Understanding 
the molecular mechanisms governing Wnt/β-catenin signaling is critical towards both 
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understanding the pathophysiological effects of Wnt/β-catenin misregulation and 
designing therapeutics against the Wnt/β-catenin signaling pathway. 
The Current Model of the Wnt/β-catenin Signaling Pathway 
 Wnt signaling promotes a variety of cellular responses in development, 
physiology, and disease. The original hypothesis was that Wnt signaling promotes these 
responses by activating different transcriptional target genes in different cellular 
contexts. This pathway, in which Wnt signaling activates specific transcriptional target 
genes, was previously referred to as “canonical” Wnt signaling. I have referred to it as 
Wnt/β-catenin signaling to distinguish it from other Wnt-mediated pathways. Other Wnt-
mediated pathways signal cytoplasmic changes involving the action cytoskeleton 
(Wnt/PCP pathway) and intracellular calcium stores (Wnt/Ca2+ pathway). These other 
pathways may be regulated by the tyrosine kinase receptors ROR and RYK (Nusse, 
2008). In recent years, even the simplicity of the two pathway model has been 
questioned (van Amerongen et al., 2008). These other pathways are outside the scope 
of this document. For all intents and purposes, every reference to Wnt signaling refers 
to Wnt/β-catenin signaling.  
 The Wnt/β-catenin signaling pathway, fundamentally, results in the cytoplasmic 
protein β-catenin entering the nucleus to modulate transcription. When Wnt ligand is not 
bound, β-catenin is continually degraded by the β-catenin destruction complex. The 
destruction complex consists of the scaffold proteins Axin and APC and the protein 
kinases GSK3 and Casein Kinase 1 (CK1) [Figure 1.1 (Saito-Diaz et al., 2013)].  
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Figure 1.1. The current model of Wnt/β-catenin signaling. (Left panel) In the absence of Wnt, 
cytoplasmic β-catenin forms a complex with APC, Axin, GSK3, and CK1α. β-Catenin is 
phosphorylated by CK1α and subsequently phosphorylated by GSK3. The phosphorylated form 
of β-catenin is recognized by the E3 ubiquitin ligase SCFβ-TRCP, which targets β-catenin for 
proteasomal degradation. In the absence of nuclear β-catenin, Wnt target genes are repressed. 
APC, adenomatous polyposis coli; GSK3, glycogen synthase kinase 3; CK1α, casein kinase 1 
alpha. (Right panel) In the presence of Wnt ligand, a receptor complex forms between Fz, 
LRP5/6, and Wnt. The recruitment of Dsh by Fz leads to LRP5/6 phosphorylation by CK1α and 
GSK3 followed by recruitment of Axin to LRP5/6. The latter disrupts Axin-mediated 
phosphorylation/degradation of β-catenin, leading to accumulation of β-catenin in the cytoplasm 
and its translocation to the nucleus, where it acts as a transcriptional co-activator with TCF to 
activate Wnt-responsive target genes. Fz, Frizzled; Dsh, Dishevelled; TCF, T-cell factor [Figure 
from (Saito-Diaz et al., 2013)].  
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Activation of Wnt/β-catenin signaling removes APC from the complex and 
relocalizes the other components to the plasma membrane via the adaptor Dsh, thus 
stabilizing β-catenin which enters the nucleus to mediate transcription (Figure 1). Thus, 
Wnt/β-catenin signaling can be divided into three general molecular events: (1) surface 
receptor activation, (2) inhibition of the β-catenin destruction complex, and (3) activation 
of a Wnt-specific nuclear transcriptional complex. The next sections of this document 
consider each of these steps more closely. 
Wnt/β-catenin Signaling: Surface Receptor Activation 
 The secreted Wnt proteins are cysteine-rich morphogens between approximately 
350-400 amino acids which can act in both short-range and long-range signaling. There 
are at least 19 vertebrate Wnt proteins and are capable of activating the pathway. Wnt 
ligands bind to their receptor Frizzled (Fz). The structural basis of Wnt-receptor 
interactions has been characterized (Janda et al., 2012). All of the Wnt ligands contain 
an N-terminal signal peptide for secretion and are N-linked glycosylated (Smolich et al., 
1993; Takada et al., 2006; Willert et al., 2003). The N-glycosylation of the Drosophila 
Wnt homolog Wg is stimulated by lipid modifications (Tanaka et al., 2002). Early studies 
suggested that glycosylation of Wnt was dispensable for Wnt activity (Mason et al., 
1992), but more recent studies have demonstrated the requirement of glycosylation for 
Wnt secretion (Komekado et al., 2007; Kurayoshi et al., 2007). 
 The Wnt proteins contain multiple charged amino acids and undergo lipid 
modifications which are required for activity (Bradley and Brown, 1990). Wnt3a protein 
(and by extension Wnts in general) is acylated with a palmitate at Cys77 and a 
palmitoleate at Ser209 (Takada et al., 2006; Willert et al., 2003). Interestingly, the 
10 
 
crystal structure of the Wnt/receptor complex shows Cys77 engaged in disulfide 
bonding and the palmitoleate at Ser209 docked inside a hydrophobic groove on a 
cysteine-rich domain (CRD) of the receptor, playing a direct role in Wnt-receptor 
interaction (Janda et al., 2012).  
 These lipid modifications of Wnt are mediated by an endoplasmic reticulum (ER)-
embedded, multi-pass transmembrane O-acetyl transferase known as Porcupine (Porc) 
[reviewed in (MacDonald et al., 2009; Port and Basler, 2010; Saito-Diaz et al., 2013)]. 
Porc was initially identified in Drosophila as a segment polarity gene was the first gene 
shown to be required in Wnt-secreting cells. Loss-of-function of Porc leads to 
accumulation of Wnt in the ER (Kadowaki et al., 1996; van den Heuvel et al., 1993) and 
overexpression of Porc results in a high percentage of Wnts that are lipid-modified (Galli 
et al., 2007). The p24 family of proteins is required for modified Wnts to get transported 
from the ER to the Golgi (Buechling et al., 2011; Port et al., 2011). Once in the Golgi, 
the trans-Golgi seven-pass transmembrane protein Wntless (Wls transports Wnt from 
the Golgi to the plasma membrane. Wls binds to the palmitoylated Ser209 which is 
mediated by Porc (Herr and Basler, 2011). WIs is recycled back to the plasma 
membrane via a protein complex known as the retromer. The retromer complex routes 
WIs back from endosomes into trans-Golgi in a retrograde manner (Coudreuse et al., 
2006; Port and Basler, 2010). WIs gets degraded in the endosome in the absence of the 
retromer complex (Yang et al., 2008). The addition of exogenous WIs bypasses the 
requirement of the retromer (Franch-Marro et al., 2008; Port et al., 2008) Together, 
Porc, Wls, and indirectly, the retromer complex, form a pathway critical for secretion of 
Wnt ligands (Figure 1.2).  
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Figure 1.2. Synthesis and export of Wnt ligand. Wnt ligand undergoes multiple posttranslational 
modifications in the ER. Glycosylation and palmitoylation of Wnt ligand (the latter mediated by 
the transmembrane protein Porc) are required for its translocation to the Golgi apparatus. 
Palmitoylation of Wnt allows it to bind Wls, which provides a mechanism for transportation to the 
plasma membrane. The retromer complex recycles Wls from the plasma membrane back to the 
Golgi [Figure from (Saito-Diaz et al., 2013)]. 
12 
 
  
The soluble Wnt ligands bind to the Frizzled (Fz) family of seven transmembrane 
domain receptors, which share structural features with G-protein coupled receptors 
(GPCRs). Biochemical experiments showed that Wnt binds to the CRD domain of Fz 
with a binding affinity in the low nanomolar range (Bhanot et al., 1996; Hsieh et al., 
1999). Because of Fz’s topological similarity to classical GPCRs, heterotrimeric G-
protein signaling has been hypothesized as critical in transducing Wnt signaling. A link 
between G proteins and Wnt signaling has been suggested in several studies. First, in 
Drosophila, studies suggest that Gαo transduces signaling through Fz and interacts with 
the scaffold protein Axin to promote its localization to the plasma membrane (Egger-
Adam and Katanaev, 2009; Katanaev et al., 2005). In mammalian cell culture, depletion 
of Gαo and Gαq inhibited Wnt/β-catenin (Liu et al., 2005). Reconstitution experiments in 
Xenopus egg extract show that Gαo, Gαq. Gαi2, and Gβγ can inhibit β-catenin 
phosphorylation and turnover. Gβγ was proposed to promote GSK3 recruitment to the 
membrane that enhanced low-density lipoprotein receptor-related protein 6  (LRP6) 
phosphorylation and activation (Jernigan et al., 2010).  
 LRP5 and LRP6 are functionally redundant single pass transmembrane 
receptors which serve as co-receptors of Wnt/β-catenin signaling (Pinson et al., 2000; 
Tamai et al., 2000; Wehrli et al., 2000). In Drosophila wingless signaling, the lone LRP 
family member is known as Arrow. Although there have been some differences in 
potency, LRP5 and LRP6 were shown to be mechanistically nearly identical in the 
Wnt/β-catenin signaling pathway, despite some differences during development (He et 
al., 2004; Mi and Johnson, 2005). Biochemical and structural studies have shown that 
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different Wnt ligands bind to different extracellular domains of LRP5/6 (Ahn et al., 2011; 
Bourhis et al., 2010; Chen et al., 2011; Cheng et al., 2011). Wnt binding to Fz and 
LRP5/6 leads to the production of phosphatidylinositol 4,5-biphosphate (PIP2) (Pan et 
al., 2008). The production of PIP2 has been hypothesized to promote the 
oligomerization and clustering of Fz and LRP6 into “signalosomes” upon activation of 
Wnt/β-catenin signaling. The in vivo physiological significance of signalosome formation 
is still being investigated (Bilić et al., 2007; Cong et al., 2004b). PIP2 production also 
promotes recruitment of destruction complex components to LRP5/6 on the plasma 
membrane, possibly through Amer1/WTX (APC membrane recruitment 1 or Wilms 
tumor gene on the X chromosome), a tumor suppressor in Wilms’ tumor which binds to 
Axin and GSK3. Amer1/WTX’s recruitment to the plasma membrane is PIP2- dependent 
(Major et al., 2007; Tanneberger et al., 2011). The recruitment of the destruction 
complex to the plasma membrane upon Wnt binding leads to the phosphorylation of 
LRP5/6 in an event known as the “initiation step” of Wnt/β-catenin signaling (Baig-Lewis 
et al., 2007). LRP5/6 is phosphorylated by the destruction complex kinases GSK3 and 
CK1 at PPPSPxS motifs on LRP5/6 which are both necessary and sufficient to activate 
Wnt/β-catenin signaling (Davidson et al., 2005; MacDonald et al., 2009; MacDonald et 
al., 2008; Tamai et al., 2004; Wolf et al., 2008; Zeng et al., 2005). The recruitment of the 
concentration-limiting scaffold protein Axin (Lee et al., 2003) brings additional GSK3 
and CK1 molecules to the plasma membrane during the “amplification step” (Baig-Lewis 
et al., 2007). Subsequently, the activated and phosphorylated LRP6 intracellular domain 
inhibits further GSK3 activity by directly binding to it (Cselenyi et al., 2008; Piao et al., 
2008; Wu et al., 2009). This GSK3 inhibition by phosphorylated LRP6 frees up β-catenin 
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from getting phosphorylated by GSK3 and targeted for ubiquitin-mediated degradation, 
thus transducing the signal further downstream. The mechanistic relationship between 
LRP6 and GSK3 amplification and then inhibition requires further study.  
 Other molecules linked to agonizing or antagonizing Wnt/β-catenin signaling 
have been identified. There are two classes of secreted Wnt/β-catenin antagonists. One 
class, consisting of secreted Fz-related proteins (sFRPs) and Wnt inhibitory factors 
(WIFs), bind and sequester Wnt ligands and prevent their interaction with Wnt receptors 
(Bovolenta et al., 2008). The other class, made up of Dkk1 and Wise/SOST members, 
binds to LRP5/6 and blocks its interaction with Wnt ligands (Mao et al., 2002; Semenov 
et al., 2001). Other Wnt/β-catenin agonists include Norrin and R-Spondin (Kazanskaya 
et al., 2004; Kim et al., 2006; Nam et al., 2006; Wei et al., 2007; Xu et al., 2004). R-
spondin may be a driver of colorectal cancer (Seshagiri et al., 2012) and has been 
shown to bind to leucine-rich repeat-containing GPCRs 4,5 and 6 (LGR4/5/6), which are 
intestinal stem cell markers , but how this binding agonizes Wnt/β-catenin signaling is 
still unclear (Barker et al., 2007; Carmon et al., 2011; de Lau et al., 2011; Glinka et al., 
2011; Snippert et al., 2010). Recent studies suggest that R-spondin stabilizes the 
Wnt/β-catenin receptors Fz and LRP5/6 by inhibiting the activity of two E3 Ubiquitin 
Ligases, RNF43 and ZNRF3, which target Fz and LRP6 for degradation (Hao et al., 
2012; Koo et al., 2012). This stabilization of Fz and LRP5/6 potentiates Wnt/β-catenin 
signaling. Very recently, the type 1 transmembrane protein Tiki was identified in an 
expression cloning screen that perturbed axis formation in X. laevis embryos (Zhang et 
al., 2012). Tiki was identified as a novel metalloprotease that cleaves the N-terminal 8 
amino acids of mature Wnt proteins which results in the formation of large, soluble 
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oligomeric Wnt complexes due to oxidation and the formation of disulfide bonds in vitro. 
Whether the formation of these inactive Wnt complexes is how Tiki affects the Wnt/β-
catenin pathway in vivo is still unclear. 
 Another critical component of the Wnt/β-catenin pathway is the cytoplasmic 
effector protein Dishevelled (Dsh). Dsh is required genetically in Drosophila wingless 
signaling (Klingensmith et al., 1994) and there are 3 vertebrate paralogs encoded by 3 
distinct genes (Dvl1-3) (Semenov and Snyder, 1997; Sussman et al., 1994; Yang et al., 
1996). Dsh gets phosphorylated and recruited to the cytoplasmic portion of the receptor 
upon Wnt-receptor binding (Rothbacher et al., 2000; Semenov and Snyder, 1997; 
Yanagawa et al., 1995). This Dsh phosphorylation is independent of LRP6 activation 
(Gonzalez-Sancho et al., 2004). Dsh contains 3 known structural domains, the DEP, the 
PDZ, and the DIX domains. The PDZ and DIX domains have been shown to be 
important in Dsh binding to Fz (Tauriello et al., 2012; Wong et al., 2003; Wong et al., 
2000). The DIX domain is thought to polymerize and promote receptor clustering 
(Schwarz-Romond et al., 2007). Though Dsh is thought to be upstream of LRP6 in the 
Wnt/β-catenin pathway (Tolwinski et al., 2003) and can stimulate PIP2 production (Pan 
et al., 2008), in Drosophila and Xenopus egg extracts Dsh activates Wnt/β-catenin 
independently of Arrow/LRP6 (Salic et al., 2000b; Wehrli et al., 2000). In another 
invertebrate species, Caenorhabditis elegans, there is a Dsh homolog but no LRP5/6 
homolog, suggesting that Dsh might play a more critical role in different phyla (Phillips 
and Kimble, 2009). Dsh is likely regulated by ubiquitin-mediated proteasomal 
degradation through at least 3 known E3 ubiquitin ligases, the HECT-type ligases 
NEDL1 and ITCH and the SCF-type ligase KLHL12 (Angers et al., 2006; Miyazaki et al., 
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2004; Wei et al., 2012). This degradation is also mediated by the Naked2 protein as a 
co-factor (Hu et al., 2010). Additionally, the deubiquitinase CYLD (encoded by the 
familial cylindromatosis tumor suppressor gene) negatively regulated Wnt/β-catenin 
signaling (Tauriello et al., 2010). 
 These Wnt/β-catenin pathway components (Wnt, Fz, LRP5/6, and Dsh) and their 
regulators (Porc, WIs, sFRPs, WIFs, PIP2, ITCH, NEDL1, KLHL12, and others) combine 
to form a highly regulated network of plasma membrane surface proteins that are critical 
for Wnt/β-catenin signal transduction. After surface receptor activation and transduction 
of the signal, the cytoplasmic β-catenin destruction complex comes into play. 
Wnt/β-catenin Signaling: The β-catenin destruction complex 
The β-catenin destruction complex is a macromolecular machine that efficiently 
phosphorylates β-catenin and targets it for degradation. I will first describe the 
molecules involved in the formation of the β-catenin destruction complex (Figure 1.1) 
and follow with the current model of Wnt/β-catenin signaling pathway upon receptor 
activation [reviewed in (Chen et al., 2014b; Saito-Diaz et al., 2013)]. 
 The transcriptional regulator β-catenin, as mentioned earlier, is the primary 
effector of the Wnt/β-catenin signaling pathway.  In the absence of Wnt/β-catenin 
signaling, the destruction complex targets β-catenin for degradation by SCFβ-TRCP, a 
Skp1-Cullin-Fbox (SCF) E3 Ubiquitin Ligase complex family member. When Wnt/β-
catenin signaling is active, β-catenin degradation is inhibited and translocates from the 
cytoplasm to the nucleus to activate Wnt/β-catenin signaling. There are other substrates 
of the destruction complex but their physiological relevance is still unclear. β-catenin 
was originally identified in Drosophila as the segment polarity armadillo as a component 
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of the adherens junction in Xenopus (McCrea et al., 1991; Nusslein-Volhard and 
Wieschaus, 1980). Structurally, β-catenin contains a central core consisting of 12 helical 
42 amino acid armadillo repeats which form a superhelix (Huber et al., 1997). The 
unstructured N-terminal and C-terminal ends of β-catenin form dynamic interactions with 
the armadillo repeats (Xing et al., 2008). These armadillo repeats form a positively 
charged groove which regulates β-catenin’s interaction with other Wnt/β-catenin 
pathway components (i.e. APC, Axin, TCF/Lef) as well as E-cadherin (Graham et al., 
2000; Huber et al., 1997; Huber and Weis, 2001; Xing et al., 2003; Xing et al., 2004). 
The cellular signals that regulate whether newly synthesized β-catenin mediates gene 
transcription or maintains the adherens junction are not well-understood. There is 
substantial evidence that overexpression of cadherins inhibits Wnt/β-catenin gene 
transcription and promotes localization of β-catenin to the membrane (Gottardi et al., 
2001; Heasman et al., 1994; Sadot et al., 1998; Sanson et al., 1996; Shtutman et al., 
1999; Stockinger et al., 2001). Further evidence of the interplay between cadherins and 
Wnt/β-catenin signaling occurs when the proteolytic cleavage of cadherins by ADAM1- 
and presinilin-1 (a subunit of γ-secretase) activates Wnt/β-catenin target gene 
expression (Marambaud et al., 2002; Maretzky et al., 2005; Reiss et al., 2005; Uemura 
et al., 2006). Evidence for direct crosstalk between cadherins and Wnt/β-catenin 
signaling has been elusive, as E-cadherin knockdowns did not activate Wnt/β-catenin 
signaling (Herzig et al., 2007; Kuphal and Behrens, 2006). These results combine to 
suggest that there are two distinct pools of β-catenin, which is further supported by a 
study demonstrating that β-catenin can exist as a monomer and a dimer bound to α-
catenin (Gottardi and Gumbiner, 2004). The monomeric form preferentially activates 
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Wnt/β-catenin signaling and the dimeric form preferentially binds cadherins. 
Surprisingly, β-catenin’s mechanism of nuclear translocation is still unclear. 
 The scaffold protein Axin is a critical, concentration-limiting negative regulator of 
Wnt/β-catenin signaling (Lee et al., 2003). Axin is encoded by the fused gene locus in 
mice (Zeng et al., 1997). Its primary function is to serve as a scaffold for the destruction 
complex by binding to the other components and bringing them into close proximity with 
each other (Figure 1.1). Structural analysis has visualized the interactions between Axin 
and APC (Spink et al., 2000), Axin and β-catenin (Xing et al., 2003), and Axin and 
GSK3β (Dajani et al., 2003). Studies in Drosophila embryos suggest that Axin forms 
oligomers in vivo, and can potentially act as a cytoplasmic anchor  of Armadillo/β-
catenin and prevent nuclear translocation, thus inhibiting Wnt/β-catenin signaling 
(Peterson-Nedry et al., 2008; Tolwinski and Wieschaus, 2001). Axin is found at low 
concentrations and serves as the concentration-limiting component of destruction 
complex formation in Xenopus (Lee et al., 2003). The concentration of Axin plays a 
critical role in creating specificity for Wnt/β-catenin signaling as many component of the 
destruction complex play roles in other signaling pathway (i.e. GSK3) (Forde and Dale, 
2007; Lee et al., 2003). Due to the critical nature of Axin concentration on Wnt/β-catenin 
signaling, Axin protein levels are very highly regulated. GSK3 phosphorylation inhibits 
Axin degradation (Yamamoto et al., 1999), and studies in Xenopus egg extract and in 
Drosophila show that APC is required for Axin turnover, likely due to compensatory 
regulation due to fluctuation in APC protein levels (Lee et al., 2003). Axin stability is 
regulated by the E3 Smad ubiquitin regulatory factor 2 (Smurf2) (Kim and Jho, 2010) 
and the poly(ADP-Ribose) Polymerase (PARP) Tankyrase, which poly(ADP-ribosy)lates 
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(PARsylates) Axin through the addition of poly(ADP-Ribose) moieties to promote the 
ubiquitination and degradation of Axin through its poly(ADP-Ribose) moieties (Huang et 
al., 2009a). The discovery of two distinct Tankyrase inhibitors, IWR-1 and XAV939, 
which stabilize Axin and inhibit Wnt/β-catenin signaling further confirms the importance 
of Axin protein levels (Chen et al., 2009; Huang et al., 2009a). These tankyrase 
inhibitors act by inhibiting Axin PARsylation and thus inhibiting Axin turnover. Recently, 
two separate groups have identified RNF146 as the poly(ADP-Ribose)-directed E3 
ubiquitin ligase that ubiquitinates and targets Axin for degradation (Callow et al., 2011; 
Zhang et al., 2011). RNF146 directly binds to poly(ADP-Ribose) and maintains low 
steady-state levels of Axin. In addition, the deubiquitinase ubiquitin-specific protease 34 
(USP34), catalyzed the deubiquitination of Axin and increases its steady-state levels in 
cells (Lui et al., 2011). Axin can also be stabilized by SUMOylation at its C-terminus 
which inhibits ubiquitination (Kim et al., 2008). Very recently, quantitative measurements 
of Axin protein levels in a large panel of mammalian cells suggest that Axin protein 
levels dynamically regulate the dynamics of Wnt/β-catenin signaling (Tan et al., 2012). 
These results combine to strongly suggest that regulating Axin protein levels is likely a 
major mechanism for regulating Wnt/β-catenin signaling. 
 The serine/threonine kinase GSK3 is a critical regulator of β-catenin degradation. 
GSK3 is widely expressed and plays a role in many different cellular processes (Forde 
and Dale, 2007) and inhibition of GSK3 activity is critical for activation of Wnt/β-catenin 
signaling in all paradigms. The Drosophila homolog of GSK3 is called shaggy, or zeste 
white 3 (Siegfried et al., 1992). Mammals have two distinct GSK3 genes, α and β, which 
are functionally redundant in Wnt/β-catenin signaling (Doble et al., 2007). GSK3 gets its 
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name from its initial discovery in glucose metabolism as a kinase for glycogen synthase 
(Embi et al., 1980). GSK3 usually requires its substrates to be phosphorylated (or 
primed), and thus often acts in concert with other kinases. GSK3 phosphorylates β-
catenin at Ser33, Ser37, and Thr41 and this phosphorylation is required for β-catenin 
degradation (Peifer et al., 1994; Yost et al., 1996). The structure of GSK3β contains an 
activation loop which gives it its priming mechanism and a bilobed topology including a 
β-sheet domain linked to a C-terminal α-helix domain (Dajani et al., 2001; Haar et al., 
2001). GSK3 activity is also regulated by an auto-inhibitory phosphorylation at Ser9 
which blocks access to the catalytic site (Cross et al., 1995; Dajani et al., 2001). GSK3 
phosphorylates other components of the Wnt/β-catenin pathway in addition to β-catenin 
(Rubinfeld et al., 1996; Willert et al., 1999; Zeng et al., 2005). 
 The priming kinase that acts in concert with GSK3 to regulate Wnt/β-catenin 
signaling is CK1α. The CK1 family of kinases has seven different paralogs encoded by 
7 distinct genes (α, β, γ1, γ2, γ3, δ, and ε) (Knippschild et al., 2005; Price, 2006). 
Similar to GSK3, CK1 is widely expressed and plays important roles in multiple cellular 
processes. All the CK1 family members have highly similar catalytic domains, but the 
length and sequence of their C-terminal non-catalytic domains differ significantly. CK1α, 
which contains a short (~24 amino acid) C-terminal domain, appears to be an outlier 
compared with the other family members, which contain longer C-terminal tails (~200 
amino acids). CK1α, γ, δ, and ε are thought to be positive regulators of the Wnt/β-
catenin pathway through phosphorylation of pathway components (Cong et al., 2004a; 
Gao et al., 2002; Kishida et al., 2001; Lee et al., 2001; Peters et al., 1999; Sakanaka et 
al., 1999; Swiatek et al., 2004; Yanagawa et al., 1995; Zeng et al., 2005; Zhang et al., 
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2006). Some CK1 paralogs are also thought to negatively regulate the Wnt/β-catenin 
pathway (Gao et al., 2002; Hammerlein et al., 2005; Kishida et al., 2001; Liu et al., 
2002; Rubinfeld et al., 2001). CK1α phosphorylates β-catenin at Ser45 and serves as 
the priming kinase for GSK3 at the destruction complex (Liu et al., 2002). Two separate 
genome-wide S2 Drosophila RNAi screens identified CKIα as critical to suppress Wnt/β-
catenin signaling, which is consistent with the dual kinase (priming kinase followed by 
processive kinase) model at the destruction complex (DasGupta et al., 2005; Lum et al., 
2003). Consistent with this model, CK1α activation by the antihelminthic drug pyrvinium 
strongly inhibited Wnt/β-catenin signaling by enhancing β-catenin phosphorylation and 
subsequent degradation (Thorne et al., 2010). 
 The 2843 amino acid scaffold protein APC, which is 310 kDa, acts as a negative 
regulator of Wnt/β-catenin signaling. The gene was first identified as a mutation site in 
FAP, a familial form of colon cancer (Kinzler et al., 1991). Like β-catenin, APC plays 
many cellular roles and which likely occur due to different subpopulations of protein 
(Faux et al., 2008). The C-terminal region of APC regulates microtubule dynamics in 
mitosis and cell migration through binding to EB1 and Discs large (Matsumine et al., 
1996; Su et al., 1995), though this function is independent of Wnt/β-catenin signaling 
(Nathke, 2006). APC binds to β-catenin and mutations in APC increased β-catenin 
protein levels in cancer cells (Rubinfeld et al., 1993; Su et al., 1993). APC also binds to 
GSK3 and Axin (Fagotto et al., 1999; Ikeda et al., 1998; Itoh et al., 1998; Rubinfeld et 
al., 1996). In fact, overexpression of the concentration-limiting protein Axin can 
compensate for the loss of APC (Lee et al., 2003). Additionally, a mutant form of Axin 
which can’t bind to APC can still inhibit Wnt/β-catenin signaling similarly to wild-type 
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Axin, suggesting that APC isn’t strictly required for Wnt/β-catenin inhibition in the 
presence of Axin (Hart et al., 1998). Unfortunately, APC’s precise mechanistic role in 
regulating Wnt/β-catenin signaling is still unclear and several different models have 
been proposed [reviewed in (Cadigan and Peifer, 2009; Chen et al., 2014b; MacDonald 
et al., 2009; Saito-Diaz et al., 2013)]. None of the proposed models are mutually 
exclusive and the strongest evidence supports APC’s role in regulating the steady state 
levels of cytoplasmic β-catenin, but it is very likely that APC plays multiple roles in the 
Wnt/β-catenin signaling pathway similar to several other components of the pathway 
(Chen et al., 2014b; Saito-Diaz et al., 2013). APC is regulated by post-translational 
modifications such as phosphorylation (Morin et al., 1997; Rubinfeld et al., 1996; Salic 
et al., 2000b) and ubiquitination. The E3 ubiquitin ligase that targets APC for 
degradation is still unknown. APC has, however, been linked to two deubiquitinases: the 
COP9 signalosome-associated deubiquitinase, USP15, which stabilizes APC and binds 
the destruction complex(Huang et al., 2009b), and Trabid, which removes K63-linked 
ubiquitin chains from APC and acts as a positive regulator of Wnt/β-catenin signaling 
(consistent with APC being a negative regulator of Wnt/β-catenin signaling) (Tran et al., 
2008). The mechanism of K63-linked ubiquitin chains regulating APC is still unknown. 
 All the previous destruction complex components mentioned have been 
reconstituted biochemically and are considered “core” components of the destruction 
complex. Some molecular studies have identified other components which may also be 
a part of the destruction complex which have not been confirmed biochemically. One of 
these is the heterotrimeric phosphatase PP2A. Multiple studies in multiple systems have 
implicated PP2A as both an activator of Wnt/β-catenin signaling (Hsu et al., 1999; 
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Ratcliffe et al., 2000; Willert et al., 1999) but also as an inhibitor of Wnt/β-catenin 
signaling (Gao et al., 2002; Li et al., 2001; Seeling et al., 1999). It is likely that PP2A, 
similar to GSK3 and CK1, can both activate and inhibit the Wnt/β-catenin in a context-
dependent manner. Presenilin 1 (PS1), the catalytic subunit of γ-secretase, a protease 
critical in both Notch signaling and Alzheimer’s disease, has been shown to inhibit 
Wnt/β-catenin signaling (Kang et al., 2002; Killick et al., 2001). PS1 appears to function 
as an alternative scaffold to Axin to promote GSK3 phosphorylation of β-catenin and 
uses Protein Kinase A (PKA) as a priming kinase instead of CK1 (Kang et al., 2002). 
Interestingly, PS1’s ability to promote β-catenin degradation is dependent on E-
cadherin, possibly linking the hypothesized two pools of β-catenin described earlier 
(Serban et al., 2005). Other proteins that have been implicated in regulating Wnt/β-
catenin signaling through the destruction complex include PP2C, PP1, Amer1/WTX, and 
the ankyrin protein Diversin (Itoh et al., 2009; Luo et al., 2007; Major et al., 2007; 
Schwarz-Romond et al., 2002; Strovel et al., 2000). 
 The β-catenin destruction complex is evolutionarily conserved from metazoans to 
humans. Even though it is traditionally considered a cytoplasmic complex, it has also 
been found functional in the nucleus (Bienz, 2002; Cong and Varmus, 2004; Sierra et 
al., 2006; Wiechens et al., 2004). The complex is constitutively active, with cells 
constantly cycling between synthesis and degradation of β-catenin. On the surface, this 
appears to be a futile cycle of synthesis and degradation. However, the existence of 
these futile cycles in signaling is thought to be critical for more diverse modulation of 
these signals, allowing for complex behaviors such as stochastic bistability (Samoilov et 
al., 2005). Axin nucleates the formation of the complex by binding to GSK3, CK1, and 
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APC. These interactions have already been mapped (Dajani et al., 2003; Sobrado et al., 
2005; Spink et al., 2000). β-catenin then binds to APC and Axin and enters the 
assembled complex. The kinetics of complex formation and whether it is stochastic or 
ordered are still unclear (Lee et al., 2003). The phosphorylation of Axin by GSK3 and of 
APC by CK1 and GSK3 increases their respective affinities for β-catenin (Ha et al., 
2004; Willert et al., 1999). The N-terminal region of β-catenin, upon Axin binding, 
becomes positioned for phosphorylation by CK1 at Ser45. This priming phosphorylation 
leads to subsequence successive phosphorylation at Thr41, Ser37, and Ser33 (Amit et 
al., 2002; Liu et al., 2002). Phosphorylated APC competes β-catenin off of Axin and thus 
allows for a new β-catenin molecule to bind Axin, continuing the cycle (Kimelman and 
Xu, 2006). APC phosphorylation may also prevent the action of PP2A on β-catenin (Su 
et al., 2008). GSK3 phosphorylation of β-catenin causes recognition of β-catenin by β-
TRCP, a recognition subunit of SCF complex E3 ubiquitin ligases (Jiang and Struhl, 
1998; Kitagawa et al., 1999; Lagna et al., 1999; Liu et al., 1999; Marikawa and Elinson, 
1998). SCFβ-TRCP directly catalyzes the polyubiquitination of β-catenin (via K48 linkages) 
and its subsequent proteasome-mediated degradation. This degradation ensures low 
steady state levels of β-catenin are maintained to prevent aberrant signal transduction. 
One recent study shows that the HECT domain E3 Ligase EDD ubiquitinates β-catenin 
and prevents its degradation (Hay-Koren et al., 2010). The full physiological significance 
of EDD ubiquitination still needs to be elucidated.  
 The constitutively active β-catenin destruction complex becomes inhibited upon 
Wnt binding and receptor activation and β-catenin protein levels increase. The actual 
mechanistic details are still being investigated but the central unifying principle in all 
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proposed models is the inhibition of GSK3 enzymatic activity. These models are as 
follows: 1) Dissociation of the destruction complex upon Wnt activation, 2) Inhibitory 
phosphorylation of GSK3 at Ser9, 3) LRP6 Binding and direct inhibition of GSK3, 4) 
Axin degradation upon Wnt activation which prevents formation of the complex and 5) 
global inhibition of GSK3 through sequestration into multi-vesicular bodies (MVBs). The 
details of each individual model are reviewed in [(Saito-Diaz et al., 2013) and (Chen et 
al., 2014b)]. The inhibition of GSK3 and thus the β-catenin destruction complex allows 
for the accumulation of β-catenin in the cytoplasm where it eventually translocates to 
the nucleus and activates a Wnt/β-catenin specific transcriptional response. As 
mentioned earlier, β-catenin serves as the main effector of the pathway and transduces 
the signal into the nucleus. 
Wnt/β-catenin signaling: Transcriptional activation 
β-catenin accumulation in the cytoplasm, and subsequently the nucleus, was 
widely considered the driving force of Wnt/βcatenin signaling. Contrary to the prevailing 
model, recent studies have shown that the fold change, rather than the absolute 
concentration increase, of β-catenin activates Wnt/β-catenin signaling (Goentoro and 
Kirschner, 2009). The same group also showed that an approximately 2 fold change in 
β-catenin levels is sufficient to activate Wnt/β-catenin signaling (Goentoro et al., 2009). 
β-catenin does not contain any classical nuclear localization signals (NLS) or nuclear 
export signals (NES) and how its localization is regulated is still under intense 
investigation. Once it gets into the nucleus, β-catenin interacts and acts as a co-factor 
with the TCF/LEF family of transcription factors which are critical for Wnt/β-catenin 
signal transduction (Behrens et al., 1996; Molenaar et al., 1996). TCF, in the absence of 
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β-catenin, interacts with the co-repressor Groucho/transduction-like enhancer 
(Gro/TLE1-3) to repress gene transcription. TCF binds to the DNA at a Wnt-responsive 
element (WRE), of which there are over 6000 in a colon cancer cell line that regulate 
the transcription of 300-400 genes (Hatzis et al., 2008). These TCF proteins are 
regulated by post-translational modifications such as phosphorylation (Hammerlein et 
al., 2005; Hikasa et al., 2010; Hikasa and Sokol, 2011; Ishitani et al., 2003; Ishitani et 
al., 1999; Lee et al., 2001; Lo et al., 2004; Smit et al., 2004) and ubiquitination (Yamada 
et al., 2006). There is also evidence of a deubiquitinase USP4 regulating TCF4 (Zhao et 
al., 2009). In the classical model of Wnt/β-catenin signaling, the displacement of 
Gro/TLE by β-catenin causes TCF/LEF to switch from a repressor to a transcriptional 
activator. This was originally thought to be due to direct displacement (Daniels and 
Weis, 2005), but recent studies show that the X-linked inhibitor of apoptosis (XIAP) 
monoubiquitinates Gro/TLE and decreases its affinity for TCF/LEF, thus allowing β-
catenin to bind TCF/LEF (Hanson et al., 2012). 
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Figure 1.3. Nuclear TCF/β-catenin transcriptional complexes. Upon Wnt/β-catenin signaling, 
DNA-bound TCF/β-catenin recruits many other transcriptional complexes to Wnt target genes. 
Dotted lines represent interactions between the transcriptional complexes and β-catenin. 
During active Wnt target gene transcription, the co-repressor Gro/TLE cycles on and off of 
β-catenin in an XIAP-dependent manner with the other transcriptional complexes. Gro/TLE, 
Groucho/transducin-like enhancer of split [Figure from (Saito-Diaz et al., 2013)]. 
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β-catenin binds to the nuclear transcriptional co-factors BCL9 and Pygopus 
(Pygo) to mediate Wnt/β-catenin pathway-specific transcription (Figure 1.3) (Belenkaya 
et al., 2002; Parker et al., 2002; Thompson et al., 2002). Pygo, BCL9, TCF, and β-
catenin represent a core transcriptional complex required for Wnt/β-catenin transcription 
(Fiedler et al., 2008; Schwab et al., 2007; Sustmann et al., 2008). In addition, β-catenin 
also interacts with multiple proteins involved in chromatin remodeling (Mosimann et al., 
2009; Willert and Jones, 2006). Wnt/β-catenin signaling requires responses at the 
plasma membrane, in the cytoplasm via the destruction complex, and in the nucleus via 
the β-catenin transcriptional complex. The Notch signaling pathway, the other pathway I 
will be describing, shares many features in common with the Wnt/β-catenin pathway, 
including a role for ligand-receptor interactions at the membrane, cytoplasmic regulatory 
events on the primary effector of the pathway, and required transcriptional complex 
formation in the nucleus leading to transcriptional activation. In fact, the Wnt/β-catenin 
and the Notch pathway have extensive cross-talk and there is evidence that activation 
of one pathway can regulate the activation of the other pathway. These will be 
discussed later on in this chapter. 
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Historical Significance: Notch Signaling in Development and Disease 
The canonical Notch signaling pathway is a highly conserved developmental 
signaling pathway critical in cell fate determination through lateral inhibition, 
differentiation, proliferation, cell death, and neuronal development in developing 
embryos and stem cell and tissue maintenance in adults. The Notch pathway is named 
for its family of single transmembrane Notch receptors. The Notch gene was first 
identified by John Dexter in the lab of Thomas Hunt Morgan who noticed a notched 
wing phenotype in Drosophila melanogaster (Dexter, 1914). A few short years later, 
Morgan identified the mutant alleles (Mohr, 1919; Morgan, 1917; Morgan and Bridges, 
1916). Details about the Notch pathway can be found in several excellent reviews 
[reviewed in (Fortini, 2012; Kopan, 2010)]. 
 The following decades yielded genetic data indicating that the Notch locus was 
X-linked and had extremely complex allelic interactions [reviewed in (Artavanis-
Tsakonas and Muskavitch, 2010)] leading to multiple speculative hypotheses on its 
biochemical nature (Foster, 1973; Thorig et al., 1981a; Thorig et al., 1981b). The Notch 
gene was identified as a “neurogenic” mutation in Drosophila in the 1980s, linking the 
mutation to developmental phenotypes (Lehmann et al., 1983). Further confirming the 
importance of Notch signaling in development, Nusslein-Volhard and Weischaus 
conducted a series of Drosophila mutagenesis screens for embryonic phenotypes 
yielded six loci that were later identified as core components in the Notch signaling 
pathway (Nüsslein-Volhard et al., 1984; Nusslein-Volhard and Wieschaus, 1980). In the 
mid-1980s, Spyros Artavanis-Tsakanos and Michael Young independently cloned the 
Notch receptor and identified it as a single-pass transmembrane receptor and attributed 
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its wing-notching phenotype to gene haploinsufficiency (Artavanis-Tsakonas et al., 
1983; Kidd et al., 1986; Kidd et al., 1983; Wharton et al., 1985). Notch was 
subsequently cloned in other organisms, including C. elegans and Xenopus (Austin and 
Kimble, 1987; Coffman et al., 1990; Greenwald et al., 1987). These initial studies 
provided insight into the role of Notch signaling in multiple fields of biology, including 
developmental and stem cell biology, neuroscience, and cancer biology (Fortini et al., 
1993).  
 The Notch locus in Drosophila and was shown to be both pleiotropic and 
haploinsufficient. Notch loss-of-function mutations lead to a change in cell fate from 
dermoblasts to neuroblasts in Drosophila embryos. One of the major insights from the 
experiments in Drosophila embryos was the apparent necessity for the Notch-sending 
and Notch-receiving cells to be adjacent to each other (Doe and Goodman, 1985; 
Greenspan, 1990). Further studies in other tissues and other animals confirmed Notch’s 
broad pleiotropic effect and its requirement in signaling between neighboring cells. 
Proper regulation of Notch pathway is critical in nearly all cell fate decisions made 
between neighboring cells and this pleiotropic effect can be extended to multiple 
developmental processes including differentiation, proliferation, and apoptosis. The 
particular developmental process affected by Notch affects in a specific tissue is likely 
context-dependent, but it is clear that very tight regulation of Notch activity is critical for 
determining cell fates in adjacent cells. The Notch pathway is very sensitive to dosage 
effects, as loss-of-function and gain-of function mutations in Notch can often lead to the 
“same phenotype”. Notch signaling has also been associated with stem cell 
maintenance and proliferation (Austin and Kimble, 1987). Stem cell maintenance and 
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differentiation is dependent on cell-cell communication between stem cells and their 
surrounding environment, or niche, and as mentioned above, Notch is critical for 
processes that require cell-cell communication. The list of tissue-specific stem cells 
regulated by proper Notch signaling is expanding rapidly (Liu et al., 2010).  In fact, many 
Notch reviewers have termed Notch a “stem cell pathway” because of its extensive 
involvement in stem cell biology (Brack et al., 2008; Casali and Batlle, 2009; Dreesen 
and Brivanlou, 2007; Farnie and Clarke, 2006). 
 Developmental pathways are often misregulated in cancers due to their critical 
roles in cellular growth, differentiation, proliferation, and cell-cell signaling. The Notch 
pathway, similar to the Wnt pathway, is misregulated in many types of cancers. Perhaps 
the most well-characterized link between the Notch signaling pathway and 
tumorigenesis is from studies on the molecular mechanisms underlying T-cell acute 
lymphoblastic leukemia (T-ALL). Gain-of-function mutations in the Notch pathway were 
first identified in cancer in the early 1990s (Ellisen et al., 1991; Gallahan and Callahan, 
1997; Gallahan et al., 1987; Jhappan et al., 1992; Reynolds et al., 1987). These were 
the first human homologs of the Drosophila Notch gene and they were identified as a 
chromosomal translocation within T-ALL patients (Ellisen et al., 1991; Reynolds et al., 
1987). In the original study, four out of the 40 T-ALL patients had this mutation, that 
results in a dominant active, ligand-independent NOTCH1 receptor, which was termed 
TAN1 for translocation-associated Notch homolog. This discovery was the first direct 
link between Notch signaling and human cancer. A few years later, experiments using 
murine bone marrow (BM) reconstitution showed that TAN1 was causative for disease 
development. Mice transplanted with TAN1-expressing BM progenitors developed T cell 
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neoplasms two weeks after BM transplantation (Pear et al., 1996). This evidence was 
supported by in vitro studies and in vivo studies (Capobianco et al., 1997; Girard et al., 
1996). It wasn’t until the early 2000s, however, when Aster and colleagues identified 
activating mutations in NOTCH1 were present in over 50% of all T-ALL patient cases 
(Weng et al., 2004). NOTCH1 mutations were later identified in many other types of 
hematopoietic tumors as well as solid tumors [reviewed in (Ntziachristos et al., 2014; 
South et al., 2012). Interestingly, the Notch pathway has both oncogenic and tumor 
suppressive roles in human cancers in a context-dependent manner , including breast 
cancer, lung cancer, skin cancer, liver cancer, colorectal cancer, glioblastoma, AML, 
CLL, and others (Balint et al., 2005; Fabbri et al., 2011; Klinakis et al., 2011; Licciulli et 
al., 2013; Qi et al., 2003; Sun et al., 2014; Villanueva et al., 2012; Wang et al., 2011; 
Weng et al., 2004). Unsurprisingly, Notch signaling is also often misregulated in 
congenital developmental diseases consistent with its role in progenitor cell regulation 
(Eldadah et al., 2001; Garg et al., 2005; Joutel et al., 1996; Li et al., 1997; McDaniell et 
al., 2006; Oda et al., 1997; Simpson et al., 2011; Sparrow et al., 2006). Due to the 
Notch pathway’s critical roles in both development and disease, understanding the 
molecular mechanisms governing Notch signaling is critical for our understanding of the 
pathophysiological effects of Notch pathway misregulation and for designing 
therapeutics against the Notch signaling pathway. Unfortunately, many of the molecular 
mechanisms of the Notch pathway have not been fully elucidated biochemically and 
many of the present therapeutics for the Notch pathway have proven unsuccessful 
when taken to clinical trials due to non-therapeutic Notch-mediated effects in the GI 
tract and the formation of skin cancers.  
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The Current Model of the Notch Signaling pathway 
The most widely characterized pathway initiated by the classical Notch-ligand 
interaction is generally referred to as “canonical” Notch signaling. Other Notch-
dependent signaling pathways can occur independently of the processes and molecules 
required for the classical Notch pathway or through cross-talk with other pathways (such 
as the Wnt/β-catenin pathway). These other Notch pathways are referred to as “non-
canonical” Notch signaling. Details on non-canonical Notch signaling has been reviewed 
elsewhere [reviewed in (D'Souza et al., 2010; Heitzler, 2010)] and is outside the scope 
of this document. Unless specifically referred to as non-canonical, all references to 
Notch signaling refer to canonical Notch signaling.  
The Notch signaling pathway, at its core, results in the generation and 
translocation of the Notch Intracellular Domain (NICD) into the nucleus to activate a 
Notch-specific transcriptional program. In the core Notch signaling pathway, the Notch 
transmembrane receptor (existing as a heterodimer) on a signal-receiving cell interacts 
extracellularly with the canonical Notch pathway ligands Delta/Serrate/Lag-2 (DSL) on a 
neighboring signal-sending cell. This ligand-receptor interaction initiates an ADAM 10 
metalloprotease proteolysis (S2) which allows the remaining Notch receptor to be 
proteolyzed by the ubiquitously expressed protease γ-secretase (S3). This γ-secretase 
proteolysis generates the release of NICD. The S3 proteolysis can occur at the plasma 
membrane or in the early endosome, as γ-secretase is present at both cellular 
compartments. Recent studies suggest that γ-secretase is more active at the low PH of 
the early endosome. The stability of the NICD is regulated but very little is known about 
how NICD stability is regulated. Finally, the NICD translocates to the nucleus and binds 
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to the transcriptional co-activator C-promoter binding factor1 [CBF1 (also known as 
recombination signal binding protein for immunoglobulin kappa J region (RBPJ-κ)]. In 
Drosophila, CBF1 is known as Suppressor of Hairless (Su(H)) and in C. elegans, 
Longevity-assurance gene-1 (LAG-1). Collectively, this transcriptional co-factor is called 
CSL (for CBF1/Su(H)/LAG-1). The transcriptional complex, consisting of NICD, MAM, 
and CSL is thought to activate a canonical Notch-mediated transcriptional program 
[Figure 1.4, adapted from (Andersson et al., 2011)].  
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Figure 1.4. The core Notch pathway contains a limited set of components that form the signal 
transmitting chain in the pathway: a ligand (light blue), a Notch receptor (green and red) and the 
transcription factor CSL (green). In addition, some components (Furin (not shown), ADAM 10 
secretase (green lightning bolt), γ-secretase (yellow lightning bolt) and MAML (blue oval)) are 
not part of conveying the signal but are nevertheless crucial for allowing the signal to be 
transmitted from one step to the next in the pathway. Briefly, the Notch receptor is synthesized 
as a single transmembrane receptor that is Furin cleaved to yield a bipartite heterodimeric 
Notch receptor, which is presented on the cell surface of a ‘receptor-expressing’ cell. This 
receptor can be activated at the plasma membrane by binding to Notch ligands on ‘ligand-
expressing’ cells. This leads to the removal of the extracellular domain of Notch, which is then 
targeted for lysosomal degradation. The remaining portion of the receptor, termed the Notch 
extracellular truncated (NEXT) domain, undergoes sequential cleavage by ADAM secretases 
and γ-secretase as it becomes endocytosed, yielding the Notch intracellular domain (NICD). 
NICD then translocates to the nucleus where it binds the DNA-binding protein CSL 
(CBF1/Suppressor of Hairless/LAG-1) and activates the transcription of Notch target genes 
[adapted from (Andersson et al., 2011)]. 
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The Notch pathway is very unusual among signal transduction pathways 
because there is no evidence of an amplification step in between receptor activation 
and transcriptional activation. The Notch receptor also serves as the transcriptional co-
activator rather than acting through another effector protein. Interestingly, each 
activated Notch receptor generates one NICD and is consumed during the signal 
transduction process, making the Notch pathway particularly sensitive to gene dosage. 
The core Notch signal transduction pathway can be broken down into three distinct 
molecular events: 1) Notch surface receptor activation, 2) Regulation of the NICD, and 
3) Activation of a Notch-specific nuclear transcriptional complex by NICD. The next 
sections of this document will describe each of these steps in greater detail as well as 
how the non-core components regulate the Notch pathway.  
 
Notch Signaling: Surface Receptor Activation 
 The Notch receptor is a family of single pass trans-membrane receptors that is 
critical in cell-cell signaling. In mammals, there are 4 Notch receptors (called Notch1-4) 
[reviewed in (D'Souza et al., 2010)]. All of the mammalian Notch receptors share 
structural similarities (Figure 1.5). These receptors contain many of the same structural 
motifs and are likely to be regulated in a similar fashion. These Notch receptors bind to 
the cell surface expressed Delta-Serrate-LAG-2 ligands (Jagged1, Jagged 2, Delta-like 
1 (Dll1), Delta-like 3 (Dll3), and Delta-like 4 (Dll4)) (Figure 1.6).  
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Figure 1.5. The structural conservation of mammalian Notch receptors. Diagrammatic 
representation of the four known mammalian receptors. EGF: epidermal growth factor; HD: 
heterodimerization domain; ICN: intracellular domain; LNR: cysteine-rich LNR repeats; TM: 
transmembrane domain; RAM: RAM domain; NLS: nuclear localizing signals; ANK: ankyrin 
repeat domain; NCR: cysteine response region; TAD: transactivation domain; PEST: region rich 
in proline (P), glutamine (E), serine (S) and threonine (T) residues [adapted from (Pancewicz 
and Nicot, 2011)]. 
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The Notch receptors are translated as pre-proproteins and are cleaved by a 
Furin-like protease (S1) in the trans-Golgi network and then trafficked to the plasma 
membrane. This cleaved heterodimer is prsented on the cell surface composed of a 
large extracellular domain non-covalently linked to the intracellular domain (Blaumueller 
et al., 1997; Logeat et al., 1998). The extracellular domain of all Notch receptors 
contains different numbers of epidermal growth-factor-like repeats (EGF-like) (36 for 
Notch1 and Notch2, 34 for Notch3, and 29 for Notch4) which are critical in ligand-
receptor binding (Fig 1.5). A subset of the EGF-like repeats are calcium-binding EGF-
like repeats (cbEGF), that are required for ligand binding. Genetic experiments in 
Drosophila and cell aggregation assays have identified EGF-like repeats 11 and 12 on 
Notch as the major ligand-binding site. This region binds in a calcium-dependent 
manner but does not have full functionality, suggesting that other EGF-like repeats likely 
also contribute to ligand binding (Rebay et al., 1993; Rebay et al., 1991). Structural 
studies later indicated that EGF-like 12, via an interaction between an aromatic residue 
(Y/F/W) and a both a hydrophobic residue (I/L/V/P) with a glycine is the critical binding 
pocket for the Notch ligand in a calcium-dependent manner (Cordle et al., 2008; 
Hambleton et al., 2004). Additionally, the relative strength of receptor-ligand binding can 
be modulated by post-translational modifications of these EGF-like repeats. O-
glycosylation of the EGF-like repeats, including the addition of O-fucose and O-glucose 
on EGF-like repeat 12, primes the Notch receptor for further modification (Stanley and 
Okajima, 2010). The addition of O-fucose is mediated by O-fucosyltransferase 1 
(Pofut1) and is not directly required for Notch signaling (Okajima et al., 2008) but is 
required for subsequent glycosylation of Notch receptors by the glycosyltransferase 
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Fringe proteins (Lunatic Fringe, Manic Fringe, and Radical Fringe in mammals). The 
Fringe proteins add N-acetylglucosamine (GlcNAc) sugars to the O-fucose moiety and 
modulate ligand-receptor binding by increasing the affinity for Delta-like and decreasing 
affinity for Serrate-like ligands (Hicks et al., 2000; Kato et al., 2010; Okajima et al., 
2003). The expression domains of Fringe genes often coincides with either Delta or 
Jagged but not both and this expression often leads to active Notch signaling only at the 
margins in between the Delta and Jagged expressed regions (Irvine and Wieschaus, 
1994; Marklund et al., 2010; Wu and Rao, 1999). A substitution in the O-fucose site on 
EGF-like repeat 12 led to decreased Notch signaling (Ge and Stanley, 2008; Lei et al., 
2003). Notch can also be glycosylated by the glycosyltransferase Rumi (Poglut1) and 
this glycosylation is required for Notch signaling (Acar et al., 2008; Fernandez-Valdivia 
et al., 2011). Two enzymes of the glycosyltransferase 8 family also glycosylate the 
Notch receptor (Sethi et al., 2010). Recently, a secreted Fringe protein, chondroitin 
sulfate synthase 1(CHSY1) was identified as a negative regulator of Notch signaling 
(Tian et al., 2010). It is clear that glycosylation plays a critical role in regulating Notch 
signaling through regulation of receptor-ligand binding, but further structural, molecular, 
and biochemical studies are still needed to identify the individual contributions of each 
glycosylation event.  
The extracellular domain of the Notch receptor also contains three LIN-12-Notch 
(LNR) repeats and a hydrophobic region known to mediate heterodimerization (HD). 
Those two regions, along with the S1 cleavage site (Furin-mediated) and the S2 
cleavage site (ADAM 10/17 metalloprotease-mediated) comprise the negative 
regulatory region (NRR) of the Notch receptor. The NRR normally autoinhibits the S2 
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cleavage by sterically blocking access to the S2 cleavage site through a hydrophobic 
core (Gordon et al., 2009). Mutations in the NRR which mutate the hydrophobic core 
and cause ligand-independent Notch receptor activation are the most common mutation 
in T-ALL, a Notch-mediated cancer (Malecki et al., 2006; Weng et al., 2004). The 
autoinhibitory conformation of the NRR is calcium-dependent, as depletion of calcium 
activates the receptor (Rand et al., 2000). The autoinhibitory effect of the NRR is 
relieved by a conformational change in the Notch heterodimer, through ligand 
endocytosis in response to ligand-receptor binding.   
The 5 canonical mammalian Notch ligands (Jagged1, Jagged2, Dll1, Dll3, Dll4) 
can be divided into two general classes, a Delta/Delta-like family and a Serrate/Jagged 
family. All of the ligands have a Notch-binding site within a DSL domain as well as N-
terminal domain and EGF-like repeats. The Jagged family of ligands also contains a 
cysteine rich domain (CRD) and Jagged1, Jagged2, and Dll1 all contain two Delta and 
OSM-11-like proteins (DOS) domains (Figure 1.6).  
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Figure 1.6. Domain organization of mammalian Notch ligands. Five mammalian ligands are 
classified into two categories, Delta-like (Dll1, Dll3, Dll4) and Serrate-like (Jagged1, Jagged2), 
based on structural homology to the two Drosophila ligands, Delta and Serrate. All Notch 
ligands have an N-terminal domain, a DSL (Delta/Serrate/LAG-2) domain and EGF-like repeats. 
Jagged1 and Jagged2 contain a cysteine-rich domain, whereas Jagged1, Jagged2 and Dll1 
have two DOS (Delta and OSM-11-like proteins) domains located immediately following the 
DSL domain. DSL ligands are transmembrane proteins of which the extracellular domain 
contains a characteristic number of EGF-like repeats and a cysteine rich N-terminal DSL 
domain. The DSL domain is a conserved motif found in all DSL ligands and required for their 
interaction with Notch [adapted from (Kume, 2012)]. 
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To date, there is little evidence of differences in signaling output between 
different receptor-ligand combinations with the exception of Dll3, which lacks a DOS 
domain and is the most structurally divergent of the Notch ligands (Dunwoodie et al., 
1997). Dll3 is incapable of activating Notch receptors from a neighboring cell (Ladi et al., 
2005) and is rarely present on the cell surface (Chapman et al., 2011; Geffers et al., 
2007). Because there are differences in signaling output between different receptor-
ligand combinations, there must be some mechanism for establishing the specificity of 
Notch signaling. One way that Notch provides specificity is through restricting the 
distribution of specific ligands and receptors to specific intracellular compartments. An 
example of this phenomenon is in Drosophila sensory organ development, in which 
Delta is specifically recycled during asymmetric cell division and sorted exclusively into 
cells adjacent to Notch-expressing cells (Emery et al., 2005; Jafar-Nejad et al., 2005). 
Notch ligands can also be specifically localized to cellular extensions such as filopodia, 
which can activate signaling at distances larger than typical cell-cell distances (Cohen et 
al., 2010b; De Joussineau et al., 2003). There is also some evidence that cell motility 
dynamics can affect the specificity of Notch signaling (Del Bene et al., 2008).  
Because most cells express both canonical Notch pathway ligands and Notch 
receptors at their cell surface, the proper directionality of Notch signaling must be firmly 
established. One way that directionality of Notch signaling is established is through cis-
inhibition, in which ligands that activate receptors on neighboring cells (trans-activation), 
inhibit receptors expressed on the same cell surface (de Celis and Bray, 1997; del 
Alamo et al., 2011; Micchelli et al., 1997; Miller et al., 2009; Sprinzak et al., 2010). Cis-
inhibition downregulates the Notch receptor at the cell surface (Matsuda and Chitnis, 
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2009) but this does not always occur (Fiuza et al., 2010), and cis- inhibition also cell-
autonomously downregulates Notch target genes. As mentioned earlier, Dll3 likely 
serves exclusively as a cis-inhibiting ligand and cannot activate receptors in trans (Ladi 
et al., 2005). Some recent reports have started to unravel how the individual ligands can 
affect trans-activation and cis-inhibition. The extracellular DSL-EGF-like repeat 3 
domain of Serrate is critical in both trans-activation and cis-inhibition (Cordle et al., 
2008) and mutations in the intracellular domain of Serrate affect trans-activation but not 
cis-inhibition (Glittenberg et al., 2006). Additionally, reports have shown that Notch 
ligand and receptor intracellular domains (ICDs) display competitive interactions. NICD 
can suppress the antiproliferative effect of Delta ICD in endothelial cells (Kolev et al., 
2005). Conversely, Jag1 ICD suppresses NICD-induced transcription in COS cells 
(LaVoie and Selkoe, 2003). Interestingly, the signal-sending cell can also undergo cis-
inhibition in which the Notch receptor inhibits the ligand on the same cell surface 
(Becam et al., 2010). Also, many of the non-canonical ligands of Notch signaling are 
capable of cis-inhibition. One specific example is Delta-like homolog 1/2 (Dlk1/2), which 
competes with trans-presented canonical ligands to bind Notch receptors (Baladron et 
al., 2005). A model for trans-activation vs. cis-inhibition was proposed in which trans-
activation occurs in a graded manner in response to increasing concentrations of ligand, 
while cis-inactivation occurs with a sharp threshold of Notch ligand co-expression, 
potentially leading to a bistable switch which generates mutually exclusive sending and 
receiving states (Sprinzak et al., 2010) .This model still needs to be further tested in 
vivo.  
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Upon ligand-receptor binding, the ADAM metalloproteases cleave the Notch 
receptor (whose autoinhibitory NRR has been removed) in the extracellular space 
between the two cells at the S2 cleavage site. Different ADAM proteases have been 
implicated in Notch S2 cleavage (Brou et al., 2000; Canault et al., 2010; Tian et al., 
2008; Tousseyn et al., 2009; van Tetering et al., 2009), and one recent study claims that 
specific ADAM proteases cleave Notch in a ligand-dependent  or  –independent manner 
(Bozkulak and Weinmaster, 2009). The structural aspects of S2 cleavage were 
reviewed recently [reviewed in (Kovall and Blacklow, 2010)]. The S2 cleavage is often 
considered the limiting regulatory step in Notch receptor activation. 
The S2 cleavage creates the membrane-tethered Notch extracellular truncation 
(NEXT) region. The NEXT immediately becomes a substrate for regulated 
transmembrane cleavage by the γ-secretase complex at the S3 cleavage site. γ-
secretase is a multi-subunit protease complex containing presenilin, nicastrin, presenilin 
enhancer 2 (Pen2) and anterior pharynx-defective 1 (Aph1) (Jorissen and De Strooper, 
2010). γ-secretase is ubiquitously expressed and cleaves transmembrane proteins at 
residues within the transmembrane domain. Although the original model for S3 
cleavage suggested that it follows constitutively after the S2 cleavage, recent studies 
suggest that the activity of γ-secretase is regulated, both with regard to cleavage 
efficacy and the position of the cleavage site in the receptor. γ-secretase complexes 
containing different presenilin subunits (PS1 or PS2) have different cleavage 
preferences for amyloid precursor protein (APP), although how this difference affects 
Notch signaling is yet to be determined (Jorissen and De Strooper, 2010). One report 
suggests that nicastrin is not required for γ-secretase-mediated processing of Notch, but 
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important for the stability of the γ-secretase complex (Zhao et al., 2010). Other proteins 
that regulate the function of the γ-secretase complex include CD147 (also known as 
BSG), transmembrane protein 21 (Tm21, also known as Tmed10) and γ-secretase 
activating protein (GSAP also known as Pion) (Chen et al., 2006; He et al., 2010; Zhou 
et al., 2006). The actual effect of these regulatory proteins on Notch receptor processing 
still needs to be investigated. The S3 cleavage has been shown heterogeneous in terms 
of the cleavage site. NICD fragments generated by S3 cleavage can have either an N-
terminal valine (Val) or an N-terminal serine/leucine (Ser/Leu) and the Ser/Leu-NICD 
fragments are less stable than Val-NICD fragments (Tagami et al., 2008). Notch 
processing is also regulated by the estrogen receptor (ER), and inhibition of ER activity 
by tamoxifen increases Notch activity (Rizzo et al., 2008). Neuronal activity can also 
enhance Notch processing through the protein activity-regulated cytoskeleton-
associated protein (Arc)/activity-regulated gene 3.1 protein homolog (Arg3.1) (Alberi et 
al., 2011), giving another way to modulate Notch signaling.  
 
Notch Signaling: Regulation of the NICD 
It is not clear whether the S3 cleavage occurs at the cell surface or in the early 
endosome upon endocytosis of the receptor. Endocytosis of the Notch receptor is 
thought to be a critical step in transduction of the Notch signal. Notch initially binds to 
the γ-secretase complex at the cell surface (Hansson et al., 2005), but there is evidence 
that the majority of cleavage occurs after internalization of the receptor by endocytosis 
(Vaccari et al., 2008) as well as evidence of cleavage at the membrane (Kaether et al., 
2006; Sorensen and Conner, 2010; Tarassishin et al., 2004). It is likely that the 
localization of Notch cleavage is context-dependent and serves as another method of 
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modulating Notch signaling (Tagami et al., 2008). Notch receptor endocytosis requires 
monoubiquitination of the receptor at lysine 1749 (Gupta-Rossi et al., 2004). This 
monoubiquitination is followed by deubiquitination by eIF3f, a subunit of translation 
initiation factor E74-like factor 3 (EIf3), which is required for Notch to be processed by γ-
secretase (Moretti et al., 2010). The Notch receptor is regulated by the putative E3 
ubiquitin ligase Deltex, which has been implicated in the regulation of Notch processing 
and internalization (Diederich et al., 1994; Hori et al., 2004; Matsuno et al., 1995; Wilkin 
et al., 2008; Yamada et al., 2011). Deltex also may serve as a bridge between eIF3f and 
Notch in early endosomes (Moretti et al., 2010). The exact role of Deltex in the Notch 
pathway is still in question. It has mostly been described as a positive regulator of Notch 
signaling (Fuwa et al., 2006; Matsuno et al., 1995; Matsuno et al., 2002; Wilkin et al., 
2008), but several reports have also described it as a negative regulator of Notch 
signaling (Mukherjee et al., 2005; Sestan et al., 1999). Additionally, Deltex may not be 
required for Notch signaling in all developmental contexts (Fuwa et al., 2006). Loss of 
Deltex function does not seem to severely affect T-cell development, a Notch-
dependent process, in the mouse (Lehar and Bevan, 2006). Recently, it has been 
hypothesized that canonical Notch signaling and Deltex-activated Notch signaling are 
two distinct events activated in different endocytic compartments (Yamada et al., 2011). 
Another regulator of Notch signaling is the endocytic adaptor protein Numb. 
Numb, which is found in both Drosophila and vertebrates, and Numb-like, the 
mammalian homolog of Numb, act as suppressors of Notch signaling (Rhyu et al., 1994; 
Uemura et al., 1989; Zhong et al., 1997). Numb acts mechanistically by recruiting the 
E3 ubiquitin ligase itchy (Itch), the mammalian homolog of Drosophila Suppressor of 
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deltex [Su(dx)], to promote degradation of the Notch receptor (Beres et al., 2011) and to 
regulate post-endocytic sorting for Notch1 (McGill et al., 2009). Numb differentially 
regulates the different Notch receptors and a recent report shows that Numb can 
negatively regulate Notch1 and Notch2 but not Notch3 during myogenic differentiation 
(Beres et al., 2011). There are 6 alternatively spliced NUMB isoforms in humans. The 
two most recently identified ones, NUMB5 and NUMB6, are less potent Notch 
antagonists than the others (Karaczyn et al., 2010), though it is possible that the 
observed difference is due to Numb’s interaction with other signaling pathway 
components such as p53 and Gli1, a Hedgehog pathway effector (Colaluca et al., 2008; 
Di Marcotullio et al., 2006). Sanpodo, a Drosophila transmembrane protein with no 
known vertebrate homolog, also regulates Notch signaling by associating with Notch 
and Numb during asymmetric cell division (O'Connor-Giles and Skeath, 2003). Sanpodo 
agonizes Notch signaling in the absence of Numb but inhibits Notch signaling in the 
presence of Numb (Babaoglan et al., 2009). These data suggest that the relationship 
between Notch and Numb may not be unidirectional as Notch may regulate Numb as 
well. For example, high levels of Notch reduce Numb and Numb-like protein levels in 
the developing chick CNs and in cultured cells (Chapman et al., 2006). In addition, 
Notch controls the expression of Numb by upregulating it in cells that not did inherit 
Numb during cell division but require Numb for Notch repression (Rebeiz et al., 2011). 
Intracellular trafficking has been shown to regulate Notch signaling after its 
internalization. Ectopic ligand-independent Notch signaling is activated when the sorting 
of Notch from early endocytic vesicle to multivesicular bodies (MVBs) or lysosomal 
compartments is defective. This is shown in endosomal sorting complex required for 
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transport (ESCRT) and lethal giant discs [lgd; also known as l(2)gdl] mutants (Childress 
et al., 2006; Jaekel and Klein, 2006; Vaccari et al., 2008). Drosophila sensory organ 
precursors (SOPs) traffic Notch via a specialized endocytic route which generates 
differential Notch signaling in the resulting daughter cells. This trafficking is mediated by 
Smad anchor for receptor activation (SARA) endosomes, which segregate into one of 
the two daughter cells during asymmetric SOP cell division. Delta and Notch are both 
internalized into SARA endosomes and asymmetrically localized to one of the cells 
during SOP mitosis, resulting in the ligand-dependent appearance of NICD in only that 
cell (Coumailleau et al., 2009). SARA itself is not required for this process. 
The Notch intracellular domain serves as the major effector of the canonical 
Notch signaling pathway. All Notch receptors contain the RAM23 domain (which 
mediate interactions with CSL) and seven Ankyrin/CDC10 repeats (ANK), necessary for 
protein-protein interactions. In addition, Notch receptors 1-3 contain two nuclear 
localization signals (NLS) compared to one NLS in Notch4. The NLS is necessary to 
target the intracellular domain to the nucleus where the transcriptional activation domain 
(TAD) activates downstream events. Notch3 and Notch4 contain no identifiable TAD 
domain and weakly activate transcription. All four Notch receptors contain a C-terminal 
Pro-Glu-Ser-Thr rich domain (PEST) for degradation (Kovall and Blacklow, 2010). It has 
become increasingly clear in recent years that the NICD is subject to a large number of 
post-translational modifications which have the potential to modulate Notch signaling.  
NICD undergoes multiple post-translational modifications, including 
phosphorylation, ubiquitination, hydroxylation, and acetylation [Figure 1.7; adapted from 
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(Andersson et al., 2011)]. Below, I will describe, separately, the regulation of each type 
of post-translational modification on NICD and their impact on Notch signaling. 
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Figure 1.7. The NICD undergoes multiple post-translational modifications. The NICD is 
composed of several domains (JM, RAM, ANK, TAD and PEST), two nuclear localization 
signals and several ankyrin repeats. These various domains and motifs can be modified by 
phosphorylation, hydroxylation, ubiquitination or acetylation to alter signaling through NICD. The 
specific proteins that mediate these modifications are described in the text [from (Andersson et 
al., 2011)].  
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Phosphorylation: The NICD is modified extensively by phosphorylation. One of 
the key kinases in developmental signaling pathways is GSK3β. The literature is 
conflicted about GSK3’s role in Notch signaling. One report suggests that GSK3β 
phosphorylates NICD C-terminally to the ANK repeats and inhibits NICD2-mediated 
induction of Notch target genes such as hairy and enhancer of split 1 (Hes1) (Espinosa 
et al., 2003) but another suggests that GSK3 stabilizes NICD1 (Foltz et al., 2002). Other 
reports have been published which suggest GSK3 as a positive regulator of Notch 
signaling through stability or localization (Guha et al., 2011; Han et al., 2012). Other 
reports suggest that GSK3 is in fact a negative regulator of Notch signaling (Jin et al., 
2009b; Kim et al., 2009). Cyclin C/CDK8 phosphorylates NICD and has been shown to 
be critical in regulating the activity and stability of the NICD (Fryer et al., 2002; Fryer et 
al., 2004). Granulocyte colony stimulating factor (Csf) also phosphorylates NICD2 at Ser 
2078, leading to its transcriptional activation (Ingles-Esteve et al., 2001). Notch has also 
been shown to be phosphorylated by Akt (Song et al., 2008), Calcium/Calmodulin-
dependent kinase IV (CaMKIV) (Choi et al., 2013), CK2 (Ranganathan et al., 2011a), 
Nemo-like kinase (NLK) (Ishitani et al., 2010), Down syndrome associated kinase 
DYRK1A (Fernandez-Martinez et al., 2009), Abelson tyrosine kinase (Abl) (Xiong et al., 
2013), CaMKII (Ann et al., 2012; Mamaeva et al., 2009), Disabled-1 (Dab-1) tyrosine 
kinase (Keilani et al., 2012), Protein Kinase Cδ (PKCδ) (Kim et al., 2012), Adaptor-
Associated Kinase 1 (AAK1) (Gupta-Rossi et al., 2011), and DDR1 tyrosine kinase (Kim 
et al., 2011). 
 Ubiquitination: The NICD can also be modified by ubiquitination. The 
ubiquitination of NICD has been shown to modulate its half-life [reviewed in (Le Bras et 
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al., 2011)]. As mentioned earlier, the putative E3 ubiquitin ligase Deltex likely serves as 
a positive regulator of Notch signaling, possibly through a ligand-independent pathway 
distinct from canonical Notch signaling (Yamada et al., 2011). The most well-
characterized E3 ubiquitin ligase for NICD is F-box and WD-40 domain protein 7 
(Fbxw7; also known as Cdc4 and SEL-10), which ubiquitinates NICD within the PEST 
domain and promotes its rapid degradation (Fryer et al., 2004; Gupta-Rossi et al., 2001; 
Oberg et al., 2001; Wu et al., 2001). Functionally, Fbxw7 is critical in controlling 
stemness and neuronal fate versus glial differentiation in the developing brain 
(Matsumoto et al., 2011). The transcriptional activity of NICD1, but not NICD4, was 
enhanced in by a dominant negative form of Fbxw7 (Wu et al., 2001).  In contrast to 
those results, Fbxw7-/- mice showed that Notch4 ICD, but not Notch1, 2, and 3 ICDs 
was elevated following Fbxw7 knockout (Tsunematsu et al., 2004). These results also 
strongly suggest that the individual Notch receptors are regulated differently. Recently, it 
has been shown serum- and glucocorticoid-inducible kinase (SGK1) forms a trimeric 
complex with NICD and Fbxw7 and enhances Fbxw7-mediated NICD degradation (Mo 
et al., 2011). The importance of NICD stability is supported by the fact that NOTCH1 
and FBXW7 mutations are found in T-cell acute lymphoblastic leukemia (T-ALL) 
(Erbilgin et al., 2010; Malyukova et al., 2007). Gain-of-function mutations in NOTCH1 
are found in over 50% of T-ALL patients (Weng et al., 2004) and loss-of-function 
mutations in FBXW7 have also been found (Malyukova et al., 2007; Mansour et al., 
2009; O'Neil et al., 2007).  Interestingly, there is some evidence that NICD1 stability is 
still modulated even in the absence of FBXW7/PEST domain-mediated ubiquitination 
(O'Neil et al., 2007; Tsunematsu et al., 2004). These results suggest that there is 
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another region of NICD1 that regulates its stability. These NOTCH1 mutations are 
concentrated at the HD domain and the PEST domain; the HD domain mutants promote 
ligand-independent activation and the PEST domain mutants confers resistance to 
ubiquitination and subsequent degradation (Weng et al., 2004). Additionally, T-ALL cell 
lines lacking functional FBXW7 have extended NICD1 half-lives (Malyukova et al., 2007; 
Mansour et al., 2009; O'Neil et al., 2007). Mutations in the PEST domain of NOTCH1 
have also been found in non-small-cell lung cancer (Westhoff et al., 2009), suggesting 
that NICD stability, and consequently Notch signaling, can lead to cancer. One other E3 
ubiquitin ligase that ubiquitinates Notch is Itch (Cornell et al., 1999; Qiu et al., 2000) 
which is required for Notch1 degradation in the absence of ligand (Chastagner et al., 
2008). An extensive list of NICD interacting proteins can be found in (Andersson et al., 
2011). Much is still not known about many of these interactions, which have only been 
observed in overexpression studies. Whether they interact with NICD under 
physiological conditions in cultured cells or in vivo, with free NICD in the cytoplasm or 
nucleoplasm of the signal-receiving cell, or with the NICD-CSL-MAML transactivating 
complex inside the nucleus could inform future studies on NICD regulation.  
 Hydroxylation and Acetylation: NICD is also affected by two other types of post-
translational modification, hydroxylation and acetylation. NICD is hydroxylated by the 
asparagines hydroxylase factor-inhibiting HIF1α (FIH1l also known as HIF1AN), which 
hydroxylates NICD at N1945 and N2012 (Coleman et al., 2007; Zheng et al., 2008). 
This might contribute to signaling specificity because Notch2 and Notch3 are 
hydroxylated whereas Notch4 is not. The in vitro studies suggest that HIF1α a negative 
regulator of Notch, but HIF1α targeted mice do not display a Notch gain-of-function 
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phenotype (Zhang et al., 2010). Another recent study has recently identified the 
deacetylase sirtuin 1 (Sirt1) as critical to the acetylation/deacetylation of NICD in 
endothelial cells, affecting NICD half-life (Guarani et al., 2011).  
 These results clearly indicate that the NICD is extensively modified by post-
translational modifications, which serve to regulate the NICD. Most of these 
modifications affect the stability or half-life of NICD, implicating NICD protein turnover as 
a critical step in regulating the canonical Notch signaling pathway. Further studies on 
the regulation of NICD protein turnover would be extremely critical for understanding the 
mechanisms of the pathway between receptor activation and transcriptional activation. 
Not much is known about how these mechanisms that affect NICD turnover alter 
canonical Notch signaling. 
 
Notch Signaling: Activation of a NICD-CSL-MAML transcriptional complex 
 Upon Notch activation, the liberated NICD translocates to the nucleus where it 
binds to CSL and the scaffold protein MAML; this NICD-CSL-MAML complex 
subsequently activates downstream target genes. This transcriptional activation is 
central to canonical Notch signaling (Kovall and Blacklow, 2010). The Notch-mediated 
transcriptome appears to be very diverse in different cell types, contributing to the 
specificity of Notch signaling. Genome-wide Notch transcriptome studies in healthy or 
mutated T-cells (Chadwick et al., 2009; Dohda et al., 2007; Palomero et al., 2006; 
Weerkamp et al., 2006), mouse embryonic stem (ES) cells (Main et al., 2010; Meier-
Stiegen et al., 2010), alveolar epithelial cells (Aoyagi-Ikeda et al., 2011), endometrial 
stromal cells (Mikhailik et al., 2009), C2C12 mouse myoblast cells (Buas et al., 2009), 
and Drosophila myogenic cells (Krejci et al., 2009) yield a vast array of diversity in their 
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target gene transcriptomes. In addition to the diversity in target gene activation, Notch 
signaling is also affected by cell cycle stage [reviewed in (Kageyama et al., 2009)], and 
through cell lineage progression(e.g. in T-cell development [reviewed in (Radtke et al., 
2010)]), and during neural differentiation of ES cells in vitro, when cyclin D1 is activated 
in a specific temporal window during ES cell neural differentiation (Das et al., 2010).  
The canonical Notch signaling pathway directly activates the downstream hairy 
and enhancer of split-related (HESR) genes, a family of basic helix-loop-helix (bHLH) 
transcriptional repressors. The HESR genes have been shown to be activated by Notch 
during tumor progression (Sethi et al., 2011; Wendorff et al., 2010). Surprisingly, in the 
five cell types listed above which have done genome-wide transcriptome analysis, 
hairy/enhancer-of-split related with YRPQ motif 1 (Hey1) was upregulated in four of the 
five.  Additionally, Hes5 was upregulated in only the ES cells. These data suggest that 
even though there are some common upregulated target genes, there is no universal 
target gene upregulated in all cases of Notch signaling. The list of immediate Notch 
target genes which are upregulated in parallel with the HESR genes is quite extensive; 
including c-Myc (Rao and Kadesch, 2003; Satoh et al., 2004; Weng et al., 2006), cyclin 
D1 (Cohen et al., 2010a; Ronchini and Capobianco, 2001; Satoh et al., 2004), cyclin D3 
(Joshi et al., 2009), cyclin-dependent kinase 5 (CDK5) (Palomero et al., 2006), p21 
(Rangarajan et al., 2001), Snail (Sahlgren et al., 2008), and platelet-derived growth 
factor receptor beta (PDGFRβ) (Jin et al., 2008; Morimoto et al., 2010). The differences 
in Notch-mediated transcriptome response after receptor activation is only partially 
understood. The prevailing model is that CSL binds DNA via conserved CGTGGGAA 
motifs to target promoters and in the absence of NICD represses transcription. Upon 
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Notch pathway activation, NICD, along with MAML, is thought to displace co-repressors 
and recruit co-activators to the NICD-CSL complex, leading to transcriptional activation 
of target genes. Certain genes, at least in Drosophila, appear repressed in the absence 
of Notch signaling (Bardin et al., 2010; Castro et al., 2005; Koelzer and Klein, 2006). 
However, other studies in Drosophila suggest that Su(H), the Drosophila homolog of 
CSL, is actively recruited to its binding sites by NICD rather than being placed there 
during the “Notch-off” state (Krejci and Bray, 2007). The binding coefficient between 
CSL and DNA is weaker than previously thought (Friedmann and Kovall, 2010), and the 
affinity of CSL for the RAM domain of NICD is unchanged by DNA binding (Friedmann 
et al., 2008), suggesting that the interaction between CSL and DNA is likely to be 
dynamic.   
 Each different Notch receptor has distinct tissue-specific expression patterns, 
and this distinction between the Notch receptors can lead to transcriptional specificity. 
The configuration of CSL-binding sites influences the likelihood of recruiting NICD1 or 
NICD3 (Ong et al., 2006). NICD1 is highly active on paired CSL binding sites while 
NICD3 is highly active when binding to CSL motifs adjacent to zinc-finger transcription 
factor binding sites (Ong et al., 2006). The dimerization potential of NICD can also 
influence the target gene repertoire by restricting the response to dimeric CSL binding 
sites (Cave et al., 2005). Structural analysis of the NICD dimeric complex suggests 
flexibility in spacer length is tolerable (Arnett et al., 2010). There is evidence that NICD 
multimerization is an initial step in forming the active transcriptional complex (Vasquez-
Del Carpio et al., 2011). Additionally, because there is some difference in target gene 
expression, it is likely that there might be distinct biological functions for each Notch 
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receptor. NICD2, but not NICD1, promotes tumor growth in xenografts in a 
medulloblastoma model (Fan et al., 2004). NICD1 and NICD3 signaling generate 
distinct phenotypes in the pancreas (Apelqvist et al., 1999; Hald et al., 2003) but have 
similar phenotypes in adult CNS progenitor cells (Tanigaki et al., 2001). NICD3, but not 
NICD1 or NICD2, can drive the formation of invasive gliomas during embryonic CNS 
development (Pierfelice et al., 2011). One recent study suggests that the difference in 
signaling between the Notch receptors comes primarily from its extracellular domain 
(Liu et al., 2013). 
 Another way to generate signaling specificity is through feedback loops with 
downstream target genes. One example is c-Myc, which activates genes in concert with 
NICD-CSL that NICD-CSL does not activate alone (Palomero et al., 2006). In smooth 
muscle cells, Hey1 and Hey2 are activated by Notch and dampen Notch-mediated 
transcription by blocking NICD-CSL binding to DNA (Tang et al., 2008) that may affect 
the duration of the Notch signal. Another example of Notch feedback is the Notch target 
gene Notch-regulated ankyrin repeat protein (Nrarp), which feeds back to modulate 
Notch signaling while also potentiating Wnt signaling (Ishitani et al., 2005; Phng et al., 
2009).  
 The cooperation of NICD-CSL and other transcription factors may also play a 
role in generating signal specificity. Proneural bHLH proteins cooperate with NICD-CSL 
to regulate HESR gene expression (Holmberg et al., 2008) and synergistic 
transcriptional responses between NICD-CSL and GATA factors (Neves et al., 2007), 
NF-κB (Vilimas et al., 2007), and Twist (Bernard et al., 2010) has also been 
demonstrated. In addition, the spacing between the binding sites has been shown to be 
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important (Swanson et al., 2010). The binding of CSL to the N-terminal region of NICD 
likely also affects the regulation of the NICD itself, as described earlier. As mentioned 
previously, SCFFbxw7 then serves as an “off” switch to turn off Notch transcription by 
binding and degrading the NICD. This degradation also serves as a mechanism to 
continually refresh the Notch signal by degrading a post-transcriptionally active NICD 
and freeing up CSL and MAML to bind another NICD. Much remains unknown about 
why CSL is sometimes bound to the DNA in the absence of NICD but in other cases is 
recruited to the DNA by NICD.  
 The Notch signaling pathway has many key features in common with other 
developmental signaling pathways, including the Wnt/β-catenin pathway. However, very 
little is known about the cytoplasmic mechanism of the Notch pathway relative to other 
pathways. Notch is unique in that an obvious amplification step in the cytoplasm has yet 
to be identified, and the receptor itself serves as the downstream effector and 
transcriptional co-activator. Due to the importance of the NICD and the critical role that 
the downstream effector plays in other pathways, it is very likely that the NICD is very 
highly regulated at the protein level, possibly through cross-talk with other pathways but 
also through distinct mechanisms that affect only the NICD. The next section of the 
introduction focuses on regulation of Notch signaling through crosstalk with other 
developmental pathways, specifically the Wnt/β-catenin pathway.  
 
Notch and Wnt Signaling: Evidence for Wntch Signaling? 
 Due to the small number of developmentally critical signaling pathways and the 
diverse functions required for embryonic development, it has become increasingly clear 
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that many of these pathways operate cooperatively to form a signaling network. 
Interestingly, Notch cross-talk has been shown to occur at all three levels of pathway 
interaction; epistasis of one pathway to another, convergence of two pathways to the 
same target genes, and direct interaction between components of each pathway.. The 
most well-characterized pathway that has been shown to cross-talk with the Notch 
pathway is the Wnt/β-catenin pathway and in this document I will focus on the cross-talk 
between canonical Notch signaling and canonical Wnt/β-catenin signaling. 
 Wnt/β-catenin signaling and Notch signaling are oftentimes required for similar 
developmental processes (Arias and Hayward, 2006) and multiple instances of Wnt-
Notch crosstalk have been observed. Wnt/β-catenin signaling upregulates Jag1 as a 
target gene of β-catenin in the hair follicle (Estrach et al., 2006), upregulates Dll4 during 
vascular remodeling (Corada et al., 2010) and induced Notch2 expression in colorectal 
cancer cells (Ungerback et al., 2011). These studies suggest that Wnt/β-catenin 
signaling promotes Notch signaling. These two pathways can also converge 
downstream of the receptor; β-catenin can bind to NICD in neural precursor cells 
(Shimizu et al., 2008) and form complexes with NICD-CSL in arterial cells but not 
venous endothelial cells (Yamamizu et al., 2010). Intriguingly, the Dll1 ICD induces Wnt 
reporter activity and upregulates the expression of connective tissue growth factor 
(CTGF) (Bordonaro et al., 2011). Additionally, the scaffold protein MAML, which is 
critical for Notch transcriptional activation, binds to both GSK3β (Saint Just Ribeiro et 
al., 2009) and β-catenin (Alves-Guerra et al., 2007). MAML binding to GSK3β (which is 
inhibited by Wnt/β-catenin signaling) decreases MAML-mediated transcriptional activity 
(Saint Just Ribeiro et al., 2009) and MAML can act as a transcriptional co-activator for 
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β-catenin to increase expression of cyclin D1 and c-myc, target genes of Wnt/β-catenin 
signaling (Alves-Guerra et al., 2007). These data further supports that Notch signaling 
and Wnt/β-catenin signaling can positively regulate each other. Another unexpected 
level of crosstalk occurs at the receptor level, where the soluble Frizzled-related 
proteins (sFRPs), Wnt/β-catenin antagonists, bind to ADAM10 metalloprotease and 
downregulate its activity, inhibiting Notch signaling. This regulation affects the Notch-
dependent process of retinal neurogenesis, which is also Wnt-independent (Esteve et 
al., 2011). All of these suggest that Notch signaling and Wnt/β-catenin signaling affect 
each other positively. However, other studies have actually identified another method of 
crosstalk in which Notch signaling inhibits Wnt/β-catenin signaling (Hayward et al., 
2008; Munoz-Descalzo et al., 2012).  
Notch loss of function has been shown to result in ligand independent activation 
of Wnt/β-catenin signaling (Brennan et al., 1999a; Demehri and Kopan, 2009; Hanlon et 
al., 2010; Kwon et al., 2011; Kwon et al., 2009; Lawrence et al., 2001; Lin et al., 2008; 
Nicolas et al., 2003; Pan et al., 2004). This regulation is likely a post-translational effect 
of Notch on Wnt signaling. In some systems, gain of function of Notch downregulates 
the activity of β-catenin (Acosta et al., 2011; Deregowski et al., 2006; Hayward et al., 
2005; Kwon et al., 2011; Langdon et al., 2006; Nicolas et al., 2003; Sanders et al., 
2009). Additionally, Notch’s regulation of Wnt/β-catenin signaling is independent of its 
transcriptional activity as it does not depend on CSL binding or generation of the NICD 
(Acosta et al., 2011; Hayward et al., 2005; Kwon et al., 2011; Sanders et al., 2009). 
Genetic experiments in Drosophila have also identified alleles of Notch that affect 
interactions with Wnt/β-catenin signaling (Brennan et al., 1997; Brennan et al., 1999c; 
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Langdon et al., 2006; Ramain et al., 2001; Ruel et al., 1993). These data all strongly 
suggest a role for Notch in inhibiting Wnt/β-catenin signaling in vivo and in vitro. 
Structure function analysis has identified functionally distinct domains in Notch 
receptors for Wnt/β-catenin signaling and for canonical Notch signaling (Arias, 2002; 
Brennan et al., 1999b; Brennan et al., 1999c; Heitzler, 2010; Langdon et al., 2006). This 
suggests that Notch may interact with components of Wnt/β-catenin signaling directly. In 
support of this possibility, multiple reports have shown that Notch interacts either 
genetically or molecularly with key components of the Wnt/β-catenin signaling pathway: 
Dishevelled, APC, Axin, TCF/LEF, GSK3 and β-catenin itself (Axelrod et al., 1996; 
Espinosa et al., 2003; Foltz et al., 2002; Hayward et al., 2006; Hayward et al., 2005; 
Herranz et al., 2008; Jin et al., 2009a; Kwon et al., 2011; Langdon et al., 2006; Lee et 
al., 2009; Munoz-Descalzo et al., 2010; Munoz-Descalzo et al., 2011; Sanders et al., 
2009; Shimizu et al., 2008; Strutt et al., 2002). Furthermore, NICD and β-catenin can be 
found in the same endocytic vesicles.  
There is strong evidence that Notch signaling and Wnt/β-catenin signaling can be 
described as two arms of a signaling network rather than as two distinct, discrete 
signaling pathways. In cell culture studies, the Wnt/β-catenin and Notch pathways 
cooperate to maintain adult stem cells in the skin (Blanpain and Fuchs, 2009; Blanpain 
et al., 2006; Lowry et al., 2005), the intestine (Robine et al., 2005; Sancho et al., 2004; 
van Es et al., 2005), and skeletal muscle (Brack et al., 2008). In the intestine, treatment 
with gamma secretase inhibitors (GSIs) to inhibit Notch signaling also inhibits Wnt/β-
catenin signaling (van Es et al., 2005) but loss of function of CSL does not suppress 
Wnt/β-catenin signaling (Peignon et al., 2011). These results strongly favor a model in 
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which Notch and Wnt signaling are functionally interconnected and can be integrated 
into a single functional signaling unit which some have termed “Wntch” signaling 
(Hayward et al., 2008; Munoz-Descalzo et al., 2010; Munoz-Descalzo et al., 2011; 
Munoz Descalzo and Martinez Arias, 2012; Sanders et al., 2009). These interactions 
can be summarized as one interconnected molecular network in Figure 1.8 [Figure 1.8, 
from (Munoz Descalzo and Martinez Arias, 2012)]. 
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Figure 1.8. Structure and function of Wntch. (A) Summary of the interactions between elements 
of Wnt and Notch signalling and outline of the network that configures Wntch signalling. For 
details see text. The transcriptional interactions are labelled in yellow. (1) Effects of GSK3 
activity that destabilized β-catenin and NICD. (2) Wnt signalling inhibits GSK3 and thus 
stimulates β-catenin and CSL/NICD function. These effects are likely to be cell type specific and 
depend on basal levels of GSK3 activity. (3) Notch, in a CSL independent manner, inactivates 
the transcriptional activity of β-catenin. (4) Wnt signalling inhibits the CSL independent activity of 
Notch. (B) Activity of the network outlined in A in different conditions. Notice that activation of 
Wnt signalling can lead to DSL-Notch-CSL signalling [from (Munoz Descalzo and Martinez 
Arias, 2012)]. 
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The simplest and most obvious explanation for “Wntch” signaling is that the 
transcriptional effectors somehow converge to then regulate both pathways. However, 
the results have that been observed cannot be easily explained by that hypothesis 
alone. One key observation is that ligand independent Notch trafficking inhibits Wnt/β-
catenin signaling. Experiments in Drosophila imaginal discs, mammalian cells, and 
embryos show that Notch inhibits β-catenin activity even when the Notch receptors 
cannot interact with DSL ligands nor bind to CSL for transcriptional activation (Hayward 
et al., 2005; Kwon et al., 2011; Sanders et al., 2009). Even though these Notch 
receptors cannot activate canonical Notch signaling, they still get endocytosed and 
trafficked, which allows them to specifically target the transcriptionally competent form 
of Arm/β-catenin but does not significantly affect the overall cytosolic pool of β-catenin 
(Hayward et al., 2005; Kwon et al., 2011; Sanders et al., 2009). There is evidence that 
the dephosphorylated transcriptionally competent form of β-catenin is recruited to the 
plasma membrane upon Wnt activation and might have different regulators than the 
cytosolic pool (Hendriksen et al., 2008). Notch’s regulatory effect on β-catenin might be 
through Axin, which is thought to be membrane-anchored and has been shown to 
interact with Notch and APC to regulate Armadillo in Drosophila (Hayward et al., 2006; 
Munoz-Descalzo et al., 2011; Tolwinski et al., 2003; Tolwinski and Wieschaus, 2001). It 
is still unclear whether Axin’s interactions with Notch are related to its function as a 
membrane anchor.  
The effect of Notch on dephosphorylated β-catenin likely occurs through other 
adaptor proteins. In Drosophila, ligand independent trafficking of Notch requires Dsh, a 
positive regulator of Wnt/β-catenin signaling (Munoz-Descalzo et al., 2010; Munoz-
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Descalzo et al., 2011). In mammalian cells, the Notch regulation of β-catenin is likely 
through the adaptor protein Numb (Cheng et al., 2008; Kwon et al., 2011). In both 
Drosophila and mammalian cells, the putative E3 and adaptor protein Deltex 
participates in CSL independent Notch signaling to regulate β-catenin (Langdon et al., 
2006; Ordentlich et al., 1998; Ramain et al., 2001). Taken together, a model for Notch-
mediated inhibition of Wnt/β-catenin signaling emerges where Notch interacts with 
dephosphorylated β-catenin at the membrane and degrades or sequesters β-catenin. 
This likely requires some combination of Dsh, Numb, and Deltex (Gupta-Rossi et al., 
2004). Validation of such a model will require further biochemical studies.  
There is also evidence that Wnt signaling can modulate Notch signaling. 
Wingless, the Drosophila homolog of Wnt, has been shown to regulate Notch signaling 
(Munoz-Descalzo et al., 2010; Wesley, 1999). Multiple reports have also shown that the 
classical DSL ligand Jagged1 is a target gene of β-catenin-mediated transcription 
(Amoyel et al., 2005; Estrach et al., 2006; Galceran et al., 2004; Rodilla et al., 2009). 
Interestingly, MAML is also a transcriptional co-activator for β-catenin (Alves-Guerra et 
al., 2007; Kankel et al., 2007).  
The idea of a single functional Wntch signaling module is a compelling one, as 
evidence shows that each of these individual pathways can influence the output of the 
other one. This strongly suggests that these two pathways are functionally 
interconnected, forming a signaling network to regulate cell growth and proliferation and 
cell fate decisions. This is likely the first step towards integrating signal transduction into 
one large network where the activation of one pathway regulates the activation of other 
pathways. More studies to elucidate the mechanistic underpinnings of “Wntch” signaling 
66 
 
will critical towards an integration of Notch and Wnt signaling into a single functional 
paradigm. 
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CHAPTER II 
 
MATERIALS AND METHODS: PROTEIN DEGRADATION IN XENOPUS EGG 
EXTRACT 
  
One critical aspect of studying developmental signaling networks is the use of 
proper systems to study them in. I used Xenopus egg extract as one of the primary 
systems to study degradation of Notch. Details about the use of Xenopus egg extract 
can be found in this chapter and in Chen et al. 2014a (Chen et al., 2014a). This system 
can be used to study both Wnt signaling and Notch signaling. 
 
Reconstitution of β-catenin degradation in Xenopus egg extract 
Introduction 
Xenopus laevis egg extract has been used extensively to study many cell 
biological processes including cytoskeletal dynamics, nuclear assembly and import, 
apoptosis, ubiquitin metabolism, cell cycle progression, signal transduction, and protein 
turnover(Blow and Laskey, 1986; Chan and Forbes, 2006; Dabauvalle and Scheer, 
1991; Forbes et al., 1983; Glotzer et al., 1991; Kornbluth et al., 2006; Lohka and Masui, 
1983; Maresca and Heald, 2006; Masui and Markert, 1971; Mitchison and Kirschner, 
1984; Murray, 1991; Newport and Kirschner, 1984; Salic et al., 2000b; Shennan, 2006; 
Theriot et al., 1994; Tutter and Walter, 2006; Verma et al., 2004). The Xenopus egg 
extract system is amenable to the biochemical analysis of a legion of cellular processes 
because egg extract represents essentially undiluted cytoplasm that contains all the 
essential cytoplasmic components necessary to execute these processes and enable 
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investigation. Large quantities of egg extract can be prepared at one time for 
biochemical manipulations that require large amounts of material (e.g. protein 
purification or high-throughput screening)(Thorne et al., 2010; Thorne et al., 2011; Yu et 
al., 1996). Another advantage is that the concentration of specific proteins in Xenopus 
egg extract can be precisely adjusted by addition of recombinant protein and/or 
immunodepletion of endogenous proteins in contrast to transfection of plasmid DNA 
where expression of the protein of interest is difficult to control. In addition, the lack of 
available recombinant proteins can be overcome by the addition of transcripts encoding 
the protein of interest, taking advantage of the freshly prepared Xenopus egg extract’s 
high capacity to translate exogenously added mRNA.  
The regulation of protein degradation is critical for the control of many cellular 
pathways and processes(Hinkson and Elias, 2011). Xenopus egg extract has been 
used extensively to study protein degradation as the system allows for multiple ways to 
monitor protein turnover without confounding influences of transcription and translation. 
The Wnt signaling pathway is a highly conserved signaling pathway that plays critical 
roles in development and disease. The turnover of β-catenin, the major effector of the 
Wnt pathway, is highly regulated, and an increased steady-state level of -catenin is 
critical for the activation of Wnt target genes. The importance of -catenin degradation 
is highlighted by the fact that mutations in the Wnt pathway that inhibit β-catenin 
degradation found in ~90% of all sporadic cases of colorectal cancer(Kinzler and 
Vogelstein, 1996). -catenin degradation by components of the Wnt pathway can be 
faithfully recapitulated in Xenopus egg extract to study the mechanism of its turnover as 
well as to identify novel small molecule modulators of its degradation (Cselenyi et al., 
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2008; Guger and Gumbiner, 1995; Jernigan et al., 2010; Lee et al., 2001; Lee et al., 
2003; Major et al., 2007; Salic et al., 2000b; Seeling et al., 1999; Thorne et al., 2010; 
Thorne et al., 2011).  
Methods for the preparation of Xenopus egg extract for studying the cell cycle 
have been described in previous JoVE publications (Cross and Powers, 2008a; Cross 
and Powers, 2008b; Willis et al., 2012). The current protocol describes a modification of 
these methods and is optimized for the degradation of [35S]-radiolabeled -catenin and 
luciferase-tagged -catenin in Xenopus egg extract. The radiolabeled degradation 
assay allows for direct visualization of protein levels via autoradiography. 
[35S]methionine is incorporated into the protein of interest using an in vitro translation 
reaction that can then be directly added to a degradation reaction. In addition, the 
radiolabeled protein turnover assay does not require an antibody against the protein of 
interest or an epitope tag, which can influence protein stability. Because even small 
changes in protein levels, as reflected in changes in the intensity of the radiolabeled 
protein band, are readily visualized by autoradiography, the [35S]-radiolabeled 
degradation assay represents a very useful method for visualization of protein 
turnover(Salic et al., 2000b).  
Fusion of -catenin to firefly luciferase (hereafter referred to as 
simply”luciferase”) allows for more precise and quantitative measurements of protein 
level, and the capacity to more readily determine the kinetic properties of -catenin 
turnover(Thorne et al., 2010; Thorne et al., 2011). A major advantage of the luciferase 
assay is that it provides a strong quantitative system that is easily scaled up. The 
following protocol provides simple methods for assaying -catenin degradation and a 
70 
 
robust, efficient, and effective method for high-throughput screening of novel -catenin 
modulators. 
 
Protocol 
1. Preparation of Xenopus egg extract 
Each frog yields approximately 1 mL of usable egg extract. Extracts from 10 
frogs are typically prepared at one time, and the volume of buffer described below is for 
performing a 10-frog Xenopus egg extract prep. The buffer volume can be adjusted 
accordingly for larger or smaller preparations of egg extract. The process of collecting 
eggs and processing them into extract is most efficient when conducted by two people. 
1.1) Egg collection  
1.1.1) To prime the frogs, inject each female frog with 100 U of Pregnant Mare Serum 
Gonadotropin (PMSG) from a freshly made 250 U/mL stock. Use a 3 mL tuberculin 
syringe with a 27g needle to inject subcutaneously, with the bevel of the needle up, into 
the dorsal lymph sac. This is approximately 1 cm towards the midline from the notched 
discolorations along the length of the legs of the frog.  
1.1.2) Store primed frogs in water at 18°C for 5-10 days. For standing water tank 
systems, the animal density is approximately 4 liters of water per female frog. The 
minimum time required for priming to take effect is 5 days, and the effects of priming 
wear off after 10 days.  
1.1.3) Prepare 0.5 x Marc’s Modified Ringers (MMR) solution from a 20 x MMR stock. 
20 x MMR consists of 2 M sodium chloride, 40 mM potassium chloride, 40 mM calcium 
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chloride, 20 mM magnesium chloride, and 100 mM 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid  (HEPES), pH 7.4.  
1.1.4) Set up buckets for all injected frogs (one frog per 4 L bucket). Although more than 
one frog can be placed in the same bucket for egg collection, if one of the frogs lays 
predominantly poor quality eggs, a substantial amount of effort will be required to 
separate the poor quality eggs from those that are suitable for making extract. Thus, 
maximizing the number of frogs in the same tank to minimize the amount of buffer used 
for egg collect is not worth the risk.   
1.1.5) Inject 750 U Human Chorionic Gonadotropin (HCG) into the dorsal lymph sac of 
each frog using a 27g needle as described in 1.1.1.  
1.1.6) Place each of the HCG-injected frogs into individual 4 L buckets containing 0.5 x 
MMR cooled to 16°C.  
1.1.7) Place the containers with the frogs in a 16°C incubator to collect eggs overnight 
(15-16 hours). Maintaining the proper temperature is critical for the entire procedure, 
from collecting eggs to preparing egg extract. 
1.2 Dejellying eggs  
Eggs are covered with a jelly coat that must be removed prior to making extract. The 
likelihood of spontaneous lysis of the eggs increases as the time between egg laying 
and extract preparation increases. Thus, it is important to proceed through the following 
steps as rapidly as possible.  
1.2.1) Prepare 4 L of 1 x MMR, 50 mL of 0.1 x MMR, and 400 mL of 2% cysteine, pH 
7.7, made in distilled water. All solutions should be maintained at 16°C.  
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1.2.2) To expel additional eggs, one can gently squeeze the lower back and abdomen 
of the frog.  
1.2.3) Remove the frogs and the bulk of the MMR, to leave the eggs in approximately 1-
200 mL of MMR in each bucket.  
1.2.4) Remove debris with a transfer pipet, and assess the quality of the eggs. High 
quality eggs are generally marked by a clear separation between the darkly pigmented 
animal hemisphere and the lightly colored vegetal hemisphere and have the highest 
dark-to-light contrast. Discard with a transfer pipet any eggs that appear stringy, 
mottled, or lysed (white and puffy) as they will decrease the overall quality of the extract. 
If >10% of the eggs are of poor quality, the entire batch should be discarded. 
1.2.5) Combine eggs into a 500 mL glass beaker and pour out as much MMR as 
possible while keeping eggs submerged.  
1.2.6) Rinse eggs by gentle swirling with twice the egg volume of MMR. Repeat 2X, and 
remove any debris or obviously poor quality eggs.  
1.2.7)  Add approximately 100 mL of 2% cysteine to the glass beaker, swirl gently to 
mix, and allow eggs to settle for 5 minutes at 16°C. Pour off the cysteine. Dejellying is 
marked by the gradual appearance of jelly coats floating above the eggs and the more 
compact packing of the eggs as they now occupy a smaller volume without the jelly 
coat.  
1.2.8) Add another 100 mL of 2% cysteine, gently swirl, wait 5 minutes, and then slowly 
pour off the cysteine. Repeat until eggs have become tightly compacted (usually by the 
third cysteine treatment). Note that if eggs are left too long in cysteine, they are prone to 
lysis. Similarly, dejellied eggs are fragile and prone to mechanical lysis if they are 
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swirled too vigorously or if they are exposed to air. Once the eggs have been dejellied, it 
is important to rapidly proceed to the centrifugation steps. 
1.2.9) Pour off cysteine, and rinse away the jelly coat and other debris by gently 
washing eggs in 1 x MMR. Pour off buffer carefully along the side of the beaker. Repeat 
2X or until MMR solution is no longer cloudy. While rinsing with 1 x MMR continue to 
remove the bad eggs using a transfer pipet.  
1.2.10) Perform a final gentle rinse with 30 mL 0.1 x MMR, and gently pour off as much 
of the buffer as possible. Again, remove any obviously bad eggs.  
1.3) Packing and crushing eggs by centrifugation 
The extract described below that is used for -catenin degradation is a variant of 
the cytostatic factor extract (metaphase II-arrested). In contrast to the low-speed and 
high-speed extract used for cell cycle studies, intermediate speed extract works best for 
-catenin degradation. Interphase extract similarly promote robust -catenin 
degradation although is more labor intensive to prepare.  
1.3.1) Add Leupeptin, Pepstatin, Aprotinin mixture (LPA, a protease inhibitor) at 10 
μg/mL (diluted from a 10 mg/mL stock solution in DMSO) and Cytochalasin D at 20 
μg/mL (diluted from a 10 mg/mL stock solution in DMSO) into the remaining 20 mL of 
0.1 x MMR.  
1.3.2) Add 0.1 x MMR containing LPA and Cytochalasin D to the washed eggs, swirl 
gently, and incubate for 5 minutes at 16°C. 
1.3.3) Transfer eggs into 16°C pre-chilled 50 mL centrifuge tubes, allow the eggs to 
settle, and remove residual buffer from the top. To prevent exposure to air, withdraw a 
small amount of buffer into the transfer pipet prior to withdrawing eggs for transfer. 
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Continue to transfer additional eggs into the centrifuge tubes and remove residual buffer 
from the top until the eggs fill the centrifuge tube to the top (maximize the yield of 
extract).  
1.3.4) To pack the eggs, spin centrifuge tubes at 400 x g for 60 seconds at 4°C. 
Remove residual buffer from the top of the centrifuge tubes.  
1.3.5) For the crushing spin, spin tubes at 15,000 x g for 5 minutes at 4°C. 
1.4) Collecting cytoplasmic layer of extract  
(At this point extract should be kept cold during throughout the process, and all steps 
should be performed at 4°C.) 
1.4.1) Clear a hole in the lipid layer using P1000 pipet tip. 
1.4.2) Collect the cytoplasmic layer (between the dark pigmented layer and the light lipid 
layer) using a new P1000 pipet tip (See Figure 1) into clean pre-chilled centrifuge tubes. 
For high-quality extract that robustly degrades -catenin, the amount of pigmented and 
lipid layer that is withdrawn with the cytoplasmic layer should be minimized.  
1.4.3) Spin extracted cytoplasmic layer at 15,000 x g for 10 minutes at 4°C and again 
collect the cytoplasmic layer. Repeat the spin and extraction 1X. The extract should be 
“straw colored.”  If there is substantial contamination with the pigmented and lipid layers 
at this point, one can repeat the spin one more time (although excessive spins will 
decrease the capacity of the extract to degrade -catenin). 
1.4.4) Add LPA and Cytochalasin D to the extract at final concentrations of 10 μg/mL 
each. 
1.4.5) (optional) Freshly prepared extract has a high capacity to translated exogenously 
added mRNA. Unfortunately, this capacity is lost once the extract is frozen. For 
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translation, add capped mRNA (0.1 mg/ml), RNAsin (1.5 U/L), and energy 
regeneration mix (2.1.1) and incubate the reaction at RT for 2 hr. Use translated extract 
immediately for -catenin degradation assays or snap-freeze in liquid nitrogen for later 
use. Capped mRNA can be readily prepared using commercially available kits. 
1.4.6) Snap-freeze extract in liquid nitrogen. Extracts are stored in small (200 μL) 
aliquots for single use because they rapidly lose their capacity to degrade -catenin if 
refrozen. For long-term storage, extract can be stored in liquid nitrogen. For short-term 
storage, extract can be stored at -80°C, although the capacity of extract to degrade -
catenin can be dramatically reduced with extended storage at -80°C (longer than 2 
months).  
2. Preparing extract for -catenin degradation assay  
2.1) Depletion from Xenopus extract 
A major advantage of Xenopus extract is the capacity to readily deplete components of 
a pathway and precisely add back a defined amount of a protein in order to determine 
its dose-dependent effects. 
2.1.1) Use freshly prepared Xenopus egg extract or quickly thaw frozen extract and 
place on ice. All manipulations should be performed in the cold.   
2.1.2) Add extract to 1/10 the volume of pelleted antibody or affinity beads (e.g. 20 L 
pelleted beads to 200 L extract). In order to minimize dilution of the extract, care 
should be taken to withdraw as much liquid from the beads as possible before addition 
of extract. Gel loading tips with long, tapered tips used for gel loading work well for this 
purpose. 
2.1.3) Rotate extract-bead mix at 4°C for 1 hour. 
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2.1.4) Spin extract-bead mix at 12,600 x g in microfuge at 4 °C for 30 seconds. 
Alternatively, if magnetic beads are used, apply magnetic field to collect beads. 
2.1.5) Transfer depleted extract to a fresh microfuge tube on ice. Be careful not to 
transfer any beads with the extract. 
2.1.6) Prepare extract for -catenin degradation assay as described in 2.2. 
2.1.7) Confirm efficiency of depletion by immunoblotting both depleted extract and 
beads. 
2.2) Optimizing Xenopus extract for -catenin degradation 
-catenin degradation in Xenopus egg extract is an energy-dependent process that 
quickly depletes the endogenous ATP stores. Consequently, an energy regeneration 
system is required to maintain robust -catenin degradation. 
2.2.1) Prepare a 20 x energy regeneration (ER) mix consisting of 150 mM creatine 
phosphate, 20 mM ATP, 600 μg/mL creatine phosphokinase, and 20 mM MgCl2. ER 
should be aliquoted and stored at -80°C. Repeated freeze/thaw cycles should be 
avoided, so small frozen aliquots are preferable.  
2.2.2) Quickly thaw Xenopus egg extract by rubbing the frozen tube between your 
hands. Place the tube on ice just before all of the extract has melted.  
2.2.3) Add 10 μL of energy regeneration mix (20 x ER) into an aliquot (200 uL) of 
Xenopus egg extract. Mix thoroughly by quickly flicking the tube and vortexing. Pulse-
spin and immediately place on ice. 
2.2.4) (optional) The turnover of -catenin can be slightly enhanced in Xenopus egg 
extract by addition of ubiquitin (1.25 mg/ml final). Cycloheximide (0.1 mg/ml final) can 
also be added to minimize translation of endogenous transcripts. 
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2.2.5) Aliquot the appropriate volumes for degradation assay into pre-chilled microfuge 
tubes on ice. For radiolabeled -catenin degradation assays, withdraw 2-5 l extract for 
each time point.   
3. Radiolabeled -catenin degradation assay in Xenopus egg extract 
(All steps should be performed on ice unless otherwise indicated). 
3.1) Preparing radiolabeled -catenin  
3.1.1) Prepare freshly in vitro-synthesized [35S]methionine-radiolabeled protein using 
commercially available kits. Generating 35S-labeled proteins are easily and efficiently 
produced using commercially available in vitro-coupled transcription-translation kits. It is 
important that the translated protein is sufficiently labeled such that changes in protein 
turnover can be readily visualized.  
3.1.2) To confirm successful radiolabeling, perform SDS-PAGE/autoradiography with 
0.5 μL of the translated protein. The radiolabeled -catenin protein band should be 
clearly visible on film within a few hours (4-6 hours). The intensity of the radiolabeled -
catenin band can be quantified using ImageJ, ImageQuant, or an alternative 
quantitative software program.  
3.1.3) Snap-freeze the radiolabeled protein in liquid nitrogen for storage until use. 
Prolonged storage (>2 months) and multiple freeze/thaw (greater than 2) can severely 
impact the capacity of the radiolabeled -catenin to degrade robustly in Xenopus egg 
extract. 
3.2) Performing -catenin degradation assay 
3.2.1) Add 1-3 μL (depending on the strength of the radiolabeled band signal) of in vitro-
translated -catenin (and other proteins, small molecules, etc. that are being tested) into 
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20 μL of Xenopus reaction mix on ice. Mix thoroughly by quickly flicking the tube and 
vortexing. This is an important step as Xenopus egg extract is very viscous, and 
incomplete mixing will affect the consistency of the results. Pulse spin and place on ice.   
3.2.2) Start the -catenin degradation reaction by shifting the tubes to room 
temperature. 
3.2.3) At the designated time point, remove 1-5 L of the sample and mix immediately 
with SDS sample buffer (5 x volume) to stop the reaction. To make sure the degradation 
reaction is completely terminated, flick tube several times and vortex vigorously. 
3.2.4) Perform SDS-PAGE/autoradiography. Run 1 L equivalents (~ 50 g of protein) 
of the extract for each time point/lane. Degradation of -catenin in Xenopus egg extract 
should be evidenced by the time-dependent decrease in intensity of the radiolabeled -
catenin band (see Figure 2). Results can be quantified using ImageJ, ImageQuant, or 
other preferred imaging software if necessary. 
3.2.5) (optional) Soak SDS-polyacrylamide gel in fixing solution (10% acetic acid and 
30% methanol in distilled water) prior to drying to decrease background radioactivity 
and increase the quality of the image. 
4. -catenin-luciferase degradation assay in Xenopus egg extract  
Perform all steps on ice unless otherwise indicated. 
4.1) Preparing -catenin-luciferase 
4.1.1) Non-radiolabeled, luciferase-tagged -catenin can be synthesized using the 
transcription-translation coupled system with complete amino acid mix.  
4.1.2) Confirm production of the luciferase-tagged -catenin by measuring luciferase 
activity from 0.5-1 μL of the reaction. Background luminescence can be assessed by 
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measuring luminescence from an untranslated reaction mix. Multiple commercial kits 
are available for measuring luciferase activity. Long-lived luminescence, however, 
works particularly well for the degradation assay. 
4.2) Performing -catenin-luciferase degradation assay 
4.2.1) Thaw and prepare and Xenopus egg extract as in 2.2. 
4.2.2) Add in vitro-translated -catenin-luciferase fusion (from 4.1) into prepared 
Xenopus reaction mix (from 2.2) on ice and mix well as in 3.2.1. The activity of the -
catenin luciferase that is added to the extract is typically between 20-50,000 relative 
luminescence units (RLU)/L of extract (based on measurements obtained from 4.1.2).  
Starting signal should be approximately 100,000 RLU (2-5 L of the in vitro-translated -
catenin-luciferase fusion).  
4.2.3) Shift the extract to room temperature to start the degradation reaction. 
4.2.4) Remove an aliquot of the reaction at the indicated time and snap-freeze in liquid 
nitrogen. Triplicate samples are typically removed for analysis for each time point. 
Frozen extract can be stored at -80°C until they are ready to be analyzed.  
4.2.5) Thaw samples ice, transfer samples to standard white 96 well plates on ice, and 
process for luciferase activity. 
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Representative Results 
Xenopus egg extract is a robust biochemical system for investigating -catenin 
turnover. The concentration of -catenin in Xenopus egg extract is ~25 nM (Salic et al., 
2000b). Under optimal conditions, the egg extract is capable of degrading -catenin at a 
rate of 50-100 nM/hr and is half-maximal at 200 nM (Lee et al., 2003). There are several 
critical steps for successful reconstitution of -catenin degradation using Xenopus egg 
extract. These include 1) generating high quality Xenopus egg extract and the manner 
by which egg extract is prepared, 2) generating quality radiolabeled -catenin and -
catenin-luciferase protein, 3) optimizing reaction conditions to support -catenin 
degradation, and 4) proper processing of reaction time points. 
A high-quality preparation of Xenopus egg extract in which -catenin is robustly 
degraded depends on both the quality of the eggs and how the eggs are handled prior 
to the crushing step as well how the extract is subsequently centrifuged to obtain the 
final extract. As mentioned in the protocol, it is important to ensure that only high quality 
eggs (evidenced by sharp contrast between the dark animal hemisphere and light 
vegetal hemisphere) are used, that poor quality eggs (stringy, mottled, or white puffs) 
are removed throughout the process, that eggs are maintained at a cool temperature 
(16°C) throughout the procedure, and that the procedure is carried out as quickly as 
possible. It is important not to sacrifice quality for quantity of extract. Additionally, as 
previously mentioned, eggs from a frog that lays poor quality eggs (>10%) should be 
entirely discarded.  
The extract described above is a modification of meiosis II-arrested CSF extract 
(Masui and Markert, 1971). The preparation of Xenopus egg extract for -catenin 
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degradation (intermediate speed extract) differs from classic extracts prepared for 
studying cell cycle (Cross and Powers, 2008a; Cross and Powers, 2008b; Willis et al., 
2012), which are low-speed or high-speed extracts (Salic and King, 2005). Adapting 
Xenopus egg extract for optimal degradation of other proteins may require altering the 
centrifugation speed and number of spins. Low-speed extract contains intact organelles 
and other large cellular components. Thus, higher speed spins will alter the composition 
of the extract and potentially remove inhibitory and/or essential components that will 
affect degradation of the protein of interest. The preparation of intermediate speed 
extract herein described is optimized for degradation of -catenin by components of the 
Wnt pathway. Spinning the extract greater than 4X can significantly decrease the 
capacity of the extract to degrade -catenin (although it has minimal effect on the 
degradation of another Wnt component, Axin). -catenin is susceptible to caspase-
mediated proteolysis in low-speed spin extract and does not noticeably degrade in high-
speed spin extract. Thus, it is likely that different speed extracts will be optimal for 
degradation of components of other signaling pathways.  
The generation of 35S--catenin and -catenin-luciferase can be performed using 
a number of commercially available kits. Protein production using transcription-
translation coupled systems is highly dependent on the quality of the plasmid: highly 
pure midi-preparations of plasmids work better and are more reliable compared to DNA 
mini-preparations. For radiolabeling -catenin, freshly obtained [35S]methionine or 
translabel ([35S]methionine plus [35S]cysteine) is preferred. Note that methionine and 
cysteine both have a tendency to oxidize with prolonged storage thereby decreasing 
their incorporation into -catenin in the in vitro transcription-translation coupled reaction. 
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Because prolonged storage and repeated freeze-thawing cycles can inhibit degradation, 
small amounts of the radiolabeled -catenin are prepared at a time and used soon after.  
The amount of protein translated and the number of methionines in the protein 
determine the strength of the radiolabeled signal. For -catenin, there should be no 
problems obtaining strong radioactive signals for degradation assays. For proteins with 
few methionines and/or that do not translate well, a [35S]methionine and [35S]cysteine 
mix can be used instead of [35S]methionine and/or added an epitope tag (Myc) that 
contains multiple methionines. Although success with various expression plasmids 
containing the appropriate phage promoters (T7, T3, and SP6) can be obtained for in 
vitro transcription-translation reactions, pCS2-based plasmid generally gives the best 
results. In addition, the signal of the translated protein can sometimes be dramatically 
increased by deleting the endogenous 5’ UTR. Finally, for large-scale experiments (e.g. 
high-throughput screening), a large quantity of recombinant -catenin-luciferase may be 
required. -catenin-luciferase from the Sf9/baculovirus system degrades with similar 
kinetics as the wild-type -catenin in Xenopus extract and embryos (Salic et al., 2000b). 
Alternatively, a high-yield in vitro expression system (e.g. wheat germ-based) has been 
successfully used for high-throughput screening (Thorne et al., 2010; Thorne et al., 
2011). 
In order to reliably measure the degradation of -catenin in the extract system, it 
is important that the initial signal from either the radiolabeled -catenin or the luciferase 
-catenin fusion is sufficiently robust. Thus, some amount of optimization by the 
experimenter on the size of the degradation assay, the number of time points needed, 
and the efficiency of the in vitro translation reaction will be required. When assembling 
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the degradation reaction, there are several steps one can take to enhance the chance 
of obtaining robust degradation. Firstly, all reagents should be thawed quickly and 
placed on ice prior to their complete thaw. Because the degradation of -catenin is 
highly energy dependent, it is important that the ER is relatively fresh. Secondly, 
Xenopus egg extract is viscous, and it is critical that the reaction is thoroughly mixed 
after addition of radiolabeled -catenin/-catenin-luciferase fusion, ER, protein, small 
molecule modulators, etc. Thirdly, pre-incubating the reaction mix for 20-30 minutes on 
ice gives more reproducible results when testing effects of small molecule modulators.   
The capacity to deplete proteins from Xenopus egg extract represents a powerful 
tool to assess protein function and their concentration-dependent effects. As an 
example, we demonstrate that depleting GSK3 from Xenopus egg extract blocks the 
degradation of -catenin, indicating the important role of GSK3 in -catenin turnover. 
Different depletion conditions will need to be empirically determined for different 
proteins. For example, abundant proteins will require an increase in the amount of 
antibody or affinity ligand beads used to achieve full depletion. A good starting point is 
to use packed beads at 1/10 the volume of the extract in order to minimize extract 
dilution. In addition to the strength of binding of the antibody/affinity ligand to the target 
protein, the type of beads (e.g. sepharose, agarose, or magnetic) used may impact the 
efficiency of protein depletion from Xenopus egg extract(Trinkle-Mulcahy et al., 2008). 
Finally, it would be ideal to analyze the extent of depletion (typically by immunoblotting). 
Once the -catenin reaction is completed, the manner by which the samples are 
processed can greatly affect the results of the experiment. The concentration of 
Xenopus egg extract preps prepared in the manner described is 52.41 mg/mL ± 5.40 
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mg/mL, and it is important not to overload the capacity of the SDS-PAGE gel; this is not 
a problem with the luciferase--catenin assay. Thus, for each time point, no more than 1 
L equivalent of extract should be loaded into each lane of an SDS-PAGE gel. To 
further enhance the quality of the results, the gel fixation step (optional) will decrease 
background radioactivity and increase the signal-to-noise ratio. For the luciferase assay, 
a decrease from an initial signal of 100,000 RLU in Xenopus egg extract faithfully 
reflects the change in the protein levels of the -catenin-luciferase fusion protein.  
The Xenopus egg extract system represents an attractive system to study the 
regulation of -catenin degradation. The extract system allows for the precise control of 
the concentration of individual proteins via depletion and reconstitution. The capacity to 
monitor their effects on the kinetics of -catenin turnover over time allows for a better 
understanding the biochemical mechanism of this crucial step in Wnt signal 
transduction. Such manipulations have provided deep insight into the complex 
molecular interactions between components of the Wnt pathway and were critical for the 
development of the first mathematical model of the Wnt pathway (Lee et al., 2003). One 
caveat is that the concentrations of Wnt pathway components in Xenopus egg extract 
and mammalian cell lysates have been found to differ, possibly reflecting differences in 
the way the Wnt pathway is regulated during embryogenesis versus the adult situation 
(Tan et al., 2012). The capacity to perform both radioactive and enzymatic, luciferase-
based assays using Xenopus egg extract provides added powerful complementary 
qualitative and qualitative tools for studying the biochemical regulation of -catenin 
degradation.    
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In addition to monitoring the turnover of -catenin, degradation of the negative 
Wnt regulator, Axin, can be monitored in Xenopus egg extract either as a radiolabeled 
protein or fusion to luciferase. Using a variant of luciferase, Renilla, fused to Axin, was 
previously adapted for the luciferase degradation assay into a high-throughput format to 
simultaneously screen for modulators of two Wnt pathway proteins, β-catenin and Axin 
(Thorne et al., 2010; Thorne et al., 2011). This biochemical screen identified the FDA-
approved drug, pyrvinium that increased and decreased the degradation rate of β-
catenin and Axin, respectively, in Xenopus egg extract (Thorne et al., 2010). Pyrvinium 
was subsequently validated in cultured human cells and in various model organisms 
(e.g. Xenopus and C. elegans) as a small molecule inhibitor of the canonical Wnt 
pathway. In summary, the Xenopus egg extract system is a versatile biochemical 
system that can be exploited in a multitude of ways to study the mechanism of Wnt 
signaling as well as for identification of small molecule modulators of the Wnt pathway. 
The biochemical method described herein can be applied to other signaling pathways in 
which protein degradation may play a critical role.   
86 
 
 
Figure 2.1. A schematic representation of the preparation of concentrated Xenopus egg extract. 
Eggs are collected from HCG-injected Xenopus laevis females, compacted with a low-speed 
(400 x g) spin, and crushed and separated with a medium-speed (15,000 x g) spin. Take care to 
inject subcutaneously into the dorsal lymph sac, remove the bad eggs carefully, and carefully 
separate the high-quality cytoplasmic extract from the lower-quality darker extract [Figure from 
(Chen et al., 2014a)]. 
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Figure 2.2. β-catenin degrades robustly when incubated in Xenopus egg extract. (A) A 
schematic of a degradation assay. (B) [35S]-labeled β-catenin prepared by an IVT reaction 
degrades robustly when incubated in Xenopus egg extract. Addition of MG132 (200 μM) to 
Xenopus egg extract inhibits β-catenin degradation. Mutation to alanines of the GSK3 
phosphosites within β-catenin (β-catenin SA) or addition of LiCl (25 mM) (C) inhibits β-catenin 
degradation. [Figure adapted from (Chen et al., 2014a)]. 
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Figure 2.3. Luciferase-tagged β-catenin degrades when incubated in Xenopus egg extract. (A) 
Radiolabeled β-catenin-luciferase degrades at a rate similar to that of untagged β-catenin 
protein. As with the wild-type protein, addition of LiCl (25 mM) inhibits -catenin-luciferase 
degradation. Luciferase alone does not noticeably turn over in Xenopus egg extract. Changes in 
luciferase activity of the -catenin-luciferase fusion parallel the changes in its protein levels. (B) 
Addition of LiCl (25 mM) or depletion of GSK3 (C) inhibits -catenin-luciferase turnover as 
assessed by measuring luciferase activity. (D) Immunoblotting for in vitro translated β-catenin-
luciferase (using an anti-luciferase antibody) revealed significant amounts of free luciferase 
protein in certain preps that likely contributes to the higher background when compared to the 
radiolabeled degradation assay. [Figure from (Chen et al., 2014a)]. 
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Figure 2.4. Regulated degradation of -catenin-luciferase in Xenopus extract can be adapted to 
a high-throughput format. A representative checkerboard analysis for -catenin-luciferase using 
MG132 (450 μM) as an inhibitor of β-catenin degradation. Shaded columns indicate MG132-
treated wells, and lighter columns represent vehicle (DMSO)-treated wells. Quantification and Z-
factor calculation result in a score of 0.3 indicating an acceptable assay for potential use in high-
throughput screening. [Figure from (Chen et al., 2014a)]. 
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CHAPTER III 
 
IDENTIFICATION OF A NOTCH1 INTRACELLULAR DOMAIN DEGRON THAT 
REGULATES SIGNALING IN A PARALOG-SPECIFIC MANNER 
 
Materials and Methods 
Preparation of Xenopus egg extract 
Meiosis II-arrested cytostatic factor (CSF) Xenopus egg extract was prepared as 
described in Chen et al. 2014 (Chen et al., 2014a). The Xenopus egg extract generated 
was used for all [S35]-methionine radiolabeled degradation assays and luciferase-tagged 
fusion protein degradation assays. A schematic showing the general process of 
preparing Xenopus egg extract is shown in Figure 2.1 (Figure 2.1). 
 
[S35]-radiolabeled degradation assay in Xenopus egg extract 
Xenopus egg extract was collected as previously described (Chen et al., 2014a). 
Either [S35] radiolabeled protein or Luciferase-tagged protein was in vitro transcribed 
and translated using rabbit reticulocyte lysate using the Promega protocol (Rabbit 
reticulocyte lysate, nuclease treated, Promega). In vitro transcribed and translated 
protein was incubated in Xenopus egg extract and samples were taken at specific time 
points and placed into SDS-PAGE sample buffer. The [S35] radiolabeled samples at 
each time point were subjected to SDS-PAGE and were assessed by autoradiography 
as previously described (Chen et al., 2014a). The difference in radioactivity over time 
directly corresponds to the protein levels at those specific time points. A decrease in 
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radioactivity is directly proportional to a decrease in protein levels also. An example of a 
[S35]-radiolabeled degradation assay in Xenopus egg extract is shown in Figure 2.2 
[Figure 2.2 (Chen et al., 2014a)]. 
 
Luciferase-tagged fusion protein degradation assay in Xenopus egg extract 
Additionally, Luciferase-tagged proteins were also used to assess protein 
degradation. Luciferase-tagged proteins are valid tools for assessing protein 
degradation because Luciferase-tagged proteins still exhibits the same kinetics as 
untagged proteins [Figure 2.3; (Chen et al., 2014a)]. Because SDS Sample Buffer 
quenches the enzymatic activity of Luciferase, the Luciferase-tagged in vitro transcribed 
and translated proteins were snap-frozen in liquid nitrogen immediately for each time 
point. After all time points have been taken, the Luciferase-tagged samples for each 
time point were placed into a 96-well plate and assessed by luminescence readings 
taken by a luminometer as previously described (Chen et al., 2014a). Just as for the 
[S35]-radiolabeled samples, a change in the luminescence over time is directly 
proportional to a change in protein levels. An example of this is shown in Figure 2.3 
[Figure 2.3; (Chen et al., 2014a)]. This change can be quantified because the 
luminescence readout gives specific numbers for each time point. Since NICD1 has 
similar degradation kinetics with [S35]-radiolabeling and Luciferase fusions, both of these 
readouts were used to assess NICD degradation. His-CSL-Flag was purified from SF21 
cells as previously described (Vasquez-Del Carpio et al., 2011). GST-β-catenin (gift 
from Wenqing Xu) was expressed and purified from bacterial cell lysates with 
glutathione beads (Merck Millipore) according to the manufacturer’s suggestions. 
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High-throughput degradation assay in Xenopus egg extract 
One advantage that studying protein degradation in Xenopus egg extract has 
over cell culture is the ability to adapt the egg extract system to high-throughput assays, 
such as screening for modulators of Notch signaling (Chen et al., 2014a; Thorne et al., 
2011). An example of data from the high-throughput luciferase assay is shown in figure 
2.4 (Figure 2.4). We used the high-throughput assay to perform a preliminary small 
molecule screen for kinase inhibitors that modulate NICD turnover. Please see future 
directions for more about this screen. 
 
Plasmids/Cloning 
The AIP4 and AIP4 C830A plasmids were generous gifts from Dr. Adriano 
Marchese at Loyola University-Chicago. The full-length mNotch1 and the Hes-1 reporter 
plasmid were gifts from Stacey Huppert. The Fbxw7 clone came from DNASU 
(HsCD00404060, DNASU).  
The hNICD(NT1-CT2), (NT1-CT3), (NT1-CT4), (CT2-NT1), (CT3-NT1), and 
(CT4-NT1) fusion plasmids were generated by NdeI digestion at an internal NdeI site at 
position 1016 of NICD1 and position 1034 of NICD2 (NdeI, NEB). NdeI sites were 
created using single site directed mutagenesis inside NICD3 and NICD4 at the 
conserved residues that corresponded to the NdeI sites in NICD1 and NICD2. These 
mutagenesis reactions did not change amino acid sequences and only changed the 
nucleotide sequence. The NdeI sites were near regions conserved in all NICD paralogs. 
The two distinct regions of each individual NICD paralog were then ligated together 
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using traditional ligation protocols (T4 DNA Ligase, NEB) and sequenced to confirm 
correct insertions.  
Other DNA plasmids were generated by traditional PCR-based subcloning 
methods. Standard PCR amplification of template DNA containing the 8 base-cutting 
restriction endonuclease FseI at the 5’ end and the 8 base-cutting restriction 
endonuclease AscI at the 3’ end (FseI, AscI, both from NEB) was performed to generate 
PCR amplicons. These PCR amplicons were then ligated into their respective vectors 
using standard ligation protocols (T4 DNA Ligase, NEB). The complete list of primers 
used for this subcloning is listed in Table 2.1. 
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Primer Name Primer sequence 
hNICD1 FseI Start extra 
A Fwd 
CGCGGGCCGGCCAATGGTGCTGCTGTCCCGCAAGCGC 
hNICD1 Stop AscI Rev CAATGGCGCGCCTTACTTGAAGGCCTCCGGAATGCGG
GC 
hNICD1 no stop AscI  R CAATGGCGCGCCCTTGAAGGCCTCCGGAATGCG 
hNICD2 FseI extra A F CGGCCGGCCAATGGTAATCATGGCAAAACGAAAGCGT 
hNICD2 AscI R CAATGGCGCGCCTCACGCATAAACCTGCATGTT 
hNICD2 no stop R CAATGGCGCGCCCGCATAAACCTGCATGTTGTT 
hNICD3 FseI extra A F CGGCCGGCCAATGGTCATGGTGGCCCGGCGCAAG 
hNICD3 AscI R CAATGGCGCGCCTCAGGCCAACACTTGCCTCTT 
hNICD3 no stop R CAATGGCGCGCCGGCCAACACTTGCCTCTTGGG 
hNICD4 FseI extra A F CGGCCGGCCAATGGTCCTCCAGCTCATCCGGCGT 
hNICD4 AscI R CAATGGCGCGCCCTATTTTTTACCCTCTCCTCCTTGGTT 
hNICD4 no stop R CAATGGCGCGCCTTTTTTACCCTCTCCTCCTTGGTT 
hNICD1 ΔPEST R CAATGGCGCGCCCTAGGAGCTGTCCAGCAGGCAGCC 
hNICD1 ΔPEST no stop 
R 
CAATGGCGCGCCGGAGCTGTCCAGCAGGCAGCC 
hNICD1 2342* AscI R  CAATGGCGCGCCTCAGGGGGCCTGTGTGCTCAG 
hNICD1 2342* no stop R CAATGGCGCGCCGGGGGCCTGTGTGCTCAGGGG 
hNICD1 2399* AscI R CAATGGCGCGCCTCACAGGTTCTGCTGCTGCATCTGTA
A 
hNICD1 2399* no stop R CAATGGCGCGCCCAGGTTCTGCTGCTGCATCTGTAACA
G 
hNICD1 2493* AscI R  CAATGGCGCGCCTCAGGAGTAGCTGTGCTGCGAGGGG
GGCGTCAG 
hNICD1 2493* no stop R CAATGGCGCGCCGGAGTAGCTGTGCTGCGAGGGGGGC
GTCAGGAA 
hNICD1 2518* AscI R CAATGGCGCGCCTCAAGGAACACGGGACGGGGTGAGG
AAGGG 
hNICD1 2518* no stop R CAATGGCGCGCCAGGAACACGGGACGGGGTGAGGAAG
GGGTG 
hNICD1- NICD2 1 Fwd CGGCGGGAGCCCCTCGGCCAGGATGCTGTGGGGCTG 
hNICD1- NICD2 1 Rev CAGCCCCACAGCATCCTGGCCGAGGGGCTCCCGCCG 
hNICD1- NICD2 2 Fwd GACGTCAATGTCCGCGGGCCAGATGGCTGCACCCCA 
hNICD1- NICD2 2 Rev TGGGGTGCAGCCATCTGGCCCGCGGACATTGACGTC 
hNICD1- NICD2 3 Fwd ACAGACCGCACGGGCGAGATGGCCCTGCACCTTGCA 
hNICD1- NICD2 3 Rev TGCAAGGTGCAGGGCCATCTCGCCCGTGCGGTCTGT 
hNICD1 NT-10aa Fwd GAATGGCCGGCCAATGCATGGCCAGCTCTGGTTCCCT 
hNICD1 NT50 Rev  ATTGGGCGCGCCACCGTCTGAAGCGTTCTTCAG 
hNICD2 NT51 Rev ATTGGGCGCGCCAGCTTCTGAGACTTGCAC 
hNICD3 NT50 Rev ATTGGGCGCGCCCTCACCCTTGGCCATGTT 
hNICD4 NT50 Rev ATTGGGCGCGCCTGCCTTTGGCTTCAGTGC 
mNICD1 FseI F  CGGCCGGCCGATGGTGCTGCTGTCCCGCAAGCGC 
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mNICD1 AscI R  CGGCGCGCCCTAGTTTATTTTCTTGGAACAG 
mNICD4 FseI F  GAATGGCCGGCCAATGGTCCTCCAGCTCATTCGGCGA 
mNICD4 AscI R CAATGGCGCGCCCTAGTTCAGATTTCTTACAAC 
dNICD FseI Fwd TATAGGCCGGCCAATGGTGAAATACGTAATTACT 
dNICD AscI Rev ATATGGCGCGCCTCAAATGTAGATGGCCTC 
Fbxw7 FseI extra A F CGGCCGGCCAATGAATCAGGAACTGCTCTCT 
Fbxw7 ΔFbox extra A  CGGCCGGCCAATGAACAAATTACGGCAAAGT 
Fbxw7 AscI R CAATGGCGCGCCTCACTTCATGTCCACATCAAA 
NICD1 CT NdeI F GGATCATATGGACCGCCTGCCGCGCGACATC 
NICD2 CT NdeI F AGACCATATGGATCGTCTTCCCCGGGATGTG 
NICD3 CT NdeI F AGACCATATGGACAGGCTGCCGCGGGACGTA 
NICD4 CT NdeI F AGACCATATGGGGCTAGCGCCGGCGGACGTC 
NICD3 Add NdeI F AACCGTGAGATCACCGACCATATGGACAGGCTGCCGC
GGGAC 
NICD3 Add NdeI R GTCCCGCGGCAGCCTGTCCATATGGTCGGTGATCTCAC
GGTT 
NICD4 Add NdeI F GCCCGAGAGCTGCGGGACCATATGGGGCTAGCGCCGG
CGGACGT 
NICD4 Add NdeI R ACGTCCGCCGGCGCTAGCCCCATATGGTCCCGCAGCT
CTCGGGC 
Table 2.1. List of all primers used in this thesis. All sequences are read from left to right and 5’ 
to 3’. 
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Site-directed Mutagenesis 
Another large portion of the DNA plasmids generated in this study were 
generated through either single site directed mutagenesis or multi site directed 
mutagenesis. Multi site directed mutagenesis was performed according to original 
Agilent Technologies protocol (QuikChange Lightning Multi Site Directed Mutagenesis 
Kit, Agilent Technologies) and using the Agilent Technologies PCR program. Single site 
directed mutagenesis was performed using the following protocol adapted from Agilent 
Technologies: 
Step 1 
PCR reaction containing: 
35.4 μL H20 
5.0 μL 10X PFU Turbo Polymerase Buffer 
5.0 μL 2.5 mM dNTPs 
1.0 μL template DNA (30 ng/μL) 
1.3 μL Forward primer (100 ng/μL) 
1.3 μL Reverse primer (100 ng/μL) 
1.0 μL PFU turbo (Agilent Technologies) 
 for a total volume of 50 μL 
 
Step 2  
PCR the reaction mix with the following program: 
Lid 95°C 
1) 95°C 50 seconds (can use 98°C if needed) 
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2) 95°C 50 seconds (can use 98°C if needed) 
3) 55°C 50 seconds 
4) 68°C 24 minutes 
Repeat Steps 2-4 17 times 
5) 68°C 24 minutes 
6) Hold at 12°C indefinitely 
Step 3 
Add 1 μL of DpnI (DpnI, NEB) into each PCR reaction mix and incubate at 37°C for 1 
hour. DpnI digests methylated DNA so should digest template DNA but not amplified 
DNA. 
Step 3 
Transform into bacteria (10 μL of DpnI-digested PCR product into 100 μL of DH5α 
competent cells) and plate onto agar plates containing antibiotic for plasmid. 
Step 4 
Pick bacterial colonies and miniprep to isolate plasmid DNA. 
Step 5 
Sequence colonies to identify the correctly mutagenized clones. 
 
The complete list of mutagenesis primers used in this study is provided in Table 2.2. 
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Primer Name Primer Sequence 
hNICD1 S2538A F  ACTGGTCCGAGGGCGTCTCCGCCCCTCCCACCAGCATGCAGTC 
hNICD1 S2538A R  GACTGCATGCTGGTGGGAGGGGCGGAGACGCCCTCGGACCAGT 
hNICD1 
S2514A/S2517A F  
AGCACCCCTTCCTCACCCCGGCCCCTGAGGCCCCTGACCAGTGGTCCAG
CTC 
hNICD1 
S2514A/S2517A R  
GAGCTGGACCACTGGTCAGGGGCCTCAGGGGCCGGGGTGAGGAAGGG
GTGCT 
hNICD1 L2X F CATCGATGGCCGGCCAATGGTGCTGTCCCGCAAGCGCCGGCGGC 
hNICD1 L2X R  GCCGCCGGCGCTTGCGGGACAGCACCATTGGCCGGCCATCGATG 
hNICD1 S4M F GGCCGGCCAATGGTGCTGCTGATGCGCAAGCGCCGGCGGCAGCATG 
hNICD1 S4M R CATGCTGCCGCCGGCGCTTGCGCATCAGCAGCACCATTGGCCGGCC 
hNICD1 R5A F CGGCCAATGGTGCTGCTGTCCGCCAAGCGCCGGCGGCAGCATGGCC 
hNICD1 R5A R GGCCATGCTGCCGCCGGCGCTTGGCGGACAGCAGCACCATTGGCCG 
hNICD1 Q10K F GCTGTCCCGCAAGCGCCGGCGGAAGCATGGCCAGCTCTGGTTCCCTG 
hNICD1 Q10K R CAGGGAACCAGAGCTGGCCATGCTTCCGCCGGCGCTTGCGGGACAGC 
hNICD1 Q13S F CAAGCGCCGGCGGCAGCATGGCTCGCTCTGGTTCCCTGAGGGCTTC 
hNICD1 Q13S R GAAGCCCTCAGGGAACCAGAGCGAGCCATGCTGCCGCCGGCGCTTG 
hNICD1 Bas Reg 1 
F 
GCTCTGGTTCCCTGAGGGCTTCACTCTTCGCCGAGAGGCCAGCAAGAAG
AAGCGG 
hNICD1 Bas Reg 1 
R 
CCGCTTCTTCTTGCTGGCCTCTCGGCGAAGAGTGAAGCCCTCAGGGAAC
CAGAGC 
hNICD1 Bas Reg 2 
F 
GAGGGCTTCACTCTTCGCCGAGATGCCAGCAATCACAAGCGGCGGGAG
CCCCTCGGC 
hNICD1 Bas Reg 2 
R 
GCCGAGGGGCTCCCGCCGCTTGTGATTGCTGGCATCTCGGCGAAGAGT
GAAGCCCTC 
hNICD1 L2X/S4M 
F 
CATCGATGGCCGGCCAATGGTGCTGATGCGCAAGCGCCGGCGGCAGC 
hNICD1 L2X/S4M 
R 
 GCTGCCGCCGGCGCTTGCGCATCAGCACCATTGGCCGGCCATCGATG 
hNICD1 L2X/S4M 
R5A F 
CATCGATGGCCGGCCAATGGTGCTGATGGCCAAGCGCCGGCGGCAGCA
TG 
hNICD1 L2X/S4M 
R5A R 
CATGCTGCCGCCGGCGCTTGGCCATCAGCACCATTGGCCGGCCATCGAT
G 
hNICD1 L2X/S4M 
Q10K F  
CTGATGCGCAAGCGCCGGCGGAAGCATGGCCAGCTCTGGTTCCC 
hNICD1 L2X/S4M 
Q10K R  
 GGGAACCAGAGCTGGCCATGCTTCCGCCGGCGCTTGCGCATCAG 
hNICD1 R1758S F CGGCCAATGGTGCTGCTGTCCTCCAAGCGCCGGCGGCAGCATGGCC 
hNICD1 R1758S R GGCCATGCTGCCGCCGGCGCTTGGAGGACAGCAGCACCATTGGCCG 
hNICD1 R1761W 
F 
GTGCTGCTGTCCCGCAAGCGCTGGCGGCAGCATGGCCAGCTCTGC 
hNICD1 R1761W 
R 
GCAGAGCTGGCCATGCTGCCGCCAGCGCTTGCGGGACAGCAGCAC 
hNICD1 S1776C F GTTCCCTGAGGGCTTCAAAGTGTGTGAGGCCAGCAAGAAGAAGCGG 
hNICD1 S1776C R CCGCTTCTTCTTGCTGGCCTCACACACTTTGAAGCCCTCAGGGAAC 
hNICD1 R1783W 
F 
GTCTGAGGCCAGCAAGAAGAAGTGGCGGGAGCCCCTCGGCGAGGAC 
hNICD1 R1783W 
R 
GTCCTCGCCGAGGGGCTCCCGCCACTTCTTCTTGCTGGCCTCAGAC 
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hNICD1 R1784L F GAGGCCAGCAAGAAGAAGCGGCTGGAGCCCCTCGGCGAGGACTCC 
hNICD1 R1784L R GGAGTCCTCGCCGAGGGGCTCCAGCCGCTTCTTCTTGCTGGCCTC 
hNICD1 P1796H F GAGGACTCCGTGGGCCTCAAGCACCTGAAGAACGCTTCAGACGGT 
hNICD1 P1796H R ACCGTCTGAAGCGTTCTTCAGGTGCTTGAGGCCCACGGAGTCCTC 
hNICD1 WAAAAP 
F  
CCTGAGTCCCCTGACCAGTGGGCCGCCGCGGCCCCGCATTCCAACGTCT
CCGAC 
hNICD1 WAAAAP 
R 
GTCGGAGACGTTGGAATGCGGGGCCGCGGCGGCCCACTGGTCAGGGGA
CTCAGG 
hNICD1 1771-
1774A F 
CAGCATGGCCAGCTCTGGTTCGCTGCGGCCGCCAAAGTGTCTGAGGCC
AGCAAG 
hNICD1 1771-
1774A R 
CTTGCTGGCCTCAGACACTTTGGCGGCCGCAGCGAACCAGAGCTGGCC
ATGCTG 
hNICD1 
D1839N/R1841Q F 
CCTGACCTGGACGACCAGACAAACCACCAGCAGTGGACTCAGCAGCAC
CTG 
hNICD1 
D1839N/R1841Q R 
CAGGTGCTGCTGAGTCCACTGCTGGTGGTTTGTCTGGTCGTCCAGGTCA
GG 
hNICD2 NT2-5 F CATCGATGGCCGGCCAATGGTACTGCTGTCCCGCAAACGAAAGCGTAA
GCATGGC 
hNICD2 NT2-5 R GCCATGCTTACGCTTTCGTTTGCGGGACAGCAGTACCATTGGCCGGCCA
TCGATG 
hNICD2 NT2-5 
K9Q F 
CTGTCCCGCAAACGAAAGCGTCAGCATGGCTCTCTCTGGCTGCCTG 
hNICD2 NT2-5 
K9Q R 
CAGGCAGCCAGAGAGAGCCATGCTGACGCTTTCGTTTGCGGGACAG 
hNICD2 N1 Bas 
Reg 1 F 
CTCTGGCTGCCTGAAGGTTTCAAAGTGTCTGAGGATGCAAGCAATCACA
AGCGT 
hNICD2 N1 Bas 
Reg 1 R 
ACGCTTGTGATTGCTTGCATCCTCAGACACTTTGAAACCTTCAGGCAGC
CAGAG 
hNICD2 N1 Bas 
Reg 2 F 
GAAGGTTTCAAAGTGTCTGAGGCCAGCAAGAAGAAGCGTCGTGAGCCA
GTGGG 
hNICD2 N1 Bas 
Reg 2 R 
CCCACTGGCTCACGACGCTTCTTCTTGCTGGCCTCAGACACTTTGAAAC
CTTC 
mN1 FL 
L1744X/S1747M F 
CTTTGTGGGCTGTGGGGTGCTGATGCGCAAGCGCCGGCGGCAGCA 
mN1 FL 
L1744X/S1747M R 
 TGCTGCCGCCGGCGCTTGCGCATCAGCACCCCACAGCCCACAAAG 
mN1 FL 
L1744X/S1747M/Q
1753K F 
CTGATGCGCAAGCGCCGGCGGAAGCATGGCCAGCTCTGGTTCCCT 
mN1 FL 
L1744X/S1747M/Q
1753K R 
 AGGGAACCAGAGCTGGCCATGCTTCCGCCGGCGCTTGCGCATCAG 
mN1 FL 2467* F CCTTCCCAGCACAGTTACTCCTAGTCCCCTGTGGACAACACCCCC 
mN1 FL 2467* R GGGGGTGTTGTCCACAGGGGACTAGGAGTAACTGTGCTGGGAAGG 
Table 2.2. List of all primers used for mutagenesis. Sequences are read left to right and 
5’ to 3’. 
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Gene Vector Collection # 
hNICD1 CS2 EL1868 
hNICD1-Luciferase  CS2 EL1869 
hNICD1-MYC CS2 EL1870 
hNICD1-GFP CS2 EL1871 
hNICD2 CS2 EL1872 
hNICD2-Luciferase CS2 EL1873 
hNICD2-MYC CS2 EL1874 
hNICD3 CS2 EL1875 
hNICD3-Luciferase CS2 EL1876 
hNICD3-MYC CS2 EL1877 
hNICD4 CS2 EL1878 
hNICD4-Luciferase CS2 EL1879 
hNICD4-MYC CS2 EL1880 
hNICD1S3A CS2 EL1881 
hNICD1S3A-Luciferase CS2 EL1882 
hNICD1S3A-MYC CS2 EL1883 
hNICD1S2493Δ CS2 EL1891 
hNICD1S2493Δ -Luciferase CS2 EL1892 
hNICD1S2493Δ -MYC CS2 EL1893 
hNICD1/2(NT1-CT2) CS2 EL1896 
hNICD1/2(NT1-CT2)-Luciferase CS2 EL1897 
hNICD1/3(NT1-CT3) CS2 EL1898 
hNICD1/3(NT1-CT3)-Luciferase CS2 EL1899 
hNICD1/4(NT1-CT4) CS2 EL1900 
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hNICD1/4(NT1-CT4)-Luciferase CS2 EL1901 
hNICD2/1(NT2-CT1) CS2 EL1902 
hNICD2/1(NT2-CT1)-Luciferase CS2 EL1903 
hNICD3/1(NT3-CT1) CS2 EL1904 
hNICD3/1(NT3-CT1)-Luciferase CS2 EL1905 
hNICD4/1(NT4-CT1) CS2 EL1906 
hNICD4/1(NT4-CT1)-Luciferase CS2 EL1907 
hNICD1/2(NT35) CS2 EL1908 
hNICD1/2(NT35)-Luciferase CS2 EL1909 
hNICD1/2(NT125) CS2 EL1910 
hNICD1/2(NT125)-Luciferase CS2 EL1911 
hNICD1/2(NT176) CS2 EL1912 
hNICD1/2(NT176)-Luciferase CS2 EL1913 
hNICD1L1755Δ CS2 EL1914 
hNICD1L1755Δ-Luciferase CS2 EL1915 
hNICD1L1755Δ-MYC CS2 EL1916 
hNICD1S1757M CS2 EL1917 
hNICD1S1757M-MYC CS2 EL1918 
hNICD1Q1763K CS2 EL1920 
hNICD1Q1763S CS2 EL1921 
hNICD1KRR CS2 EL1922 
hNICD1NTΔ10 CS2 EL1851 
hNICD1NTΔ10-Luciferase CS2 EL1852 
hNICD1NTΔ10-MYC CS2 EL1923 
hNICD1L1755Δ-GFP CS2 EL1925 
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hNICD1S1757M-GFP CS2 EL1926 
hNICD1L1755Δ / S1757M-GFP CS2 EL1927 
hNICD1LSQ CS2 EL1931 
hNICD1LSQ-MYC CS2 EL1932 
hNICD1(1-50)-Luciferase CS2 EL1933 
hNICD1(1-50)-GFP CS2 EL1934 
hNICD1(1-50)L1755Δ-Luciferase CS2 EL1935 
hNICD1(1-50)S1757M-Luciferase CS2 EL1937 
hNICD1(1-50)S1757M-GFP CS2 EL1938 
hNICD1(1-50)L1755Δ / S1757M-Luciferase CS2 EL1947 
hNICD1(1-50)L1755Δ / S1757M-GFP CS2 EL1948 
hNICD1(1-50)LS-Luciferase CS2 EL1950 
hNICD1(1-50)LS-GFP CS2 EL1951 
hNICD2(1-50)-GFP CS2 EL1952 
hNICD2(1-50)-Luciferase CS2 EL1953 
hNICD3(1-50)-GFP CS2 EL1954 
hNICD3(1-50)-Luciferase CS2 EL1955 
hNICD4(1-50)-GFP CS2 EL1956 
hNICD4(1-50)-Luciferase CS2 EL1957 
hNICD1NTΔ10 / S2493Δ-MYC   CS2 EL1958 
hNICD1NTΔ10 / S2493Δ CS2 EL1959 
hNICD1LSQ / S2493Δ CS2 EL1962 
hNICD1LSQ / S2493Δ-MYC CS2 EL1963 
hNICD1R1758S CS2 EL1964 
hNICD1R1758S-MYC CS2 EL1965 
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hNICD1R1761W CS2 EL1966 
hNICD1R1761W-MYC CS2 EL1967 
hNICD1S1776C CS2 EL1968 
hNICD1S1776C-MYC CS2 EL1969 
hNICD1R1783W CS2 EL1970 
hNICD1R1783W-MYC CS2 EL1971 
hNICD1R1784L CS2 EL1972 
hNICD1R1784L-MYC CS2 EL1973 
hNICD1LSQ / S2A CS2 EL1976 
hNICD1LSQ / S2A CS2 EL1977 
hNICD1NTΔ10 / S2A CS2 EL1978 
hNICD1NTΔ10 / S2A-MYC CS2 EL1979 
hNICD1W4AP CS2 EL1980 
hNICD1W4AP-MYC CS2 EL1981 
hNICD1S2A / W4AP CS2 EL1982 
hNICD1S2A / W4AP-MYC CS2 EL1983 
hNICD1NTΔ10 / W4AP CS2 EL1984 
hNICD1NTΔ10 / W4AP-MYC CS2 EL1985 
hNICD1NTΔ10 / S2A / W4AP CS2 EL1986 
hNICD1NTΔ10 / S2A / W4AP-MYC CS2 EL1987 
hNICD11771-74A CS2 EL1988 
hNICD11771-74A-MYC CS2 EL1989 
hNICD1/2KRR-Luciferase  CS2 EL1994 
hNICD1/2NT10 / KRR-Luciferase CS2 EL1996 
hNICD1NTΔ10 / 1771-74A-MYC CS2 EL1997 
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hNICD11771-74A / S2493Δ-MYC CS2 EL1998 
hNICDNTΔ10 / 1771-74A / S2493Δ-MYC CS2 EL1999 
mNotch1S2467Δ pcDNA3.1 EL2001 
mNotch1LSQ pcDNA3.1 EL2003 
mNotch1LSQ / S2467Δ pcDNA3.1 EL2004 
mNICD1 CS2 EL2007 
mNICD4 CS2 EL2008 
dNICD1 CS2 EL2009 
Fbxw7DN CS2 EL2013 
Fbxw7 CS2 EL2014 
mNotch1 pcDNA3.1 Gift from Stacey Huppert 
FLAG-Itch pCMV-10 Gift from Adriano 
Marchese 
FLAG-ItchC380A pCMV-10 Gift from Adriano 
Marchese 
Renilla luciferase CS2 EL986 
Hes1-Luciferase pGL2-
Basic 
Gift from Stacey Huppert 
GST-β-catenin pGEX Gift from Wenqing Xu 
GST pGEX GE Healthcare Life 
Sciences 
Table 2.3 List of all plasmids generated in this thesis 
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siRNA constructs 
Two distinct siRNA sequences for RBPj knockdown (Dharmacon) were 
transfected into HEK293 cells. The sequences are as follows:  
RBPj 1 sense 5’-GGAAAUAGUGACCAAGAAAUGUU-3’  
RBPj 1 antisense 5’-CAUUUCUUGGUCACUAUUUCCUU-3’  
RBPj 2 sense 5’-GGUGAGUGCUUCAGUUAUAGUUU-3’ 
RBPj 2 antisense 5’-ACUAUAACUGAAGCACUCACCUU-3’ 
 
Mammalian Cell Culture 
 HEK293 cells were maintained in Dulbecco’s Modified Eagle Medium 
(Corning) supplemented with 1% L-Glutamine, 10% (v/v) FBS, 100 µg/ml streptomycin, 
and 100 U/ml penicillin at 37oC with 5% CO2. Transient transfections were performed 
using Fugene HD (Promega) according to the manufacturer’s suggestions. For 
cycloheximide (Sigma-Aldrich) chase experiments, media supplemented with 100 µg/ml 
cyclohexamide was added to cells at the 0 minute time point. Cell were then incubated 
in the presence of cyclohexamide for the duration of the experiment. For microscopy, 
cell were plated on glass bottom MatTek dishes (MatTek Corporation) for imaging. 
Hes-1 Reporter Assays 
HEK293 cells were transiently transfected with 1 µg Hes1-Luciferase, 0.5 µg 
Renilla luciferase, and 1 µg of the indicated Notch construct. Luciferase and Renilla 
luciferase activities were assessed after 24 hrs using the Dual-Glo Luciferase Assay 
System (Promega) according to the manufacturer’s instructions. Experiments were 
performed in triplicate and replicated at least two times, and significance was 
determined using a two-tailed student t-test. The luciferase levels are read on a 
luminometer (Optima Fluostar, as described by Promega (Dual-Glo Luciferase Assay 
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System, Promega). Renilla is used as a control for background luciferase and for cell 
death. The readings are normalized to wild-type NICD or full-length Notch1.  
 
Zebrafish Somite Formation Assay 
mRNAs were synthesized using the SP6 or T7 mRNA Message Machine 
(Ambion). Zygotes were either injected with 25 pg/nl or 100 pg/nl mRNA mixed with 
phenol red using the MPPI-2 injection system (Applied Scientific Instruments). Injected 
embryos were incubated at 28oC until the 10-13 somite stage and scored for proper 
somitogenesis using a Zeiss stemi 2000-CS scope. Live embryos were embedded in 
0.8% agarose and images taken with an Olympus DP72 camera at 4X magnification. 
For immunostaining, embryos were permeabilized with 10 μg/ml Proteinase K and 
stained with α-EphA4 (Tyr-602) (ECM Biosciences) overnight at 40C. Primary antibodies 
were then detected with Alexa-488 secondary antibodies (Life Technologies) and 
imaged on a Nikon Eclipse 80I equipped with a photometrics CoolSNAP ES camera. 
Significance was assessed using Fisher's exact test. 
 
Immunoblot analysis 
 Cells were incubated in non-denaturing lysis buffer (50 mM Tris-HCl 
pH7.4, 300 mM NaCl, 5 mM EDTA, 1% (w/v) Trition X-100, 1 mM PMSF) for 30 min on 
ice. Lysates were rigorously vortexed once at 15 min during the incubation. At the end 
of the incubation, lysates were cleared by centrifugation. Total protein was assessed 
using the Bio-Rad protein assay dye reagent (Bio-Rad). SDS-PAGE and 
immunoblotting were performed using standard techinques. To assesses changes in 
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steady-state protein levels, 1 ug of each DNA construct was transfected into an 
equivalent number of HEK293 cells. 48 hr post-transfection, cells were lysed and 50 µg 
of total protein processed for SDS-PAGE and immunoblottting. The following antibodies 
were used: α-Fbxw7 (Bethyl Laboratories, Cat# A301-720A), α-MYC (9E10), α-Flag 
(Sigma-Aldrich), α-β-Tubulin (Clone E7, Developmental Studies Hybridoma Bank, 
University of Iowa, IA). Secondary antibodies conjugated to horseradish peroxidase 
were purchased from Bethyl Laboratories. Blots were analyzed using ImageJ software. 
 
Live-Cell Imaging 
MatTek dishes were maintained at 37°C by heated stage (Warner Instruments). 
Single-plane confocal videos were taken using a Yokogawa QLC-100/CSU-10 spinning 
disk head (Visitec assembled by Vashaw) attached to a Nikon TE2000E microscope 
using a CFI PLAN APO VC 100× oil lens, NA 1.4, with or without 1.5× intermediate 
magnification, and a back-illuminated EM-CCD camera Cascade 512B (Photometrics) 
driven by IPLab software (Scanalytics). A krypton-argon laser (75 mW 488; Melles 
Griot) with AOTF was used for color excitation. Custom double dichroic mirror and filters 
(Chroma) in a filter wheel (Ludl) were used in the emission light path. Intensity in live-
cells expressing various GFP constructs was measured using ImageJ software. Cells of 
interest were outlined with a selection tool, and measurements were set (area, 
integrated density, and mean gray value). Data points are plotted as the percent of 
initial intensity. 
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Introduction 
The Notch pathway is a highly conserved, metazoan signaling pathway critical for 
organismal development (Koch et al., 2013; Kopan and Ilagan, 2009). Improper 
regulation of the Notch pathway has been shown to contribute to numerous human 
diseases including cancer (Koch and Radtke, 2010; Louvi and Artavanis-Tsakonas, 
2012; Ntziachristos et al., 2014; Ranganathan et al., 2011b; South et al., 2012). The 
Notch pathway communicates transcriptional decisions between adjacent cells through 
the direct interaction of a Delta/Serrate/Lag-2 (DSL) type-1 transmembrane ligand on 
the signaling cell and a Notch type-1 transmembrane receptor on a receiving cell 
(D'Souza et al., 2010). The interaction between ligand and receptor promotes a series 
of proteolytic events resulting in liberation of the Notch intracellular domain (NICD) from 
its membrane tether. Once NICD is liberated into the cytoplasm, it enters the nucleus 
where it forms a complex consisting of CSL (CBF1/RBPjk/Su(H)/Lag-1), MAML 
(Mastermind-like), and CoA (coactivators) (Kovall and Blacklow, 2010). Formation of 
this multimeric complex drives transcription of Notch target genes to promote 
differentiation, stem cell maintenance, proliferation, or apoptosis. In the prevailing 
model, transcriptional termination is mediated, in part, by the E3 ubiquitin ligase 
complex, SCFFbxw7, which promotes its ubiquitin-mediated degradation (Moretti and 
Brou, 2013).  
Much of our understanding of Notch pathway regulation comes from studies of 
Notch mutations in human leukemias. Notch1 is a major driver of T-Cell Acute 
Lymphoblastic Leukemia (T-ALL), and mutations of Notch1 in T-ALL have been studied 
in detail (Ellisen et al., 1991; South et al., 2012; Sulis et al., 2008; Weng et al., 2004). 
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Most mutations occur in the heterodimerization domain (HD) that lead to constitutive 
cleavage and liberation of NICD1 from the holoprotein as well as mutations that truncate 
the C-terminal PEST domain, thereby leading to increased NICD1 stability. Enhanced 
stability of these truncated forms of NICD1 is due to loss of the Fbxw7 recognition 
sequence, LTPSPE, and a poorly characterized phosphoregulated domain (WSSSSP) 
(Chiang et al., 2006; Ellisen et al., 1991; Sulis et al., 2008; Weng et al., 2004). The 
importance of NICD1 turnover in limiting Notch signaling is further highlighted by 
findings, which implicate loss-of-function mutations in Fbxw7 to drive T-ALL (Malyukova 
et al., 2007; O'Neil et al., 2007; Thompson et al., 2007). 
Multiple studies indicate that SCFFbxw7-mediated turnover of NICD1 is not the 
sole mechanism for regulating its steady-state levels, and, thus, its transcriptional 
activity. Mutants of NICD1 that disrupt its interaction with SCFFbxw7 are still ubiquitinated 
and degraded (O'Neil et al., 2007; Thompson et al., 2007). Similarly, NICD1 is degraded 
in Fbxw7-/- mouse embryonic fibroblasts (Tsunematsu et al., 2004). Non-SCFFbxw7-
mediated degradation has been shown to occur via the HECT type E3 ligase, Itch, 
although this mechanism remains unclear (Moretti and Brou, 2013).  
 We have previously used the Xenopus egg extract system to study the 
cytoplasmic regulation of β-catenin turnover (Chen et al., 2014a; Lee et al., 2001; Salic 
et al., 2000a). We now apply the Xenopus egg extract system to study cytoplasmic 
human NICD1 (hNICD1) protein turnover and have identified a novel hNICD1-specific 
degron at its N-terminal end distinct from its C-terminal PEST domain degradation 
elements. We show that mutations in this degron stabilize hNICD1 and potentiate 
hNICD1 activity in vitro and in vivo. Degradation mediated by the N-terminal degron is 
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inhibited by hNICD1 binding to CSL. Finally, we present evidence that mutations within 
the N-terminal degron may function as a driver of Notch1 signaling in human cancers. 
Results 
NICD1 degrades robustly in Xenopus egg extract 
To recapitulate cytoplasmic NICD turnover, we utilized the Xenopus egg extract 
system that has been previously shown to support β-catenin degradation via 
components of the Wnt pathway (Chen et al., 2014a; Lee et al., 2003; Salic et al., 
2000b). We found that radiolabeled in vitro-translated (IVT) hNICD1 degrades robustly 
in Xenopus egg extract. The addition of MG132, a proteasome inhibitor, inhibited the 
degradation of both hNICD1 and β-catenin (Figure 3.1A). Recombinant GST-β-catenin, 
however, potently inhibited the turnover of radiolabeled IVT -catenin but had no effect 
on the turnover of hNICD1 (Figure 3.1B). β-catenin degradation by Wnt pathway 
components requires its phosphorylation by Glycogen synthase kinase 3 (GSK3), and 
addition of inhibitors of GSK3 (e.g. LiCl or BIO) blocks -catenin turnover in Xenopus 
egg extract (Figure 3.2; (Chen et al., 2014a; Salic et al., 2000b)); in contrast, addition of 
LiCl or BIO to extract does not observably decrease the half-life of hNICD1 (Figure 3.2). 
These results show that hNICD1 degradation in Xenopus egg extract occurs in a 
proteasome-dependent manner distinct from that of -catenin. 
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Figure 3.1. hNICD1 is degraded in Xenopus egg extract.  (A) In vitro-translated [35S]hNICD1 
and [35S]β-catenin were incubated in Xenopus egg extract in the presence of DMSO (-) or 
MG132 (+). Samples were removed at indicated times and analyzed by SDS-
PAGE/autoradiography. (B) Same as in (A) except extract was supplemented with MG132 and 
recombinant GST or GST-β-catenin. (C) Schematic of the four human NICD Notch paralogs. 
RAM is RBP-Jκ Associated Module domain, ANK is Ankyrin repeats domain, TAD is 
Transcriptional Activation Domain, and PEST is Proline, Glutamic acid, Serine, Threonine rich 
region. (D) Radiolabeled hNICD paralogs were incubated in extract. Samples were removed at 
the indicated times for analysis by SDS-PAGE/autoradiography. In contrast to hNICD1, hNICD2, 
3, and 4 did not noticeably degrade in Xenopus egg extract. (E) Graph of densitometry 
measurements from (D). (F) Degradation of hNICD Luciferase fusions (hNICD1, 2, 3, and 4-
Luc) parallels degradation of their radiolabeled, untagged versions in Xenopus egg extract. In-
vitro translated NICD Luciferase fusions were incubated in extract and samples removed at the 
indicated times for luminescence measurement. Graph represents mean Luciferase signal for 
two independent experiments (performed in triplicate) normalized to the value of the initial time 
point (100%). 
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NICD degradation within Xenopus egg extract is restricted to the NICD1 paralog 
To determine whether turnover of NICD is paralog-specific, we tested the 
capacity of extract to degrade human NICD2, NICD3, and NICD4 in Xenopus egg 
extract (Figure 3.1C). In contrast to hNICD1, we find that hNICD2, hNICD3 and hNICD4 
are stable throughout the time course of the experiment (Figure 3.1D-E). In order to 
more readily quantify the degradation of NICD proteins in Xenopus egg extract, we 
generated hNICD paralogs fused at their C-terminal ends to firefly Luciferase 
(Luciferase), normally a stable protein in extract (Chen et al., 2014a). We find that the 
hNICD1 Luciferase fusion has a similar half-life in extract as radiolabeled hNICD1 (Fig 
3.1F and Fig 3.3B). The half-lives of hNICD2, 3, and 4 Luciferase fusions were also 
similar to the half-lives of the radiolabeled non-fusion proteins (Figure 3.1F). Residual 
Luciferase activities of the fusion proteins likely reflect the presence of background 
Luciferase protein produced by internal translational start sites in the IVT reaction (Chen 
et al., 2014a). The differential degradation of NICD paralogs is evolutionarily conserved: 
both mouse NICD1 and mouse NICD4 degraded with similar kinetics as their human 
orthologs (Figure 3.3B). Interestingly, we find that the single Drosophila NICD ortholog 
is stable in Xenopus egg extract (Figure 3.3B). 
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Figure 3.2. hNICD1 degradation in Xenopus egg extract occurs independent of GSK3. 
Radiolabeled in vitro-translated [35S]β-catenin or [35S]hNICD1 were incubated in the presence or 
absence of the GSK3 inhibitors LiCl (25 mM) or BIO (375 µM). Samples were removed at the 
indicated times and processed for SDS-PAGE/autoradiography. Water and DMSO were 
controls for LiCl and BIO, respectively. 
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Figure 3.3. NICD1 is degraded in Xenopus egg extract, in contrast to other NICD 
paralogs, and degradation is not affected by C-terminal fusions. (A) [35S]Met-labeled 
hNICD1 and hNICD1-Luc (Luciferase) were incubated in Xenopus egg extract, and samples 
were removed at the indicated times for analysis by SDS-PAGE/autoradiography. (B) Mouse 
NICD1 and NICD4 paralogs (mNICD1 and mNICD4) degrade similarly to their human 
counterparts in Xenopus egg extract. Drosophila dNICD does not degrade in extract. Mouse 
NICD1 (mNICD1), mouse NICD4 (mNICD4), and Drosophila NICD (dNICD1) were incubated in 
Xenopus egg extract and analyzed as in (A). (C) Degradation rates of radiolabeled hNICD 
paralogs fused at the C-terminal end to a MYC epitope are indistinguishable from their non-
tagged versions. Radiolabeled hNICD paralogs fused at their C-terminal ends with the MYC 
epitope were incubated in Xenopus egg extract and analyzed by SDS-PAGE/autoradiography. 
(D) In contrast to Xenopus egg extract, C-terminal MYC fusions of all hNICD paralogs degrade 
when expressed in HEK293 cells. Cells expressing hNICD-MYC paralogs were collected at the 
indicated times after addition of cycloheximide (100 μg/ml) and immunoblotting was performed. 
Tubulin is loading control. 
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NICD1 degradation in Xenopus egg extract does not require its PEST domain or 
Fbxw7 
 We next sought to assess differences between the turnover of NICD proteins in 
Xenopus egg extract and in cultured human cells. To facilitate detection by 
immunoblotting, NICD paralogs were fused at their C-terminal ends with a MYC epitope. 
When NICD MYC fusions were added to Xenopus egg extract, we observed essentially 
identical turnover rates as their non-tagged versions (Figure 3.4C). We next assessed 
protein turnover in HEK293 cells by cycloheximide chase. In contrast to our Xenopus 
egg extract experiments, we find that all NICD paralogs degrade with similar half-lives 
comparable to those that have been previously reported in cultured human cells (Figure 
3.4D) (Choi et al., 2013; Fryer et al., 2004; Malyukova et al., 2007; Mo et al., 2007; 
Palermo et al., 2012; Tsunematsu et al., 2004).  
 All NICD paralogs contain a conserved C-terminal PEST domain that regulates 
its turnover and is recognized, in part, by the SCFFbxw7 ubiquitin ligase complex (Gupta-
Rossi et al., 2001; Moretti and Brou, 2013; Oberg et al., 2001; Wu et al., 2001). 
Because our Xenopus egg extract preparation is predominantly cytoplasmic in 
character, whereas the Fbxw7 E3 ligase that mediates NICD turnover is predominantly 
nuclear (O'Neil et al., 2007), it is possible the inability of extract to support degradation 
of NICD2, 3, and 4 reflects the absence of a component of the SCFFbxw7 complex. 
Consistent with this possibility, we found that, in contrast to HEK293 cell lysates, we 
were unable to detect Fbxw7 in our extract using an antibody that recognizes a highly 
conserved region of Fbxw7 present in the Xenopus protein (Figure 3.4A).  
116 
 
 If Fbxw7 is absent or present at a very low concentration in Xenopus egg extract, 
we hypothesize that hNICD1 degradation is occurring independently of the SCFFbxw7 
complex. hNICD1S3A is a mutant in which three phosphorylated serine residues at 
positions 2514, 2517, and 2539 necessary for recognition by Fbxw7 have been 
changed to alanines (Figure 3.4B) (Fryer et al., 2004; O'Neil et al., 2007; Thompson et 
al., 2007). The hNICDS2493Δ mutant (found in T-ALL patients) encodes a truncation at 
residue S2493 that removes its Fbxw7 recognition site (Figure 2B) (Weng et al., 2004). 
We found that both mutants degrade at rates indistinguishable from that of wild-type 
hNICD1 in Xenopus egg extract (Figure 3.4C-E). Essentially identical results were 
obtained with other mutants encoding truncations within the PEST domain found in T-
ALL patients and with a truncation that completely abolishes the C-terminal PEST 
domain (data not shown).  
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Figure 3.4. PEST domain mutants of hNICD1 degrade in Xenopus egg extract. (A) Fbxw7 
is not detectable in Xenopus egg extract. Equivalent amounts of HEK293 cell lysates and 
Xenopus egg extract (30 ug each) were processed for immunoblotting. Fbxw7 was detected 
using an antibody that recognizes a conserved region of Fbxw7 present in the Xenopus and 
human proteins. Asterisks indicates non-specific band. (B) Schematic of hNICD1 PEST domain 
mutants. (C) The Fbwx7 binding mutant, hNICDS3A, and the PEST domain truncation mutant 
hNICDS2493Δ degrade at similar rates as wild-type hNICD1. (D) Graph of densitometry 
measurements in (C). (E) Turnover rates of hNICD1 PEST mutants fused to Luciferase are 
similar to their untagged, radiolabeled forms in Xenopus extract. In-vitro translated hNICD1S3A 
and hNICD1S2493Δ Luciferase fusions were added to Xenopus extract and sample removed at 
the indicated times for Luciferase activity measurements. Graph represents mean of two 
independent experiments (performed in triplicate) and normalized to value of the initial time 
point (100%). 
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The N-terminal end of hNICD1 encodes a degron required for degradation in 
Xenopus egg extract 
To identify the PEST-independent degron of hNICD1, we generated chimeric 
proteins in which the N- and C-terminal portions of hNICD1 (just upstream of the ANK 
repeats) were swapped for the corresponding regions of other hNICD paralogs (Figure 
3.5A and E). We found that all swaps containing the N-terminal ends of hNICD1 
degraded at a similar rate as wild-type hNICD1 (Figure 3.5B-D). In contrast, constructs 
with C-terminal fragments of hNICD1 were stable throughout the time course of the 
experiment (Figure 3.5F-H). These data suggest that the regulatory region controlling 
hNICD1 degradation in Xenopus egg extract is located within its N-terminal end. We 
performed further swapping analysis to delineate the N-terminal region of hNICD1 
responsible for promoting its degradation in Xenopus egg extract (Figure 3.6A). We 
found that the N-terminal 35 amino acid fragment of hNICD1 is sufficient to confer 
robust degradation of hNICD2 (Figure 3.6B). Collectively, these results demonstrate 
that the amino terminus of hNICD1 contains a Notch1-specific degron (N1-Box) that is 
both necessary and sufficient to degrade hNICD1 in Xenopus egg extract. 
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Figure 3.5. The N-terminal half of hNICD1 promotes hNICD1 degradation in Xenopus egg 
extract. (A) Schematic of hNICD chimeras containing N-terminal hNICD1 fusions. (B) Chimeric 
mutants of NICD paralogs containing the N-terminal half of hNICD1 all degrade in Xenopus egg 
extract. Radiolabeled chimeric mutants were incubated in extract, and samples removed at the 
indicated time points for analysis by SDS-PAGE/autoradiography. (C) Graph of densitometry 
measurements in (B). (D) N-terminal hNICD1 chimeras fused to Luciferase degrade at a similar 
rate as the non-tagged proteins. In vitro-translated proteins were incubated in Xenopus egg 
extract, samples were removed at the indicated times, and Luciferase activity determined. 
Experiments were performed in triplicate. Graphs show mean SD of Luciferase signal 
normalized to the value of the initial time point. (E) Schematic of hNICD chimeras encoding C-
terminal hNICD1 fusions. (F) Chimeric mutants of NICD paralogs containing the C-terminal half 
of hNICD1 are stable in Xenopus egg extract. (G) Graph of densitometry measurements in (F). 
(H) Similar to their radiolabeled, untagged versions, C-terminal hNICD1 chimeras fused to 
Luciferase are stable in Xenopus egg extract. 
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Figure 3.6 Mutations within the 35 amino acid N-terminal region of hNICD1 inhibit its 
degradation in Xenopus egg extract. (A) Schematic of hNICD1 and hNICD2 chimeras. 
Parenthesis indicates the number of N-terminal amino acids of hNICD1 present in each 
chimera. (B) Radiolabeled hNICD1/2 chimeras containing at least the N-terminal 35 amino acids 
of hNICD1 degrade robustly in Xenopus extract. (C) Alignment of the N-terminal regions of the 
human NICD paralogs. (D) Mutation of hNICD1 at position L1755, S1757, or Q1763 potently 
inhibits degradation of hNICD1. Radiolabeled hNICD1 point mutants of non-conserved residues 
within the N-terminal 35 amino acids were incubated in extract and their stability analyzed by 
SDS-PAGE/autoradiography. Δ indicates amino acid deletion. KRR is Lysine rich region. (E) 
Quantification of densitometry from (D). (F) N-terminal mutants of hNICD1 are transcriptionally 
active. hNICD1 point mutants were co-transfected with a HES1-Luciferase Notch reporter into 
HEK293 cells and Luciferase activity assessed after 24 hr. Graph represents  S.D. of 
Luciferase signal normalized to Renilla luciferase (transfection control) of at least 3 independent 
experiments (performed in triplicate).. ***p-value<0.0001, **p-value<0.05 relative to wild-type 
hNCID1. ns is not significant. 
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  We next sought to identify the essential N1-Box residues that facilitate hNICD1 
turnover in Xenopus egg extract. Alignment of the N-terminal end of all four human 
NICD paralogs (Figure 3.6C) revealed non-conserved residues within the first 35 amino 
acids of hNICD1 (corresponding to amino acids 1754-1788 of full-length Notch1) that 
may contribute to hNICD1-specific degradation in extract. To test this possibility, non-
conserved residues within this region of hNICD1 were mutated to their corresponding 
hNICD2 residues, and their stability in extract was assessed (Figure 3.6D-E). We find 
that, in contrast to wild-type hNICD1, the L1755Δ (deletion of residue 2), S1757M, and 
Q1763K mutants of hNICD1 are all stable in Xenopus egg extract as is the triple mutant 
(hNICD1LSQ; Figure 3.7A). Further confirmation of the importance of the first 10 amino 
acids in hNICD1 comes from our demonstration that the hNICD1NTΔ10 mutant (lacking 
the N-terminal 10 amino acids) is stable in extract (Figure 3.7A).  
To confirm that the increased stability of point mutants is not due to protein 
misfolding, we performed Notch transcription assays (Figure 3.6F). All five mutants 
tested retained the capacity to stimulate HES1-Luciferase reporter activity, indicating 
that the proteins were not grossly misfolded. Furthermore, the three stabilized mutants 
demonstrate increased reporter activity (Figure 3.6F). Based on these results, we tested 
whether replacing the N-terminal 10 amino acids of hNICD2 with those of hNICD1 was 
sufficient to promote degradation of the predominantly hNICD2 chimera (Figure 3.7B-
C). Whereas hNICD1/2 chimeras that exchanged the first 10 residues (hNICD1/2NT10) or 
the Lysine rich region (hNICD1/2KRR) did not promote degradation, a combination of 
these swaps (hNICD1/2NT10/KRR) showed enhanced turnover (Figure 3.7B). Substantial 
degradation was observed for the hNICD1/2 chimera that replaced the N-terminal 35 
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amino acids of hNICD2 with those of hNICD1 (Figure 3.7B). These results suggest that, 
although the N-terminal 10 amino acids of hNICD1 are critical for mediating its 
degradation, the N-terminal 35 amino acids of hNICD1 represents the minimal unit that 
is required to impart hNICD2 with the capacity to degrade in extract (the N1-Box).  
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Figure 3.7. The first 10 amino acids of hNICD1 are critical for N1-Box-mediated 
degradation, whereas the first 50 amino acids of hNICD1 are required to promote 
degradation of heterologous proteins. (A) The N-terminal ten amino acids of hNICD1 contain 
amino acids critical for its degradation. Radiolabeled hNICD1NTΔ10 and hNICD1LSQ were 
incubated in Xenopus egg extract and samples removed at the indicated times for analysis by 
SDS-PAGE/autoradiography. (B) Degradation of hNICD1/2 chimera-Luciferase fusions in 
Xenopus egg extract parallels degradation of the radiolabeled, untagged versions in extract. In 
vitro-translated hNICD1/2 chimeras fused to Luciferase were incubated in extract, samples 
removed at the indicated times, and Luciferase activity determined. Graph represents mean  
s.e.m. from three independent experiments (performed in triplicate). (C) Schematic showing the 
first 35 residues of the hNICD1/2 chimeras used in (B). (D) The N-terminal 50 amino acids of 
hNICD1 and their mutants were fused to Luciferase and incubated in Xenopus egg extract. 
Samples were removed at the indicated times, and Luciferase activity measured. Graph 
represents mean  s.e.m. of two independent experiments (performed in triplicate) and 
normalized to the value of the initial time point. (E) Fusion of the N-terminal 50 amino acids of 
hNICD1 to GFP promotes its degradation in human cultured cells. GFP, hNICD1-GFP and 
hNICD1(1-50)-GFP were expressed in HEK293 cells. At time 0 min, cycloheximide (100 µg/ml) 
was added and live cell imaging performed. Representative images are shown. (F) In contrast to 
hNICD1, the N-terminal 50 amino acids of hNICD2 and 3 fused to GFP were stable in HEK293 
cells. Graph represents mean  s.e.m. of GFP fluorescence normalized to value of the initial 
time point. Experiments were performed at least twice with >10 cells quantified for each 
construct.  
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To determine whether the N-terminal region of hNICD1 can act in an 
autonomous fashion to promote turnover of a stable heterologous protein, we fused the 
N-terminal 50 residues of hNICD1 to Luciferase. We chose 50 amino acids because, 
based on secondary structure predictions, it represents a discrete structural unit, and 
we sought to minimize protein misfolding. We found that hNICD1(1-50)-Luc degraded in 
extract in contrast to Luciferase alone (Figure 3.7D). To further demonstrate that 
mutants identified in our hNICD1/2 chimera studies represent critical amino acids of the 
N1-Box (rather than altering accessibility or conformation of a degradation signal 
elsewhere on the protein), we generated the analogous L1755Δ, S1757M, and Q1763K 
mutants in the hNICD1(1-50)-Luc fusion (Figure 3.7D). As expected, all the mutants 
were stable in Xenopus extract, indicating that residues L1755Δ, S1757M, and Q1763K 
are critical for N1-Box activity.  
We tested if the hNICD1 N1-Box was functional in human cells by fusing the N1-
Box to GFP and monitoring its turnover by live-cell imaging upon cycloheximide 
treatment. In contrast to GFP alone, hNICD1(1-50)-GFP showed a loss of fluorescence 
similar to the rate for the full-length hNICD1-GFP fusion (Figure 3.7E,F). As controls, we 
showed that GFP fusions of the first 50 amino acids of hNICD2 and 3, and the 
hNICD1(1-50) triple mutant (hNICD1(1-50)LSQ) did not exhbibit substantial GFP turnover 
over the time course of our measurements (Figure 3.7F). These results indicate that the 
degradation machinery that recognizes the N1-Box of hNICD1 is evolutionarily 
conserved in both Xenopus egg extract and cultured human cells. 
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The N1-Box controls hNICD1 stability and activity in vitro and in vivo 
Our initial studies with the L1755Δ, S1757M, and Q1763K mutants of hNICD1, 
which were all more stable than the wild-type protein in Xenopus egg extract, indicate 
that they stimulated higher levels of Notch reporter activity (Figure 3.6F). We next 
examined whether N1-Box-regulated degradation of hNICD1 correlates with Notch 
transcriptional activity. The N1-Box mutants, hNICD1NTΔ10 and hNICD1LSQ, were tagged 
at their C-terminal end with the MYC epitope to facilitate their detection, equivalent 
amounts of DNA were transfected into HEK293 cells, and protein levels were assessed 
by immunoblotting (Figure 3.8A). As expected, both N1-Box mutants display higher 
steady-state levels of protein compared to wild-type hNICD1, consistent with a 
decreased rate of degradation of the mutants (Figure 3.8A and 3.9). Consistent with 
their increased stability, both hNICD1NTΔ10 and hNICD1LSQ have greater transcriptional 
activity than wild-type hNICD1 (Figure 3.8B). To ensure that the increased transcription 
we observe is not an artifact of transiently expressing the intracellular domain fragment, 
and to demonstrate evolutionary conservation, we generated the analogous N1-Box 
mutant in the full-length mouse Notch1 receptor (mNotch1LSQ). Consistent with our 
hNICD1 studies, full-length mNotch1LSQ demonstrated elevated Notch transcriptional 
activity compared to full-length wild-type mNotch1 (Figure 3.8C). A mutation in the HD 
domain of human Notch1 (L1601P) identified in T-ALL patients has been shown to 
result in a constitutively activated “leaky” Notch1 receptor due to its constitutive 
cleavage from the plasma membrane (Chiang et al., 2006; Thompson et al., 2007; 
Weng et al., 2004). When the L1601P mutant is combined with mNotch1LSQ, an 
additional increase in transcriptional activation is observed (Figure 3.8C). These studies 
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indicate that regulation of steady-state levels of NICD1 by N1-Box alters Notch1 
transcriptional activation.  
In order to demonstrate that the N1-Box regulates Notch1 function in an in vivo 
context, we assessed its effects on somite formation in the developing embryo of Danio 
rerio. The Notch1 receptor has an established role in somitogenesis in mice and in D. 
rerio (Harima and Kageyama, 2013; Lewis et al., 2009), and misregulation of Notch 
signaling during development results in readily observable disruption of the symmetric, 
bilaterally formed somites (Figure 3.8D). Conveniently, this biological readout is highly 
dose-sensitive: injecting 100 pg mNotch1 mRNA results in defects in somitogenesis in 
90% of the embryos, whereas only 25% of embryos are affected with injection of 25 pg 
mNotch1 mRNA (Figure 3.8D). Consistent with a role for N1-Box in vivo, injecting 
embryos with 25 pg mRNA of the mouse Notch1 N1-Box mutant, mNotch1LSQ, resulted 
in 47% of embryos with defective somite formation, nearly double that of wild-type 
mNotch1 mRNA (Figure 3.8E). A similar effect on somitogenesis is observed in the 
background of the constitutively activated L1601P mutation (Figure 3.8E). These results 
support a role for N1-Box in regulating Notch1 signaling in vivo. 
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Figure 3.8. hNICD1 N1-Box mutants have elevated steady-state levels and increased 
activity in cultured human cells and zebrafish embryos. (A) N1-Box mutants (hNICDNTΔ10 
and hNICDLSQ), the Fbwx7 binding mutant (hNICD1S2A), the WSSSSP mutant (hNICD1W4AP), or 
combinations of these mutants were expressed in HEK293 cells and immunoblotting of lysates 
performed. Tubulin is control. (B) Stabilizing hNICD1 mutants of the N1-Box, Fbwx7, and 
WSSSP exhibit higher transcriptional activity compared to wild-type hNICD1. hNICD1 mutants 
alone or in combination were transfected with a HES1-Luciferase Notch reporter into HEK293 
cells and luciferase activity assessed after 24 hr. Graphs show mean  S.D.. of Luciferase 
signal normalized to Renilla Luciferase (transfection control) of at least 2 independent 
experiments (performed in triplicate). p-value is <0.002 relative to wild-type hNICD1 for all 
mutants.  (C) The full-length Notch1 N1-Box mutant exhibits increased Notch transcriptional 
activity. HEK293 cells were transfected with plasmids encoding full-length mNotch1 receptor, 
mNotch1LSQ, mNotch1L1601P, or mNICD1L1601P/LSQ plus the HES1-Luciferase Notch reporter. 
mNICD1L1601p is an HD mutant that is constitutively cleaved from the holoreceptor to release the 
intracellular domain. Graphs shows the mean + S.D. Luciferase activity normalized to Renilla 
luciferase (transfection control) and is representative of four independent experiments 
performed in triplicate. *p-value<0.007 relative to wild-type. (D) The N1-Box Notch1 mutant 
exhibit enhanced capacity in zebrafish embryos to disrupt somitogenesis. (Top) Representative 
images taken at the 10-13 somite stage of an uninjected D. rerio embryo or injected with 100 pg 
of mNotch1 mRNA. (Bottom). Graph is percentage of D. rerio embryos at the 10-13 somite 
stage with defective somites. All data is from 3 clutches collected from 3 unique breeding pairs 
per clutch. n=78-200 embryos per injection. Compared to 25 pg Notch1 mRNA injection: 
P<0.05. Compared to 25 pg injection of hNICD1LSQ; S2467Δ mRNA injection: P<0.005, except for 
comparison to the Notch1 100 pg injection which is insignificant. 
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Two cis elements have been identified within the PEST domain that facilitate 
NICD turnover - the conserved LTPSPE sequence recognized by the SCFFbxw7 complex 
(Fryer et al., 2002; Fryer et al., 2004; O'Neil et al., 2007; Thompson et al., 2007) and the 
WSSSSP sequence (Chiang et al., 2006). In order to determine the contributions of 
these two degradation signals and the N1-Box on NICD1 protein stability, we made 
mutants that disrupted their functions both singly and in combination. Consistent with 
previous studies, we find that mutation within the LTPSPE (S2514A/S2517A; 
hNICD1S2A), WSSSSP (hNICD1W4AP), both LTPSPE and WSSSSP (hNICD1S2A/W4AP), or 
truncation of the PEST region (hNICD1S2493Δ), results in increased protein levels when 
expressed in cultured cells (Figure 3.8A) (Chiang et al., 2006; Fryer et al., 2004; O'Neil 
et al., 2007; Thompson et al., 2007; Weng et al., 2004). Increased steady-state levels of 
hNICD1S2A and hNICD1W4AP mutants are also observed in combination with the NTΔ10 
mutation when compared to wild-type hNICD1. Interestingly, there is an observable 
enhancement in protein levels when the hNICD1NTΔ10 mutation is combined with W4AP 
and/or S2493Δ, but not with the S2A mutation. All stabilizing mutants activate the HES1 
reporter to a greater extent than wild-type hNICD1, and differences in protein levels of 
individual hNICD1 mutants roughly correlate with the capacity of the mutant to activate 
Notch transcription in reporter assays (Figure 3.8B). Consistent with their enhanced 
stability, hNotch1W4AP and hNotch1S2493Δ, when combined with NTΔ10, exhibit increased 
transcriptional activation (in contrast to hNICD1S2A) (Figure 3.8B). These results suggest 
the WSSSSP sequence and the N1-Box act independently of each other. The absence 
of further activation by hNICD1NTΔ10 or hNICD1W4AP upon mutation in the Fbwx7 binding 
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site may indicate that stabilization by NTΔ10 or WSSSSP fully saturates the SCFFbxw7 
complex, which may be limiting.   
This pattern of interaction between the NTΔ10 and S2493Δ mutations in hNotch1 
was also observed in zebrafish embryos in our somitogenesis assay. The number of 
embryos with somitogenesis defects following injection of mNotch1S2467Δ mRNA was 
statistically greater when compared to injection of wild-type mNotch1 mRNA (Figure 
3.8E). Similarly, the N1-Box mutant (mNotchLSQ) was more potent than the PEST 
truncation mutant, and the effect of the N1-Box and PEST truncation double mutant on 
somitogenesis was greater than either one alone (Figure 3.8E). A similar pattern was 
observed in zebrafish somitogenesis in the L1601P mutant background. 
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Figure 3.9. hNICD1 degron mutants have decreased rates of degradation in cultured 
human cells. MYC-tagged hNICD1, N1-Box mutants (hNICDNTΔ10 and hNICDLSQ), PEST 
mutants (hNotch1S2A, hNotch1W4AP, and hNICD1S2493Δ) and a combination mutant 
(hNICD1NTΔ10/S2493Δ) were expressed in HEK293 cells. Cycloheximide (100 µg/ml) was added at 
0 min and samples collected at the indicated times for immunoblotting. Tubulin is loading 
control. 
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The N1-Box is not regulated by Fbxw7 or Itch 
It is possible that there are Fbxw7 sites in hNICD1 other than its PEST region. To 
more carefully assess whether Fbxw7 regulates the N1-Box, we overexpressed Fbxw7 
and a dominant-negative form (Fbxw7DN) that lacks the Fbox domain necessary for 
interaction within the SCF complex (Skaar et al., 2013; Wu et al., 2001). As previously 
reported, overexpression of Fbxw7 decreases, whereas overexpression of Fbxw7DN 
increases, steady-state levels of hNICD1 in HEK293 cells (Figure 3.10A) (Gupta-Rossi 
et al., 2001; Wu et al., 2001). In contrast, overexpressing Fbxw7 or Fbxw7DN did not 
affect levels of the Fbxw7 binding site mutant, hNICD1S2A (Figure 3.10A). The effects of 
overexpressing Fbxw7 and Fbxw7DN on wild-type hNICD1 were similarly observed for 
hNICD1W4AP (Figure 3.10A), consistent with a previous study suggesting that the 
WSSSSP site acts independently of the SCFFbxw7 complex (Chiang et al., 2006). A 
similar effect was observed with NICD1NTΔ10, indicating that the N1-Box-mediated 
degradation of NICD1 is independent of the SCFFbxw7 complex. 
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Figure 3.10. N1-Box mutants do not affect the capacities of the E3 ligases, Fbxw7 and 
Itch, to regulate hNICD1 levels in cultured human cells. (A) Overexpression of Fbxw7 and 
Fbxw7DN decreases and increases, respectively, steady-state levels of hNICD1, hNICDNTΔ10, 
and hNotch1W4AP. In contrast, overexpression of Fbxw7 and Fbxw7DN had no effect on levels of 
the Fbxw7 binding mutant, hNICDS2A. (B) Overexpression of ITCH and its dominant-negative 
mutant, ITCHC380A, decreases and increases, respectively, steady-state levels of all hNICD1 
constructs. Expression studies were performed in HEK293 cells. hNICD1 constructs were 
tagged at their C-terminal ends with MYC, and Itch and ItchC380A were tagged at their C-terminal 
ends with FLAG to facilitate their detection by immunoblotting. Tubulin is loading control. 
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The E3 ubiquitin ligase, ITCH, has also been shown to promote PEST domain-
independent NICD1 degradation, although its binding site has not been well 
characterized (Mazaleyrat et al., 2003; McGill and McGlade, 2003; Qiu et al., 2000). As 
previously shown, overexpression of ITCH decreases, whereas overexpression of a 
dominant-negative form of ITCH, ITCHC380A, increases, the steady-state levels of 
hNICD1 in HEK293 cells (Figure 3.10B). We find that similar results are obtained for all 
the mutants, indicating that ITCH does not mediate NICD1 degradation through the N1-
Box, WSSSSP, or LTPSPE.  
 
Binding of CSL to hNICD1 regulates its stability 
 Because of the sequence overlap between the N1-Box and the RAM domain (the 
major cis factor involved in CSL binding (Nam et al., 2003; Tamura et al., 1995)) (Figure 
3.11A), we tested whether the binding of CSL to hNICD1 could influence hNICD1 
stability. To examine this possibility, we incubated recombinant CSL (expressed and 
purified from the Sf21/baculovirus system) with Xenopus egg extract and assessed its 
effect on hNICD1 turnover. We find that CSL inhibits degradation of hNICD1 in extract 
in a dose-dependent manner (Figure 3.11B-C). If the regulation of NICD1 stability by 
CSL occurs via direct binding, mutants of NICD1 that prevent it from binding to CSL 
should no longer be inhibited by CSL. This appears to be the case as the degradation of 
the hNICD11771-74A mutant, which lacks the capacity to interact with CSL (Chu and 
Bresnick, 2004; Vasquez-Del Carpio et al., 2011), is not inhibited by recombinant CSL 
(Figure 3.11B-C). We speculate that the predominantly cytoplasmic character of 
Xenopus egg extract contains low levels of CSL in contrast to human cells; thus, 
hNICD11771-74A should turn over at a faster rate than wild-type hNICD1. Consistent with 
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this, we observe lower steady-state level of hNICD11771-74A than wild-type hNICD1 when 
expressed in HEK293 cells (Figure 3.11D-E).  
Because degradation of the NICD via the SCFFbxw7/PEST domain is dependent 
on assembly of a transcriptional complex involving CSL (Fryer et al., 2002; Fryer et al., 
2004), we predict that turnover of the hNICD11771-74A mutant is primarily mediated by the 
N1-Box. If this is the case, an N1-Box/CSL-binding double mutant should be more 
stable than the N1-Box mutant. This increased stability is due to incapacity of the CSL-
binding mutant to assemble into a transcriptional complex (in contrast to the N1-Box 
mutant) and, thus, would not be degraded via the SCFFbxw7 complex. Consistent with 
this idea, we find that the steady-state level of hNICD1NTΔ10/1771-74A is greater than that of 
hNICD1NTΔ10 (Figure 3.11D-E).  
Conversely, in an hNICD1 PEST mutant, the inability to bind CSL should lead to 
decreased protein stability due to enhanced N1-Box-mediated degradation. Consistent 
with this model, we find that the steady-state level of hNICD11771-74A / S2493Δ  is lower than 
that of hNICD1S2493Δ (Figure 3.11D-E). These results provide strong evidence that CSL 
binding to NICD1 inhibits its turnover by blocking N1-Box-mediated degradation. 
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Figure 3.11. N1-Box-mediated hNICD1 degradation in Xenopus egg extract and cultured 
human cells is inhibited by its binding to CSL. (A) Schematic showing overlap of the N1-Box 
(yellow) and RAM domains (blue). Overlapping sequence is displayed in green. The ΦWΦP 
motif is outlined by a black box. (B) Recombinant CSL inhibits degradation of hNICD1 (but not a 
CSL binding mutant of hNICD) in a dose-dependent manner in Xenopus egg extract. 
Radiolabeled hNICD1 or hNICD11771-74A were incubated in Xenopus egg extract in the presence 
of increasing amounts of recombinant CSL. Samples were removed after 1 hr and subjected to 
SDS-PAGE/autoradiography. (C) Graph of densitometry measurements in (B) normalized to 
Tubulin. (D) Steady-state levels of the CSL binding mutant, hNICD111771-74A, are lower than the 
wild-type protein in cultured human cells. Plasmids encoding the indicated N1-Box and CSL 
binding mutants tagged with the MYC epitope were transfected into HEK293 cells and 
immunoblotting performed. Tubulin is loading control. (E) Graph of densitometry measurements 
in (D). Graph shows mean  SD of MYC intensities normalized to Tubulin for 4 independent 
experiments. ***p-value<0.01, *p-value<0.1. 
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Mutations within the N1-Box are potential drivers of Notch-mediated 
tumorigenesis 
Multiple studies have identified mutations in the Notch1 receptor as a major 
cancer driver (Koch et al., 2013; Ntziachristos et al., 2014; South et al., 2012). Because 
our studies indicate that loss of N1-Box mutation promotes Notch signaling to an equal 
or greater extent than mutations found in T-ALL patients, we sought to determine 
whether mutations within the N1-Box also occur in human cancers. Utilizing the NIH 
Catalogue of Somatic Mutations in Cancer (COSMIC) database, we identified two gain-
of-function mutations in patient tumors that are located within the first 35 residues of 
hNICD1 (Figure 3.12A). We find that both mutants (hNICD1R1758S and hNICD1S1776C) 
exhibit greater Notch transcriptional activity than wild-type hNICD1 and have elevated 
steady state protein levels when compared to wild-type hNICD1 (Figure 3.12B-C).  
Furthermore, we demonstrate that these mutants have enhanced activity in vivo, and 
injection of D. rerio embryos with mRNA from either mutant show significantly increased 
defects in somitogenesis compared to injection of wild-type hNICD1 mRNA (Figure 
3.12D). These studies are consistent with mutations within the N1-Box as potential 
cancer drivers that act by stabilizing NICD1. 
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Figure 3.12. Mutations within the N1-Box of hNotch1 in human cancers have enhanced 
signaling activity. (A) Table of somatic mutations found within residues 1754-1788 of hNotch1 
(residues 1-35 of hNICD1) from the COSMIC database. (B) Both mutants in the N1-Box 
demonstrate elevated Notch reporter activity. HEK293 cells were transfected with plasmids 
encoding hNICD1 mutants found in human cancers in (A) and the HES1-Luciferase Notch 
reporter. Graph is representative of at least three independent experiments performed in 
triplicate and show  S.D. of Luciferase signal normalized to Renilla luciferase (transfection 
control). **p-value<0.007 for all mutants versus hNICD1. (C) The R1758S and S1776C mutants 
of hNotch1 have elevated steady-state protein levels when expressed in cultured cells. HEK293 
cells were transfected with MYC epitope-tagged hNICD1 encoding the human N1-Box cancer 
mutants and immunoblotting performed. Tubulin is loading control. Intervening lanes were 
removed. (D) Graph is percentage of D. rerio embryos at the 10-13 somite stage with defective 
somites injected with 50 pg of the indicated hNICD1 mRNA. All data is from at least 3 clutches 
collected from 3 different breeding pairs. n=30-320 embryos per injection. ***p-value<0.0005 
versus hNICD1. 
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Discussion 
In T-ALL, mutations of Notch1 that truncate the C-terminal PEST domain remove 
key cis factors necessary for its proteasomal-mediated degradation, highlighting the 
importance of regulating NICD1 protein levels upon its liberation from the plasma 
membrane (Ntziachristos et al., 2014; South et al., 2012). Prior studies indicated that 
degradation of the intracellular domain of Notch1 (the most ubiquitously expressed of 
the four Notch paralogs) differs from those of the other three Notch paralogs (Chiang et 
al., 2006; Tsunematsu et al., 2004; Wu et al., 2001). Herein, we identify the N1-Box, a 
novel degron of NICD1 that we identified using Xenopus egg extract. We show that the 
N1-Box is transferable as an autonomous degron and that its activity is inhibited by 
NICD1 binding to CSL. We show that the N1-Box is conserved in vertebrates and that 
mutations in the N1-Box lead to increased Notch1 activity in vivo in zebrafish. Finally, 
we demonstrate that mutations in the N1-box of Notch1 found in human cancers have 
increased steady-state levels and enhanced activity. Further evidence for an in vivo role 
for the N1-Box comes from a previous report demonstrating that a chimeric receptor 
encoding the Notch2 extracellular domain and the Notch1 intracellular domain 
(Notch21) is two-fold more active compared to wild-type Notch1 when expressed at 
similar levels in mice (Liu et al., 2013). Interestingly, the Notch21 chimeric fusion 
deleted the N1-Box of NICD1. Thus, it is possible that the increased activity of this 
chimera is due to increased stability of its intracellular domain. Based on our results, we 
propose a model (Figure 3.13) in which the liberated NICD1 (upon cleavage from the 
Notch1 receptor by γ-secretase) has two fates: (1) rapid degradation and inactivation via 
its N1-Box or (2) binding to CSL and Notch transcriptional complex components to drive 
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transcription of Notch target genes (Figure 3.13). Termination of Notch1 signaling 
occurs upon ubiquitin-mediated degradation by the SCFFbxw7/proteasome.  
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Figure 3.13. Model of N1-Box-mediated regulation of hNotch1 signaling. See text for 
details. 
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Previous studies have shown that the NICD has the capacity to assemble into 
higher order (intramolecular or intermolecular) forms, and disruption of these higher 
order forms are required for NICD binding to CSL (Kelly et al., 2007; Vasquez-Del 
Carpio et al., 2011). It is possible that these higher order complexes may promote N1-
box-mediated degradation by blocking NICD1 binding to CSL. Alternatively, these 
higher order structures may inhibit NICD1 turnover as well as transcriptional activation 
by blocking the activity of the N1-box and its overlapping RAM domain. Further studies 
are needed to resolve these two possibilities. 
Although it is obvious that there are advantages for a mechanism to terminate 
transcription by proteolysis, it is not as clear why a cell would have a mechanism for 
degrading cytoplasmic NICD1. Why is the cytoplasmic level of NICD1 not limited 
exclusively by its release from the holoprotein upon receptor activation? One possibility 
is that this system dampens the stochastic flux in the system, thereby minimizing noise. 
Thus, a threshold level of Notch receptor activation needs to occur in order for 
transcription to be activated. This may explain why the Drosophila NICD does not 
encode an N1-Box as stochastic flux in Notch signaling plays an important role during 
neuroblast differentiation via the mechanism of lateral inhibition (Artavanis-Tsakonas et 
al., 1999). Conversely, once the transcriptional complex is fully saturated (i.e. all CSL is 
occupied by NICD1), unbound NICD1 could be degraded to limit the activation window. 
This model is consistent with the digital response model proposed for Notch1 pathway 
activation (Ilagan et al., 2011). Regardless, the importance of NICD1-mediated 
degradation in maintaining normal Notch1 signaling in humans is evidenced by our 
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findings that mutations of the N1-Box that lead to hNICD1 stabilization are found in 
human cancers. 
Of the four Notch paralogs, why is the N1-Box only present in the Notch1 
paralog? It is possible that differences in regulation between the four Notch paralogs 
may also simply reflect differences in their transcriptional behavior. One example is the 
requirement for Notch2 over Notch1 in liver development (Sparks et al., 2010), in which 
decreased levels of the Notch2 receptor, but not Notch1, leads to Alagille syndrome 
(McDaniell et al., 2006). Also consistent with differences in the transcriptional behavior 
between different Notch paralogs is the observation that certain Notch-driven cancers 
are associated with particular Notch paralogs (Bellavia et al., 2000; Callahan and 
Raafat, 2001; Capobianco et al., 1997; Kiaris et al., 2004; Pancewicz and Nicot, 2011).   
Currently, γ-secretase inhibitors (GSIs) are the best characterized Notch pathway 
therapeutics. Unfortunately, because of their pan-Notch inhibitory activities, there are 
many associated adverse effects that limit their long-term use (Espinoza and Miele, 
2013; Extance, 2010; Milano et al., 2004; Morell and Strazzabosco, 2013; van Es et al., 
2005; Wong et al., 2004). Thus, one long-term goal for treating Notch-driven cancers is 
to develop paralog-specific drugs in order to minimize adverse effects associated with 
pan-Notch inhibition. Our identification of the NICD1-specific N1-Box provides a 
potential path to develop Notch1-selective inhibitors. Compounds that disrupt NICD1-
CSL interaction may be particularly potent as they would not only block NICD1-
mediated transcription, but also promote NICD1 degradation. The development of such 
compounds would be greatly facilitated by the identification of the E3 ubiquitin ligase for 
the N1-Box. 
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CHAPTER IV 
 
DISCUSSION AND FUTURE DIRECTIONS 
 
Introduction 
 The work presented in this dissertation represents mostly biochemical, cell-
based, and in vivo experiments identifying a novel regulatory region of NICD1 which 
stabilizes the NICD and hyperactivates Notch-mediated transcription which elucidates a 
novel mechanism that modulates the Notch signaling pathway. In the current Chapter, I 
discuss and provide future directions for the results described in the previous two 
Chapters. I have divided this chapter into parts I and II. Part I focuses exclusively on the 
regulation of the NICD via its novel N1-Box and the implications for Notch signaling. 
Part II focuses on the future of the Notch-Wnt signaling network and the implications for 
“Wntch” signaling.  
Part I 
Discussion 
 Utilizing Xenopus egg extract, cell-based assays, and zebrafish embryos we 
identified and characterized the N1-Box region of NICD1 as a regulatory domain of 
Notch signaling, which has not been previously characterized. This novel region is very 
likely a driver of Notch-mediated cancers in which Notch acts as an oncogene. 
Additionally, we have identified cis-acting factors of NICD1 that regulate the capacity of 
the N1-Box to promote degradation.  
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Our initial observation was that human NICD1 degrades robustly in Xenopus egg 
extract, and NICD2, 3, and 4 do not (Figure 3.1). NICD1 degradation is proteasome-
dependent, as the addition of MG132 inhibits its turnover (Figure 3.1). NICD1’s 
degradation occurs distinctly from the previously characterized β-catenin degradation in 
Xenopus egg extract (Figure 3.1). Additionally, degradation of NICD1 is GSK3-
independent, contradicting previous reports about Notch1 degradation (Espinosa et al., 
2003; Foltz et al., 2002; Jin et al., 2009b) (Figure 3.2). These results were validated 
using mouse NICD1 and NICD4 and tagged versions of the human NICDs, which also 
degrade differentially (Figure 3.2). Interestingly, all 4 Myc-tagged NICD constructs 
degrade in HEK293 cells as assessed by cycloheximide chase assay, even though only 
NICD1-Myc degrades in Xenopus egg extract (Figure 3.3). The Xenopus egg extract 
system allows us to separate distinct dynamic degradation pathways, which is much 
more difficult in cell culture. The degradation of NICD1 in Xenopus egg extract is 
independent of previously-identified PEST/Fbwx7-dependent degradation of NICD1 in 
cell culture (Figure 3.4). So which domain regulates NICD1 turnover in Xenopus egg 
extract? 
We generated N-terminal and C-terminal fragments of NICD1 fused with the 
respective N-terminal and C-terminal fragments of the other NICD paralogs to address 
that question. We were able to identify that NICD1 degradation is N-terminal dependent 
(Figure 3.5). We narrowed the N-terminal regulatory region of NICD1 down to the first 
35 amino acids of NICD1 (Figure 3.6). The NICD1 and the Notch 2, 3, 4 ICDS have 
conserved N-terminal domains within those 35 amino acids but the very N-terminus is 
not conserved among the Notch paralogs. We found that three key residues at the very 
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N-terminal region of NICD1 (L2, S4, and Q10 in human NICD1) stabilize the NICD1 
when they are individually mutated to resemble NICD2 in Xenopus egg extract (Figure 
3.6). These stable mutated forms of NICD1 also hyperactivate Notch signaling in 
HEK293 cells (Figure 3.6). When these three residues are collectively mutated to 
resemble NICD2, the NICD1 is stable in HEK293 cells (Figure 3.6). These results 
indicate that the N-terminal region of NICD1 is necessary for its degradation. But is this 
N-terminal region sufficient to promote degradation?  
The heterologous addition of the N-terminal region of N1ICD onto the stable 
proteins NICD2, GFP, and Luciferase was sufficient to promote their degradation in 
Xenopus egg extract and in HEK293 cells (Figure 3.6; Figure 3.7). Our results show that 
the N-terminal region of NICD1 is both necessary and sufficient to promote degradation 
of proteins, fully validating it as a novel degron. We have designated this new regulatory 
region of NICD1 as the N1-Box. Our results show that the N1-Box is both necessary 
and sufficient to promote degradation of proteins in Xenopus egg extract and HEK293 
cells.  
Next, we investigated the potential cooperation between the newly identified N1-
Box and previously established regulatory domains of NICD1, particularly the PEST 
domain and the WSSSSP domains (Chiang et al., 2006; Fryer et al., 2004). The N1-Box 
hyperactivates Notch signaling to a higher extent than the other previously established 
domains and this hyperactivation is additive with the WSSSSP domain but none of the 
others (Figure 3.8), strongly suggesting that the WSSSSP domain acts through a 
parallel pathway with the N1-Box or acts upon the N1-Box in some way. Up until this 
point, all of our experiments were performed with the NICD1 rather than the full-length 
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canonical Notch receptor. Do these stabilizing N1-Box mutations affect canonical Notch 
signaling in the context of full-length Notch receptors? 
The stabilized N1-Box mutant isoform of full-length mouse Notch1 hyperactivates 
Notch signaling in HEK293 cells and in zebrafish embryos (Figure 3.8). These results 
were validated using a constitutively active form of mouse Notch1 (Figure 3.8). 
Interestingly, the N1-Box mutant isoform of Notch1 hyperactivates Notch signaling to a 
larger extent than the PEST domain mutant of Notch1, supporting our cell culture 
transcriptional reporter assay results (Figure 3.8). These results, taken collectively, 
show that the N1-Box of Notch1 both stabilizes the NICD1 and hyperactivates canonical 
Notch signaling in mammalian cell culture and in vivo in zebrafish embryos. This 
transcriptional hyperactivation is higher for the N1-Box mutants than for the previously 
characterized PEST domain mutants. We next ask whether mutations in the N1-Box are 
found in human cancers and whether these cancers have elevated Notch signaling.  
We found that mutations in the N1-Box identified from the COSMIC database in 
Notch-driven cancers also confer stability to NICD1 in cell-based assays, which strongly 
suggests that the N1-Box mutations are correlated with Notch-driven cancers (Figure 
3.12). These results show that mutations in the N1-Box of Notch1 are associated with 
human diseases, marking the novel N1-Box regulatory region as a potential therapeutic 
for Notch-mediated cancers. Curiously, there are not a large number of mutations in the 
N1-Box that are linked to cancer. Our hypothesis is that cis-binding factors on Notch1 
affect the N1-Box’s ability to promote degradation.  
Next, we investigated the role of known cis-binding factors on regulation of the 
N1-Box-dependent degradation. Based on structural analysis, the CSL/Su(H)/Lag-1 
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binding site is located in the RAM domain, adjacent to the N1-Box. The addition of 
recombinant CSL inhibits NICD1 degradation in a dose-dependent manner in Xenopus 
egg extract and this effect is reversed in a CSL-binding mutant that cannot bind to CSL 
(1771-1774A) (Figure 3.11). These results are validated in HEK293 cells, where the 
steady state level of the CSL-binding mutant is significantly lower than wild-type NICD1 
because it can no longer be shielded from degradation by CSL (Figure 3.11). 
Interestingly, an N1-Box and CSL-binding double mutant appears to be even more 
stable than the N1-Box mutant alone (based on the quantification), further supporting 
the idea that CSL binding affects the N1-Box. These results partially elucidate a 
mechanism for regulation of the N1-Box which is dependent on CSL binding and 
subsequent CSL-mediated transcription.  
Based on our results, a model emerges in which the N1-Box is actively degrading 
NICD1 upon cleavage by δ-secretase. This degradation is independent of ligand 
activation. Then, upon recruitment of CSL to the N1ICD, the N1-Box domain no longer 
promotes degradation as it is sterically inhibited by CSL binding to the RAM domain 
(Figure 3.13). But why does Notch1 specifically have this extra level of regulation that is 
not present in the other paralogs? Notch1 is the most widely expressed paralog of 
Notch and there is some evidence of ligand-independent signaling through Deltex 
(Fuwa et al., 2006; Yamada et al., 2011). It is likely that this mechanism of regulating 
protein levels is used to modulate the natural variability of signaling between cells as 
Notch signaling requires a very precise amount to undergo proper cell-cell signaling.  
One emerging idea about signal transduction pathways is the idea of bistability 
within the system, where a threshold of signal must be reached within each individual 
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cell which then acts in a binary fashion to either activate signaling maximally or not 
activate signaling. Our data suggest that the N1-Box may be the switch that imparts 
Notch1 signaling bistability in an organismal setting. Because Notch1 is so highly 
expressed in comparison to other Notch paralogs, it is likely that Notch1 requires an 
additional level of signal modulation in order to prevent ectopic signaling, and the N1-
Box is likely at least a partial contributor to Notch1’s potential bistability. So how does 
our model for the regulation of the Notch1 intracellular domain fit into the prevailing 
models of how Notch signaling is regulated? 
 The previous prevailing model for the regulation of NICD stability was that it was 
regulated by the N-end rule of protein stability. In the N-end rule, the N-terminal amino 
acid of a protein determines its half-life (Bachmair et al., 1986). NICDs which start with 
valine or methioninie were thought to escape the N-end rule which made them stable 
enough to activate transcription (Tagami et al., 2008). Our results showed that the N-
end rule is not a likely explanation for the stability of the Notch1 mutants, as the wild-
type NICD1 starts with a valine but is significantly less stable than the NICD1 (NTΔ10) 
that starts with an histidine and should be subject to the N-end rule. In addition, point 
mutations in the N1-Box which do nto affect the initial valine can also greatly affect 
stability of the NICD1. Our results show that NICD1’s stability is regulated by additional 
factors other than the traditional N-end rule.  
One other recently proposed model is that the Notch extracellular domain is the 
only domain critical for Notch signaling. One recent report showed that a chimeric Notch 
receptor containing the Notch2 extracellular domain and the Notch1 intracellular domain 
(Notch21) is two-fold more active than wild-type Notch1 when expressed at similar 
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levels in mice. Their conclusion was that the Notch extracellular domain was the critical 
region in the regulation of Notch signaling and that the intracellular domains are actually 
interchangeable to transduce the signal (Liu et al., 2013). Ostensibly, this conflicts with 
our conclusions that the N1-Box of the intracellular domain is likely the most important 
region for regulation of Notch signaling. Interestingly, the Notch21 chimeric fusion 
deletes the N1-Box of NICD1, which according to our results leads to a more stable 
intracellular domain. Thus, it is possible that the increased activity of this chimera is due 
to increased stability of its intracellular domain. A series of experiments to fully combine 
these two models would start by comparing Notch signaling from the Notch21 chimeric 
receptor to the Notch1 receptor in which the N1-Box is mutated. Our data suggests that 
the Notch21 chimera and either the N1(LSQ) or the N1(NTΔ10) would have similar 
levels of Notch signaling, due to an increase in the stability of the NICD1. 
   
Future Directions 
Identifying the complete regulatory mechanism of the N1-Box 
 This dissertation identifies a novel regulatory region of Notch1 termed the N1-
Box which serves as a major regulator of Notch1 protein stability. It also elucidates a 
mechanism for how the N1-Box can be regulated in vivo upon CSL binding to inhibit N1-
Box-mediated degradation. However, the full mechanism of N1-Box regulation still 
needs to be elucidated. Proteins are often regulated by post-translational modifications. 
The degradation of NICD1 is proteasome-dependent in Xenopus egg extract. 
Proteasome-mediated degradation requires the involvement of an E3 ubiquitin ligase 
which adds ubiquitin moieties to lysine residues and targets the protein to the 
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proteasome. The candidate E3s which have been previously linked to Notch1 stability 
(ITCH, SCFFbxw7) degraded NICD1 in HEK293 cells in the N1-Box stabilized mutant 
similarly to wild-type NICD1 (Figure 3.10). In addition, there is a basic region in NICD1 
which contains a string of lysines that is not found in the other NICD paralogs, strongly 
suggesting that NICD1 is being regulated by an E3 distinct from those we tested. These 
residues are very likely to be targets of ubiquitination and degradation. 
One way to identify the E3 ubiquitin ligase for the N1-Box of NICD1 is to perform 
a screen for mammalian E3s that increase NICD1 turnover. The Xenopus egg extract 
system would be very amenable to this type of screen and using luciferase-tagged 
proteins we could do a high throughput screen with a quantifiable readout. Validation of 
any hits from the screen would then be performed in cell culture using a transcriptional 
reporter assay also using luciferase levels as the readout for protein levels. Any hits 
identified can be validated in cultured cells and Xenopus egg extract in a low throughput 
manner. The effect of any E3s that alter NICD1 turnover via the N1-Box of NICD1 
needs to be investigated thoroughly. If it is directly affecting the N1-Box, then the 
degradation of NICD1 would be inhibited in the N1-Box mutant. In Chapter I, I discussed 
that NICD1 is modulated by other post-translational modifications, and these can affect 
the stability of NICD1 and are worth investigating. Oftentimes, ubiquitination is regulated 
by phosphorylation at nearby residues.  
The other major post-translational modification that could potentially regulate the 
stability of the NICD1 is phosphorylation. Previous literature has suggested that 
phosphoregulation of NICD1 can regulate its stability (Choi et al., 2013; Foltz et al., 
2002; Fryer et al., 2004). Because the regulation of Notch is so tightly regulated in vivo, 
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modulation of Notch1 in either direction could be critical in affecting canonical Notch 
signaling. We have performed a small molecule kinase inhibitor screen for modulators 
of NICD1 turnover in Xenopus egg extract using luciferase-tagged NICD1 and 
assessing for changes in NICD1 degradation via luciferase signal. The library we used 
was the TOCRIS kinase inhibitor toolbox [used in (Jester et al., 2010)] 
(http://www.tocris.com/dispprod.php?ItemId=224690#.U-L8TM90zwo). 
Our screen identified Ataxia telangiectasia mutated (ATM) and Ataxia 
telangiectasia and Rad3-related protein (ATR), two well-characterized DNA damage 
responding serine/threonine kinases that phosphorylate key tumor suppressors such as 
p53 and CHK2, as modulators of NICD1 turnover in Xenopus egg extract. Further 
characterization of the role of ATM and ATR on NICD1’s stability should be pursued. 
These studies should include structure-function analysis, functional assays in cell 
culture, and then potentially even in vivo studies. Follow up validation on any other hits 
from the screen should also be investigated. If validated, the screen can begin to 
identify other novel targets for therapeutics for treatment on Notch-mediated cancers. 
Additionally, it would be interesting to identify whether any of these kinases affects the 
capacity of the N1-Box to promote degradation. The N1-Box contains multiple serines 
and threonines, making it highly likely to be phosphorylated.  
If an E3 and a kinase that act on the N1-Box can both be identified, the next step 
would be to identify the relationship between these two post-translational modifications. 
Phosphorylation can both promote and inhibit ubiquitination and subsequent 
proteasome-mediated degradation in other signaling pathways (Orford et al., 1997; 
Yamamoto et al., 1999). Would the phosphorylation of the N1-Box promote or inhibit its 
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ubiquitination? Is it context-dependent or tissue-specific? These are the key questions 
that still need to be answered about the regulation of the N1-Box.  
We have also already shown that CSL binding to the N1-Box affects its ability to 
get degraded. Previous literature showed that CSL binds to the RAM and Ankyrin 
domains of NICD with high affinity (Hsieh et al., 1996). But is CSL binding to NICD1 
regulated? Previous literature has shown that in the nucleus, the scaffold protein MAML 
binds to the CSL/NICD complex and is required to activate transcription of the 
CSL/NICD transcriptional complex (Fryer et al., 2002). Potentially the post-translational 
modifications are actually affecting CSL binding to the RAM domain in the N1-Box, 
which would then promote degradation of NICD1. The role of ubiquitination and/or 
phosphorylation on CSL binding is still unclear, and this would be another interesting 
question to address.  
How about the role of the prevailing models in the regulation of Notch signaling? 
One key experiment would be to assess the stability of the Notch21 chimera vs. wild-
type Notch1 and vs. stabilized Notch1. It is likely that the differential signaling levels for 
the Notch21 chimera vs wild-type Notch1 is due to a difference in the stability of each 
respective ICD, as we have shown that the stable mutants of NICD1 lead to 
hyperactivation of Notch signaling in mammalian cell culture and strongly suggests 
Notch hyperactivation in D. rerio embryos. 
 
In vivo disease models of the N1-Box 
Although we have identified a novel degron, called the N1-Box, in NICD1, and 
shown that it is functional in canonical Notch signaling in cell culture and in zebrafish 
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embryos, there are still many unanswered questions about the in vivo importance of the 
N1-Box in Notch-mediated disease. The first step is to do tumorigenic assays in cancer 
cell lines using our N1-Box mutants, such as colony formation assays to assess for 
tumorigenesis. If N1-Box mutants can induce tumorigenesis in cell culture, one very 
obvious next step is to make a mouse model of the stabilized N1-Box mutant of NICD1. 
Because T-ALL and other leukemias are primarily Notch-driven in humans, we propose 
to express an inducible N1-Box mutant Notch1 under the control of a leukocyte specific 
promoter in an inducible Cre-LoxP background mouse. Upon tamoxifen induction, N1-
Box-mutant NICD1 expression will potentially induce tumorigenesis in the adult mouse, 
which would demonstrate that the N1-Box can in fact induce Notch-mediated tumors in 
vivo. Alternatively, we could generate tissue-specific mouse models for the other tissues 
that are susceptible to Notch-driven cancers, such as mammary glands, liver, skin, 
lungs and others. In addition, we could make a stabilized N1-Box mouse that is not 
inducible which express mutant N1 throughout development and look for other Notch-
driven phenotypes. Generating tissue-specific mutant lines for the specific mutations 
that stabilized human NICD1 (Figure 3.5) and assessing their ability to induce 
tumorigenesis would also be quite interesting and important. Are these stable mutants 
identified from a human database actually able to induce tumorigenesis, or is the 
Notch1 mutation a secondary mutation? The mouse model is an ideal model to test 
many of these hypotheses.  
The generation of a mouse model will allow us to assess whether the differential 
signaling observed in the Notch21 chimeric mice can be explained by the increased 
stability of the N1-Box. Based on our results in Xenopus egg extract, mammalian cell 
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culture, and zebrafish embryos we would expect the N1-Box mutant mice to have an 
increased level of Notch signaling, similar to the Notch21 chimeric mice. Further 
experiments should also be performed to fully elucidate the relationship between the 
chimeric receptors and the stabilized N1-Box mutant receptors. 
Additionally, Notch mutations have been linked to multiple developmental defects 
in humans, including Alagille syndrome (McDaniell et al., 2006), aortic valve disease 
(Garg, 2006; Garg et al., 2005), Hajdu-Cheney syndrome (Simpson et al., 2011), 
CADASIL (Joutel et al., 1996), and T-ALL (Weng et al., 2004). The N1-Box mutant 
mouse models in which the mutant form of NICD is expressed at birth would be very 
useful in studies involving developmental defects caused by misregulated Notch 
signaling. In summary, a mouse model of the N1-Box mutant would be very beneficial to 
helping fully elucidate the mechanisms regulating Notch signaling and also the 
mechanisms regulating the N1-Box. 
 
Part II 
Discussion 
 As discussed in Chapter I, there appears to be extensive crosstalk between the 
Notch signaling pathway and the Wnt signaling pathway (Hayward et al., 2008; Munoz 
Descalzo and Martinez Arias, 2012), and some refer to the Wnt/Notch signaling network 
as the “Wntch” signaling network. Many aspects of these two pathways converge and 
studying how one pathway affects the other would be quite interesting and the 
identification of a novel regulatory region of NICD1 opens up new avenues for exploring 
the interplay between Wnt and Notch signaling.  
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One example of convergence into the “Wntch” pathway is the observation that 
Presenilin 1, a core subunit of the δ-secretase complex which cleaves Notch, negatively 
regulates β-catenin stability and transcriptional activity and can promote 
phosphorylation of β-catenin independent of Axin (Kang et al., 2002; Killick et al., 2001). 
Other examples of Wnt/Notch signaling convergence have been described extensively 
in Chapter I and include convergence on Dsh (Ramain et al., 2001; Sokol, 1996), 
TCF/LEF (Galceran et al., 2004; Ross and Kadesch, 2001; Shimizu et al., 2008), and 
even the core components themselves (Corada et al., 2010; Hayward et al., 2006; 
Hayward et al., 2005; Jin et al., 2009a). Based on previous literature, regulating one of 
these two pathways can also regulate the other one, allowing for combinatorial 
treatment for both Wnt and Notch-mediated diseases.  
 
Identifying Novel Therapeutic Targets of Notch Signaling 
 Due to the importance of Notch signaling in many types of diseases, both 
developmental defects and cancer, studying how this signaling network is properly 
regulated would be critical to addressing Notch-mediated disease. How would the 
discovery of the novel N1-Box of Notch1 help address that question? This allows 
researchers to identify novel targets for development of therapeutics against Notch-
mediated cancers. Most of the current treatments for Notch focus on δ-secretase 
inhibitors (GSIs), most of which are unable to pass clinical trials due to toxicity issues 
and off-target side effects due to δ-secretase’s promiscuity and effect on multiple cell 
types and tissues. Our research has uncovered both a novel regulatory region of the 
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NICD1, the N1-Box, as well as a novel regulatory mechanism involving the cis-binding 
factors CSL and the WSSSSP motif of NICD1.  
 There are two novel approaches to take for development of therapeutics based 
on our research. The first is to target the N1-Box directly by activating the E3 
responsible for promoting the degradation of NICD1. E3 activation would decrease 
NICD1 levels and reduce Notch signaling, which would be critical in treating Notch-
dependent cancers which have ectopic Notch signaling. Identifying small molecules 
which target NICD1 degradation via the N1-Box would be one way to specifically target 
Notch1 as opposed to the other Notch paralogs and other proteins that are dependent 
on δ-secretase. This would reduce potential off-target effects and likely reduce toxicity 
to the patients. One caveat with targeting an E3 is that most E3s have multiple 
substrates and it is possible that there will be other off-target effects distinct from the 
GSIs. Regardless, our studies open up a significant opportunity for the development of 
anti-cancer therapeutics against Notch1-driven cancers by increasing the specificity of 
the therapeutic and decreasing off-target effects. 
 In Chapter III, we showed that CSL binding can inhibit N1-Box-mediated 
degradation and stabilize the NICD1 in Xenopus egg extract and HEK293 cells. A 
second novel approach for therapeutics would be to target CSL binding to NICD1. 
Previous literature has suggested that CSL is a nuclear specific protein (Chiang et al., 
2006; Ong et al., 2006) which binds to DNA and activates transcription in a complex 
with NICD and MAML inside the nucleus. Inhibiting CSL binding would clearly affect 
CSL-dependent Notch signaling. Previous literature provides us evidence that CSL-
independent Notch signaling is mediated by Deltex (Hori et al., 2004). However, in 
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Xenopus egg extract (a cell-free and nucleus-free system), CSL binding disrupts NICD1 
degradation through the N1-Box. Interestingly, this inhibition is independent of the 
transcriptional inhibition due to loss of CSL binding in cell culture as a CSL-binding 
mutant further changes the stability of N1-Box mutants in Xenopus egg extract (which 
does not undergo CSL-mediated transcriptional activity). Identifying small molecules 
which disrupt CSL binding to NICD1 would allow for constitutive activation of N1-Box-
mediated degradation and modulation of Notch signaling. Although CSL binds to all the 
Notch paralogs to activate signaling, NICD2, 3, and 4 do not contain the N1-Box, and, 
thus, their stability is not likely to be affected by CSL binding.  
In addition, the disruption of the WSSSSP motif likely affects N1-Box-mediated 
degradation. The WSSSSP motif is heavily phosphorylated and is shown to regulate 
NICD stability. Identifying small molecules which could affect the phosphorylation of the 
WSSSSP motif could also serve as a potential new target for therapeutics. We showed 
that mutation of the WSSSSP motif cooperates with the N1-Box to hyperactivate Notch 
signaling, which strongly suggests that the WSSSSP motif is actually inhibiting Notch 
signaling in some fashion, likely through promoting its degradation. Being able to 
stabilize the phosphorylation of the WSSSSP motif through a potential therapeutic 
would  also help be useful in the treatment of Notch-mediated cancers. 
Collectively, our data identifies novel regulators of Notch signaling which have 
not been previously reported. WE show that NICD1 degrades in a cell-free system 
giving researchers additional tools for identifying modulators of the Notch signaling 
network (specifically the Notch pathway) that were not available previously. Because 
the N1-Box is specific to Notch1, inhibiting the N1-Box should not lead to global Notch 
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phenotypes but only Notch1-specific phenotypes, allowing researchers to parse out the 
involvement of Notch1 specifically vs. the other Notch paralogs in vivo. This work will 
help us take a small step forward towards identifying effective and usable new 
therapeutics for Notch signaling. Any potential therapeutics for Notch signaling may also 
have the potential to potentiate or dampen Wnt/β-catenin signaling because of the 
extensive crosstalk between the Notch and Wnt/β-catenin signaling pathways.  
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